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Abstract 
Cattle are constantly exposed to environmental pathogens and are susceptible to a 
number of diseases which cause significant economic loss or animal welfare concerns. 
The mucosal surface is a key barrier to infection and a greater understanding of bovine 
mucosal immunology may lead to improved disease management strategies. The 
cathelicidins are a family of host defence proteins which may play an important role in 
this defensive barrier. 
 
The cathelicidins are composed of a globular cathelin-like domain (CLD) and a  
C-terminal antimicrobial peptide (AMP) domain. The CLD is highly conserved across 
all species in which cathelicidins are found, yet the role of the CLD during infection has 
not been firmly established. The first aim of this thesis was to produce functional 
recombinant bovine CLD as a precursor to further experiments. However, the 
recombinant protein bound less lipopolysaccharide, was unable to agglutinate microbes, 
and was unable to permeabilise neutrophil membranes when compared to the activity of 
a native CLD preparation. Although further studies were not carried out with 
recombinant CLD, these results demonstrated that cell death induced by the native CLD 
and the agglutination of microbes potentially contribute to a broad anti-inflammatory 
role for the CLD during infection. 
 
In contrast to humans and mice where only one cathelicidin isoform is expressed, 
bovine express seven cathelicidins, with variable AMP domains. Therefore the second 
aim of this thesis was to profile the effect of bovine cathelicidin AMPs on neutrophil 
function. The bovine AMPs were able to modify a number of activities. Migration and 
reactive oxygen species (ROS) production were enhanced by several peptides while 
ROS production was inhibited by others. When investigated in further detail, linear 
Bac1 (bactenecin), Bac5 and BMAP-34 (bovine myeloid antimicrobial peptide) were 
able to dose-dependently induce or inhibit several key neutrophil functions including 
migration, degranulation, respiratory burst and phagocytosis, indicating significant roles 
in differential modulation of immune responses. In particular, Bac5 was able to 
differentially modify neutrophil respiratory burst without significant disruption to 
cellular homeostasis, which suggested Bac5 was acting via an intracellular mechanism. 
 iii 
 
 
The third aim of this thesis was to investigate the mechanism by which Bac5 modulated 
neutrophil function. The results demonstrated the ability of Bac5 to be internalised by 
neutrophils and that Bac5 inhibition of p47phox binding to nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase is a possible explanation for the differential 
induction and inhibition of extracellular ROS production. β-actin was identified as a 
major intracellular target for Bac5 and is consistent with the ability of Bac5 to modulate 
multiple neutrophil functions. 
 
In summary, this thesis demonstrates that the bovine cathelicidins have multiple roles in 
host defence. The conserved CLD appears to have an anti-inflammatory role through an 
as yet undefined mechanism. The variable AMPs together have multifaceted roles 
which may act in concert to promote elimination of pathogens and regulate excessive 
detrimental neutrophil activity. The combined effect of these roles will facilitate 
clearance of pathogens during infection and aid in the resolution of the innate 
inflammatory response at mucosal surfaces. 
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1.1 Overview 
The past 50 years has seen a rapid increase in all aspects of agricultural production to 
meet global demand. Modern livestock farming techniques utilise large herd sizes which 
maximise production and returns. However, intensive livestock farming methods can 
potentially suffer from a greater incidence of disease. The scope of diseases affecting 
agricultural cattle cause significant global economic losses in terms of detection, 
treatment, control, eradication and most notably, loss of production.  
 
Due to the constant exposure of cattle to environmental pathogens, common prevalent 
contagious bacterial infections are generally accrued by cattle at mucosal surfaces 
exposed to the external environment. The most notable areas susceptible to disease are 
the intestinal tract, the respiratory tract and lungs, and the mammary gland. 
Understanding how the host responds and defends itself at these mucosal surfaces, in 
terms of the etiology and progression of disease, could provide opportunities through 
which improved approaches to disease management can be developed.  
 
This general introduction provides brief examples of mucosal bacterial diseases and 
their impact on the agricultural industry. It then describes in detail the innate 
immunological strategies used by bovine to defend against infection at mucosal surfaces 
via anatomical, cellular and molecular mechanisms. Further to this, a description of the 
cathelicidins is provided, with particular attention to cathelicidin structure, localisation 
and processing, and known functions in the innate immune response. 
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1.2 Mucosal infections in bovine 
Johne’s disease (JD) is a chronic infection of the small intestine caused by 
Mycobacterium avium subspecies paratuberculosis which results in diarrhoea, weight 
loss, decreased milk production and morbidity in ruminants [1,2]. The herd prevalence 
of JD in the dairy industry of the United States is approximately 40%, with estimated 
annual losses as high as US$250 million (1999 estimates [3,4]). A recent report suggests 
the prevalence of JD in New Zealand beef cattle is approximately 31% and as high as 
73% in sheep and deer [5] although a majority of these animals do not exhibit any 
clinical symptoms of the disease. M. paratuberculosis also persists in wild life and 
survives in soil hence attempts at eradicating the disease have been unsuccessful. 
Current research focuses on developing reliable detection methods and control programs 
to prevent the spread of infection. 
 
Bovine respiratory disease (BRD) is of significant importance in the beef cattle 
industry, particularly in North America. The disease is caused by infection of the lungs 
and respiratory tract by Mannheimia haemolytica, Pasteurella multocida, Histophilus 
somni or Mycoplasma bovis [6]. Predisposing factors include viral infections, 
transportation and weather conditions [7]. Total economic losses have been estimated at 
approximately US$14,000 annually per 1,000 animals  with 14% incidence of BRD 
(2006 estimate [8]). 
 
In dairy cattle the most prevalent and costly disease is mastitis, an infection of the 
mammary gland. In New Zealand, mastitis of dairy cows is a significant animal welfare 
and production issue, with associated annual losses estimated at $180 million (2006 
calculation [9]). Mastitis causes reduced milk production (both short and long term), as 
well as costs associated with animal treatment, disposal of milk from antibiotic treated 
animals and penalty payments for herds with high levels of mastitis. Frequent mastitis-
causing pathogens include Escherichia coli, Streptococcus uberis, Streptococcus 
dysgalactiae, Streptococcus agalactiae and Staphylococcus aureus [10]. Multiple 
factors contribute to mastitis susceptibility in bovine including the age of cattle, genetic 
background, the stage of lactation, milking practices, nutrition and climate [11].  
Chapter 1: General Introduction  4 
 
 
1.3 Host defence in bovine 
Protection from pathogens relies on multiple mechanisms that include anatomical and 
innate cellular and humoral defence systems [12-15].  
 
1.3.1 Anatomical defence 
The nasal and oral mucosa provides the first line of defence against respiratory and 
gastrointestinal pathogen entry by trapping opportunistic bacteria. In the respiratory 
tract, the action of cilia on epithelial cells acts to sweep pathogens out and away from 
the lungs. In the gastrointestinal tract, peristalsis helps to remove pathogens and the 
intestinal mucosa allows colonisation by commensal bacteria, which helps to prevent 
colonisation by pathogens through competition for nutrients and excretion of 
compounds that are toxic to pathogens [16]. 
 
In the mammary gland the teat end is the first line of defence against the entry of 
pathogens (Figure 1.1). Sphincter muscles keep the streak canal tightly closed until 
milking. This creates a physical barrier which obstructs invading pathogens [17]. The 
streak canal is lined with keratin forming a mesh-like structure containing antimicrobial 
agents that assist in preventing entry of pathogens [18]. Streak canal length and 
diameter correlate with incidence of mastitis, with shorter wider canals being more 
susceptible to infection [19]. At the entry to the teat cistern is a structure called 
Furstenberg’s rosette which hosts an enhanced population of leukocytes [20]. These 
cells are capable of leaving the teat wall to neutralise pathogens.  
 
 
Figure 1.1 Structure of the bovine mammary gland 
This diagram has been adapted and adjusted from Thayer, 2007 [21]. 
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1.3.2 Innate cellular defence 
Myeloid-derived cells are the major component of cellular innate immunity. These 
include macrophages, dendritic cells and neutrophil granulocytes that recognise and 
signal pathogen exposure to initiate immune protection and eliminate pathogens  
(Figure 1.2).  
 
Infection is detected by pathogen recognition receptors on macrophages, dendritic cells 
and granulocytes. These receptors include a diverse range of Toll-like receptors (TLRs), 
complement receptors (CRs), dectin receptors, mannose receptors (MRs), 
immunoglobulin (Ig) receptors (FcRs) and cluster of differentiation (CD) cell surface 
molecules. TLRs differentially recognise common exogenous pathogen components 
such as lipopolysaccharide (LPS, also known as endotoxin), lipoteichoic acid (LTA), 
foreign double-stranded deoxyribonucleic acid (DNA), CpG DNA and flagellin [22].  
 
 
Figure 1.2 Myeloid-derived innate immune cells and associated receptors 
This diagram has been adapted from Brown et al, 2008 [23].  
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CRs recognise endogenous proteins of the complement cascade and exogenous yeast 
cell wall glucans such as zymosan [24]. Dectin receptors recognise microbial 
components and endogenous ligands [25]. Igs bind to microbes and microbial molecules 
forming antigen-antibody complexes which are recognised by FcRs. FcRs form a large 
family of receptors which are classified based on the type of Ig molecule they bind [26]. 
CD molecules are commonly associated with cells involved in immunity which 
recognise antigens, e.g. CD4 and CD8 T cells. However, cells involved in innate 
immunity express CD14 which assists in recognition of LPS [24].  
 
As part of the innate immune response, recognition of pathogens by macrophages and 
dendritic cells results in chemokine and cytokine signalling to recruit granulocytes from 
the circulation. These granulocytes are predominantly neutrophils. Granulocyte 
recruitment involves adhesion to vascular walls, diapedesis, and chemotaxis toward 
inflammatory foci. Infiltration is dramatic. For example, during mastitic infection 
myeloid cell numbers increase 1000-fold within 24 hours, with neutrophils constituting 
approximately 95% of total cells infiltrating the mammary gland [27]. This influx of 
cells into the mammary gland results in an increase in somatic cell count (SCC), a 
parameter routinely assessed by farmers and veterinarians to monitor levels of 
subclinical mastitis in milking herds. Importantly, the recruitment and activation status 
of neutrophils is critical in containing and eliminating pathogens during infection. For 
this reason bovine neutrophils are the principal cell type studied in this thesis.  
 
Neutrophil stimulation induces a range of functions designed to defend against 
pathogens, including respiratory burst, phagocytosis and degranulation. Degranulation 
releases AMPs, proteases, lipases and glycosidases into the extracellular medium that 
constitute part of the humoral innate immune response [28] (section 1.3.3). 
 
1.3.2.2 Adhesion and diapedesis 
The epithelium functions as a dynamic barrier. Release of inflammatory cytokines from 
resident immune cells and epithelial cells cause endothelial cells in the vicinity to 
increase expression of E-selectin and P-selectin adhesion molecules, allowing 
neutrophils to adhere to blood vessel walls [29]. Neutrophils upregulate macrophage-1 
antigen, which increases interaction with intercellular adhesion molecule-1 (ICAM-1) 
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on endothelial cells, allowing neutrophils to migrate across the endothelium [14]. Cell 
to cell interactions between epithelial cells are modulated by cytokines and in the 
mammary gland milk electrolyte content also modulates endothelial cell junctions [30]. 
This allows neutrophils to pass without permanently disrupting cell to cell contacts.  
 
1.3.2.3 Chemotaxis 
Chemoattractant concentration gradients allow neutrophils to migrate from the 
endothelium to the site of infection. Inflammatory environments often contain multiple 
chemoattractants, therefore neutrophils utilise an intracellular signalling hierarchy 
where end-target chemoattractants such as formyl peptides and complement C5a 
dominate over intermediary chemoattractants such as interleukin (IL)-8 and leukotriene 
B4 [31]. Although neutrophils possess multiple receptors for different chemokines, the 
exact types of receptors can differ between species resulting in different responses to 
common stimuli. Several examples are provided below which highlight the differences 
in neutrophil responses to chemotactic stimuli, not only between species, but also within 
species exhibiting polymorphisms for particular receptors.  
 
For instance, human neutrophils express formyl peptide receptor-like-1 (fPRL1) 
receptors that are activated by bacterial formyl peptides [32] and show enhanced 
chemotaxis in the presence of LPS [33]. Bovine neutrophils do not recognise formyl 
peptides [34] nor exhibit increased chemotaxis in the presence of LPS [35]. The 
anaphylatoxins C5a and C5adesArg are produced by the complement cascade [36]. 
Chemotactic responses to C5a and C5adesArg are comparable in bovine neutrophils, 
whereas human neutrophils are 20-50 times less responsive to C5adesArg [37]. IL-8 is a 
potent chemoattractant produced by macrophages, epithelial cells and to a lesser extent 
neutrophils [38]. Bovine neutrophils express two IL-8 receptors which are homologous 
to those found in humans [39]. Accordingly, bovine neutrophils respond to recombinant 
human IL-8 [40]. However, polymorphisms in the bovine chemokine CXCR1 receptor 
confer different responses to bovine IL-8 which impact on resistance to mastitis [41].  
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1.3.2.4 Degranulation 
Neutrophil degranulation releases a number of humoral innate immune components, 
including cathelicidins and defensins. These humoral innate immune components are 
discussed in section 1.3.3.3. Degranulation also increases cell surface expression of 
receptors and oxidase complexes derived from granule membranes. The process of 
neutrophil degranulation is thought to occur in a sequential manner [42] and is regulated 
by the actin cytoskeleton [43]. Neutrophil secretory vesicle release occurs during 
adherence to endothelia, which relocates vesicle membrane-bound receptors to the 
neutrophil plasma membrane, thereby altering endothelial membrane protein 
expression. Different granule subsets are then released during diapedesis, migration and 
phagocytosis. 
 
The development of granule subsets occurs from the promyelocyte stage of neutrophil 
maturation [44] and is significantly different in bovine and human neutrophils. Both 
species produce primary (azurophil) and secondary (specific) granule subsets with 
similar contents. However, bovine neutrophils also produce novel large granules [45] 
which store the bovine cathelicidins. In contrast the human homologue human 
cathelicidin antimicrobial peptide-18 (hCAP-18) is stored in the secondary granules 
[46] and human neutrophils produce tertiary, gelatinase-containing granules [47].  
 
1.3.2.5 Respiratory burst 
Respiratory burst is the process of producing ROS to kill pathogens and initiate cellular 
responses to infection. This is achieved through the formation of a membrane coupled 
NADPH oxidase complex which converts molecular oxygen to superoxide radical using 
NADPH and molecular oxygen as substrates (Figure 1.3) [48]. Receptor activation via 
pathogens, chemoattractants or other endogenous molecules activates intracellular 
kinases which phosphorylate cytosolic subunits p40phox, p47phox and p67phox of the 
NADPH oxidase complex. These subunits then translocate to plasma or phagosome 
membranes, along with Rho-related C3 botulinum toxin substrate (Rac), and bind to the 
transmembrane subunits p22phox and gp91phox, completing the oxidase assembly. 
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Chronic granulomatous disease (CGD) is a condition resulting from the absence of a 
functional NADPH oxidase due to mutations in either of four oxidase subunits [49]. The 
disease manifests as increased susceptibility to infection, particularly in the lung, skin, 
liver and lymph nodes. Although not a condition found in cattle, the lack of a functional 
oxidase complex highlights the importance of oxygen-dependent killing mechanisms in 
immune cells. 
 
 
 
Figure 1.3 The NADPH oxidase complex in resting and activated cells 
This diagram was taken from Wilkinson and Landreth, 2006 [50]. GDP, guanosine diphosphate; GTP, 
guanosine triphosphate; P, phosphate. 
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1.3.2.6 Phagocytosis 
Neutrophils can function as phagocytes in tissues for one to two days [51]. Phagocytosis 
is mediated by Fc receptors and CRs. Fc receptors recognise antibody-antigen 
complexes on pathogens and foreign bodies. CR1 and CR3 respectively recognise C3b-
opsonised or iC3b-opsonised pathogens and foreign particles [52]. In addition to 
clearing bacteria, the process of phagocytosis can stimulate the release of cytokines and 
chemokines that contribute to the progression of the immune response [53-55].  
 
1.3.2.7 Cellular functions in the mammary gland and milk 
It is speculated that the non-tissue environment of milk renders many neutrophil innate 
immune functions less effective. Diapedesis across mammary epithelium is known to 
reduce the bactericidal activity of neutrophils [56]. This includes respiratory burst 
activity and phagocytic capacity, which are diminished due to the ingestion of fat 
globules and the associated loss of pseudopodia [56,57]. However, during infection the 
composition of milk dramatically changes [58]. These studies were carried out in 
normal milk and may not accurately reflect the in vivo functionality of cellular defence 
during infection. Nevertheless, cellular components of innate immunity are critical in 
containing and eliminating pathogens but also rely on components of humoral innate 
immunity for efficient host defence. 
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1.3.3 Innate humoral defence 
Humoral components of innate immunity include proteins and peptides capable of 
directly neutralising pathogens, or proteins and peptides that aid cellular elimination of 
pathogens. These components are generally divided into two arms – sensing molecules, 
i.e. molecules that bind to pathogens and enhance recognition of pathogens by host 
defence cells, or effecting molecules i.e. molecules that initiate phagocytosis by 
phagocytes or directly neutralise pathogens by inducing cell death [28]. Additionally, 
some host defence peptides are also able to prevent recognition of pathogens [59] 
thereby regulating proinflammatory responses, and should be considered as a third arm 
of innate humoral defence. 
 
1.3.3.1 Complement system 
The complement system is a series of liver-derived proteins (C1 to C9) found in blood 
serum [60]. Activation of complement occurs via several mechanisms but most notably 
through pathogen recognition. Activation and successive cleavage of precursor proteins 
generate components with diverse immunomodulatory effects. Cleavage of C3 
generates the opsonins C3b and iC3b which initiate phagocytosis of opsonised 
pathogens. C5 is cleaved to generate C5a, a potent anaphylatoxin. C5a is rapidly 
converted to C5adesArg through the removal of the C-terminal arginine by serum 
carboxypeptidase N [61]. In humans C5adesArg has significantly less activity than C5a 
whereas in bovine both forms have equivalent activity [37]. 
 
C5a activates cellular responses via the seven-transmembrane domain, G-protein-
coupled C5a receptor (C5aR) which is highly expressed on bovine neutrophils [62]. In 
comparison to the human C5aR and C5aRs from several other species, bovine and ovine 
C5aRs appear to have unique amino acid substitutions in loop regions critical for C5a 
recognition [62]. This potentially allows recognition and activation by both C5a and 
C5adesArg, and may compensate for the absence of fPRL receptors on bovine neutrophils 
[34]. Activation by C5a induces chemotaxis, degranulation and respiratory burst [63]. 
Components C5b to C9 form the membrane attack complex [60]. Formation of this 
complex is the end-point of complement activation and results in permeabilisation of the 
target membrane, lysis and cell death. 
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1.3.3.2 Epithelial cell secretions and milk 
Epithelial cells secrete a number of chemoattractants such as IL-8 and monocyte 
chemotactic protein-1 (MCP-1) and upregulate expression of ICAM-1 to promote 
neutrophil migration during infection [64]. They also secrete proinflammatory cytokines 
such as tumour necrosis factor alpha (TNFα), granulocyte-macrophage colony-
stimulating factor (GM-CSF), IL-1α and IL-1β in a rapid but transient manner in 
response to pathogens [64]. The repertoire of antimicrobial secretions produced by both 
airway and gastrointestinal epithelial cells include β-defensin, lysozyme and 
phospholipase A2 [65,66]. Airway epithelia also secrete lactoferrin [65], and intestinal 
epithelia also secrete bactericidal/permeability-increasing protein (BPI) [66]. In contrast 
to human epithelial cells, bovine epithelial cells, including mammary epithelial cells 
(MECs), show negligible constitutive expression of cathelicidins [67-69]. 
 
The MECs lining the alveoli of the mammary gland either transport or synthesize a 
number of innate immune components, secreting them into the alveolar lumen  
(Figure 1.1). Hence milk itself is considered part of the innate immune system [12]. 
Acquired immune system components such as immunoglobulins and secretory 
component also accumulate in milk via transcellular transport through MECs from the 
blood to the lumen, while solutes accumulate in milk via paracellular transport [70]. 
MECs synthesise a number of host defence proteins such as lactoferrin, β-defensin and 
LPS-binding protein (LBP) (section 1.3.3.3) [12,13]. During secretion of these 
components the apical membranes of MECs are released, forming the milk fat globule 
membrane component of milk [71]. The milk fat globule membrane contains xanthine 
oxidase, sphingolipids and numerous other immune factors [58]. MECs are also capable 
of pathogen recognition and express several different TLRs recognising lipopeptides, 
peptidoglycan, LPS and foreign DNA [72]. 
 
Digestion of ingested milk by neonates produces a variety of humoral peptides 
generated from larger milk proteins by proteolytic degradation, including 
antihypertensive peptides, antithrombotic peptides and caseinophosphopeptides [73]. 
These peptides prevent local increases in blood pressure, prevent clotting of blood, and 
form complexes with calcium which aid intestinal absorption, respectively. Peptide 
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derivatives of αs1-casein, β-casein, κ-casein, α-lactalbumin and β-lactoglobulin also 
have multiple immune-modulating roles in the digestive tract [73,74]. 
 
1.3.3.3 Neutrophil secreted proteins and peptides 
Secretion of proteins and peptides by neutrophils occurs through secretory vesicle 
release and degranulation. Secretory vesicle release upregulates surface expression of 
membrane bound CD14 (mCD14) [75] which recognises LPS-LBP complexes, 
resulting in cellular activation. During mastitis mCD14 is cleaved from the membrane 
by proteases to release soluble CD14 (sCD14) which has high affinity for LPS [76]. The 
CD14-LPS complex can activate TLRs on epithelial cells which release chemokines to 
enhance neutrophil recruitment.  
 
Primary bovine neutrophil granules contain myeloperoxidase (MPO) which catalyses 
the formation of bactericidal hypohalous acids and nitrogen oxides [48]. In contrast to 
patients with CGD (NADPH oxidase deficiency), MPO deficiency does not result in 
higher incidence of infection due to parallel mechanisms of bacterial killing [77]. These 
mechanisms utilise lactoferrin, BPI, cathelicidin and defensin mediated bacterial killing.  
 
Lactoferrin is stored in the secondary granules of neutrophils. Lactoferrin has 
bacteriostatic activity through iron sequestration and bactericidal activity through direct 
interaction with bacteria [78]. BPI shares homology to LBP but has significantly higher 
affinity for LPS [79,80], and like lactoferrin, has direct bactericidal activity. Lysozyme 
is a component of primary, secondary and tertiary granule types in human neutrophils 
[47] but is absent in bovine, caprine and ovine neutrophils [81]. 
 
The two major families of antimicrobial peptide released by neutrophils are defensins 
and cathelicidins. The main focus of this thesis is the cathelicidins which are introduced 
in section 1.4. Defensins are small cysteine-rich cationic proteins found in immune cells 
and nearly all epithelial cells. There are three structural subfamilies termed α-, β-, and θ-
defensin [82]. Various physiological stimuli mobilise preformed defensins from 
neutrophil granules or upregulate expression in tissues. The majority of defensins have 
antimicrobial activity. Their effects on mammalian cells are numerous, including 
chemotaxis and degranulation of mast cells, recruitment and maturation of dendritic 
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cells, chemotaxis of monocytes and T cells, mitogenesis of epithelial cells, 
neovascularisation and wound healing [83].  
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1.4 Cathelicidins 
The cathelicidins are a family of diverse host defence proteins found in vertebrates 
(Figure 1.4). This section will focus on cathelicidin proteins and the cathelin-like 
domain (CLD). The cathelicidin antimicrobial peptide (AMP) domain will be discussed 
in more detail in section 1.4.6. 
 
1.4.1 History 
The discovery of oxygen-independent killing mechanisms in bovine neutrophil 
phagosomes led to the identification of bactericidal polypeptides localised to the unique 
large granules. The antibiotic activity of these peptides was broad and efficient, killing 
Gram-positive and Gram-negative bacteria at concentrations of less than 100 μg/ml 
[45,84]. Purification of large granule contents allowed identification and 
characterisation of several cationic peptides with bactericidal activity at micromolar 
concentrations. The peptides were named ‘bactenecins’ [85,86].  
 
Full length complementary DNA clones of bactenecin peptides revealed a conserved  
N-terminal pro-sequence of approximately 11.5 kDa which had 66% amino acid 
sequence identity to cathelin, a cathepsin L inhibitor from porcine neutrophils [87]. 
Hence this conserved domain was termed the ‘cathelin-like domain’. The novel protein 
has since been identified in many mammalian species and other vertebrates. The protein 
family was named ‘cathelicidins’. 
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Cathelin-like domain (CLD)Signal peptide AMP domain
12-100 aa101-114 aa17-30 aa
S-S S-S
Highly variableHighly conserved
A
B
 
Figure 1.4 Domain structure and multiple sequence alignment of cathelicidins 
(A) Domain structure of cathelicidins showing highly conserved and highly variable regions. (B) Multiple 
sequence alignment of cathelicidins from a range of species. Note the highly conserved cysteine amino 
acids at positions 93, 104, 115 and 139 which form the disulfide bonds in the CLD. Alignment created 
using Jalview 2 v2.8 [88]. 
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1.4.2 Gene structure 
Bovine chromosome 22 contains 11 distinct cathelicidin genes, seven of which are 
expressed [89]. The exon-intron organisation is highly conserved (Figure 1.5). Exons 
one to three encode the signal sequence and the highly conserved N-terminal CLD. 
Exon four encodes the cleavage site and AMP domain. The exon-intron locations avoid 
secondary structure elements and occur between amino acid codons. This is a typical 
feature of genes encoding extracellular immune proteins [90]. 
 
E 1 E 2 E 3 E 4
5’ UTR 3’ UTR
I 3I 1 I 2
Signal sequence and CLD AMP domain  
Figure 1.5 Exon and intron structure of cathelicidin genes 
Exons one to three encode the signal sequence and CLD. Exon four encodes the AMP domain. E, exon; I, 
intron; UTR, untranslated region. 
 
The cathelicidins evolved from a common ancestral cystatin scaffold and are 
phylogenetically classified in the cystatin superfamily of cysteine protease inhibitors. 
Organisation of exons one to three is identical in cystatins and cathelicidins suggesting 
cathelicidins arose through duplication of cystatin genes [90]. A proposed mechanism 
for the evolution of the AMP domain involves selection of splicing signals in the third 
intron of the gene, leading to read-through into the 3’ untranslated region. Continual 
mutations in this region potentially led to the evolution of a protease cleavage site and 
significant diversity in the AMP domain [90]. The retention of this domain, despite the 
high diversity, shows each AMP domain has a valuable function in host defence. 
 
Two natural variants of the cathelicidin-1 gene (CATHL1, accession: P22226 [91]) have 
been identified in cattle, indicating the alternative presence of either glutamine or 
arginine at position 128 of the protein sequence [87]. Sequence polymorphisms have 
also been identified in three cathelicidin genes (CATHL2, accession: P19660; 
CATHL5, accession: P54229; CATHL7, accession: P56425; [91]) across ten breeds of 
Bos taurus and Bos indicus species [92]. Seven nonsynonymous single nucleotide 
polymorphisms were identified. None were predicted to alter cathelicidin structure. 
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Because an exact function for the CLD has not been defined, the change of amino acid 
sequence identified in these genes does not rule out alteration of an unknown function, 
which may involve modification of potential active site amino acids. 
 
1.4.2.2 Response elements 
Recognition sites for nuclear factors IL-6, nuclear factor-kappa B (NF-κB) and 
interferon gamma (IFNγ) response element have been identified in the 5’ flanking 
region of bovine cathelicidin genes [89]. The presence of recognition sequences for 
immune related transcription factors suggest cathelicidin transcription could be 
regulated by cytokines during infection. Upregulation of bovine cathelicidin messenger 
ribonucleic acid (mRNA) has been reported in Mannheimia haemolytica infected cattle 
where elevated levels of Bac1 and indolicidin mRNA were detected in bronchoalveolar 
lavage fluid [93]. Bovine neutrophils exposed to Escherichia coli LPS are also reported 
to upregulate mRNA expression of Bac5 and BMAP-28 ex vivo [67]. However, it is 
unclear which transcription factors are responsible for upregulation in each example.  
 
The promoter region of the human cathelicidin gene contains a vitamin D response 
element [94]. Expression of the gene can be induced by 1,25-dihydroxyvitamin D3 and 
three of its analogues, via binding to the transcription factor vitamin D receptor [95]. 
However, this mechanism only appears to operate in primates and is absent in murine, 
canine and bovine cathelicidin promoters [96]. 
 
1.4.3 Protein structure 
Cattle express seven cathelicidins. The globular CLDs have 47.8% sequence identity 
with 55 identical positions, but vary greatly in their AMP domains. A structure-based 
sequence alignment of the cathelicidin family shows conservation in secondary structure 
elements and disulfide bond location [97]. Porcine protegrin-3 shares at least 65.8% 
sequence identity with bovine cathelicidins [91]. The structure of protegrin-3 was 
determined by nuclear magnetic resonance (NMR) spectroscopy and X-ray 
crystallography using chicken cystatin as a model [97,98]. The fold was revealed to 
have an N-terminal α-helix partially wrapped by a four-stranded β-sheet which buries 
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hydrophobic residues in the core of the protein. Two highly conserved disulfide bonds 
are essential for structural integrity [98].  
 
More recently, the structure of the human CLD was solved by x-ray crystallography 
[99] (Figure 1.6). The human CLD shares 63.4% sequence identity with protegrin-3 and 
the X-ray structures overlap with 0.88 Å root-mean-square deviation (RMSD) for 81 of 
the Cα carbon backbone atom pairs. 
 
90°
B
A
 
Figure 1.6 Topology and three-dimensional structure of the human CLD 
(A) Topology diagram indicating the sequence of secondary structure elements in human CLD [100].  
(B) Three-dimensional structure of the human CLD (Protein Data Bank ID: 4EYC [99]). 
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1.4.4 Localisation, processing and release 
Cathelicidins have been identified in myeloid cells of a number of species with 
significant variation in the number of homologues expressed [101]. Bovine cathelicidins 
are most abundant in neutrophil granules [86]. A 29 residue signal peptide at the  
N-terminus directs cathelicidin accumulation into large granules during myeloid cell 
maturation. 
 
Bovine MECs show negligible cathelicidin expression which is only slightly increased 
in response to pathogenic challenge (unpublished data, AgResearch, Food & Bio-based 
Products Group, New Zealand). Many other bovine tissues do not express cathelicidins 
however cathelicidin-7 mRNA has been detected in spleen and testis [89]. In contrast, 
hCAP-18 is expressed in numerous tissues including many types of internal squamous 
epithelia, sweat and salivary glands, and testis [102]. Generally these tissues have 
mucosal surfaces that interface with luminal or external environments. 
 
The signal sequence is cleaved by signal peptidase [103], releasing the unprocessed 
cathelicidin into the matrix of storage granules, or, into the extracellular environment in 
the case of epithelial cell production. Maturation of cathelicidin AMPs is governed by 
different neutral serine proteases in different species. Neutrophil elastase processes 
bovine and porcine cathelicidins [104,105] whereas cathepsin G processes hCAP-18 
[106]. These proteases are stored in the primary granules of neutrophils or are excreted 
by epithelial cells, and come into physiological contact with cathelicidins after 
extracellular or phagosomal release. 
 
The rapid influx of neutrophils during the innate immune response is usually paralleled 
by a large increase in the concentration of cathelicidins. For instance, in human urinary 
tract infection, cathelicidin concentration increases approximately eight-fold (from 
0.3 ng/ml in healthy individuals to 2.4 ng/ml in infected individuals) [107]. During the 
onset of bovine mastitis the CLD concentration can increase greater than 300-fold in 
clinical cases (from 300 ng/ml to 100 µg/ml), and greater than 100-fold in subclinical 
cases [108]. Hence, the cathelicidins have been proposed as a biomarker for the early 
detection of clinical mastitis and neutrophil influx [108].  
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1.4.5 CLD activity 
1.4.5.1 Structural functions 
The CLD has been described as a structural scaffold for the sequestration of the AMP 
domain prior to maturation by serine proteases [97]. Electrostatic interactions between 
the anionic surface of the CLD and the cationic AMP domain appear to inactivate the 
antimicrobial effects of the AMP domain [109]. Dissociation of the cleaved AMP 
domain from the CLD requires a pH-dependent conformational change. NMR data has 
indicated a reversible change in conformation at acidic pH compared with neutral pH 
[97]. This implies that a proportion of AMPs released into phagosomes remain inactive 
until the phagosome is acidified by lysosomes. These electrostatic interactions must 
therefore be overcome in the extracellular inflammatory environment to activate the 
AMP. Exactly how this occurs is unclear. 
 
The crystallisation study of porcine protegrin-3 showed a domain-swapped dimer could 
be produced in low pH and high ionic strength conditions [97]. The N-terminal helix 
and first β-sheet of each monomer is exchanged with the other, and the loop region 
between β-sheets one and two in each monomer forms an anti-parallel link between the 
monomers. Essential amino acid contacts are maintained in this configuration and the 
dimer backbone structure overlaps with the monomer backbone by 0.49 Å RMSD. 
Physiologically, high molecular weight forms of hCAP-18 have been detected in human 
plasma [110], and two-dimensional electrophoresis analysis of mastitic milk indicates 
several high molecular weight forms of cathelicidin-1 exist in cattle [58]. This suggests 
oligomerisation or aggregation of the CLD may occur in vivo. Domain swapping is a 
feature of the cystatin superfamily which promotes the formation of amyloid-like fibrils 
which are implicated in the development of neurodegenerative diseases such as 
Alzheimer’s, bovine spongiform encephalopathy (BSE) [111], and amyloid angiopathy 
[112]. A speculative function for the CLD may involve fibril or aggregate formation in 
the acidic environment of phagosomes which assist in permeabilisation of bacterial 
membranes. 
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1.4.5.2 Protease inhibition 
Cystatins are important immune system mediators which modulate cysteine protease 
activity and antigen presentation. The homology displayed between cystatins and the 
CLD suggested a mutual role in protease inhibition. The closest homologue, porcine 
cathelin, was shown to inhibit the plant cysteine protease papain and human cathepsin L 
with Ki values of 0.1 nM and 1 nM, respectively [113]. However later analysis of the 
cathelin isolation attributed this activity to a contaminating cysteine protease inhibitor 
[114]. 
 
Interestingly, significant variation in protease inhibitory activity has been observed for 
the CLD from different species. In assays of human cathepsin L activity, the human 
CLD was shown to moderately inhibit activity [115], while porcine protegrin-3 CLD 
significantly enhanced activity [116]. Further investigation suggested the second loop 
region between β-sheets three and four was responsible for activity, and these differed 
significantly between human CLD and protegrin-3 CLD. However, a more recent study 
using a similar inhibition assay showed human CLD had no protease inhibitory activity. 
Further analysis concluded this was due to the absence of specific residues in the first 
and second loop regions which are required for correct binding to proteases, as 
compared to established cysteine protease inhibitors [99].  
 
Among the bovine cathelicidins, only cathelicidin-2 has been investigated for inhibitory 
activity. It was found to inhibit cathepsin L with a Ki of 60 nM but was unable to inhibit 
human cathepsin B or papain [117]. Therefore cysteine protease inhibition appears to be 
a sporadic legacy from the divergence of the cathelicidin family and the cystatins, and 
indicates protease inhibition is not the driving force behind maintenance of the CLD 
structure. 
 
1.4.5.3 Chemotaxis 
The pro-form of bovine cathelicidin-3 was able to generate a chemotactic response in 
bovine monocytes [117]. This was attributable to the CLD as the AMP domain showed 
no chemotactic activity. The maximum chemotactic activity of the CLD was observed 
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at 1 nM. The CLD of cathelicidin-2 was unable to evoke a similar response despite 
having 82% sequence identity [91]. 
 
1.4.5.4 CLD activity summary 
The weak and sporadic activity exhibited by CLDs from different species indicates 
more of a structural role for the CLD. This is supported by the conservation of 
important secondary structure elements and the drifting variation in unordered regions 
between species. Whether the CLD is simply a structural scaffold for the activation of 
the AMP domain or whether higher molecular weight quaternary structure has 
significant activity remains to be determined. 
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1.4.6 AMP activity 
1.4.6.1 Structure 
The length, charge, structure and sequence of cathelicidin AMPs are highly variable. 
Their length ranges between 12 and 100 amino acids with characteristically strong net 
positive charges at neutral pH. Sub-classifications are based on structure and sequence, 
and are divided into α-helical peptides, β-turn cysteine-bridged peptides and linear 
peptides. Linear peptides are further divided into proline and arginine-rich or 
tryptophan-rich peptides (Table 1.1). The properties of the seven bovine cathelicidin 
AMPs are given in Table 1.2. 
 
Further processing of AMPs can occur either before or after cleavage from the CLD.  
C-terminal glycine residues can be converted to non-ionisable α-amides (-CONH2) by 
peptydylglycine α-amidating monooxygenase. This occurs for the bovine peptides 
indolicidin, BMAP-28, BMAP-27 and BMAP-34, whereas the C-terminal proline is 
amidated for Bac5 [103]. This has also been reported for several porcine cathelicidin 
AMPs. The C-terminal amide group is thought to increase the net charge of the peptide 
thereby increasing electrostatic interaction with target membranes. 
 
1.4.6.1 Antimicrobial activity 
The cathelicidin AMPs were originally identified as antimicrobial secretions of 
neutrophils and particular tissues, and their antimicrobial effects have been examined on 
a large range of bacteria, yeast and viruses [67,84,102,118-122]. Because 
microorganisms rarely develop resistance to the toxic effects of these peptides, the main 
impetus of cathelicidin AMP research has been the development of peptide antibiotics 
[123,124]. More recently, antimicrobial peptide elicitors (APEs) have been proposed. 
These are chemical, biological or physical agents that rapidly upregulate endogenous 
antimicrobial peptides to combat infection [125]. The immunomodulatory effects of 
cathelicidin AMPs have a significant role in host defence against infection and have 
been less intensively studied. In a clinical setting the added effects of 
immunomodulatory activity may have great significance in the application of 
therapeutic AMPs and therefore warrant continued investigation. 
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Table 1.1 Examples of cathelicidin AMP classification and diversity 
Structure Origin AMP Length (aa) 
Net 
charge PTM Reference 
α-helical Feline (cat) feCath 37 +3 - [126] 
 Galline (chicken) Fowlicidin-1 26 +8 - [119] 
 Galline (chicken) Fowlicidin-2 32 +10 - [119] 
 Galline (chicken) Fowlicidin-3 29 +7 - [119] 
 Bovine (cow) BMAP-28 27 +7 α-amidation [127] 
 Bovine (cow) BMAP-27 26 +10 α-amidation [127] 
 Bovine (cow) BMAP-34 33 +8 α-amidation [89] 
 Canine (dog) K9Cath 38 +6 - [128] 
 Equine (horse) eCath-2 27 +3 - [129] 
 Equine (horse) eCath-3 40 +7 - [129] 
 Human LL-37 37 +6 - [130] 
 Murine (mouse) mCRAMP 34 +6 - [131] 
 Porcine (pig) PMAP-23 23 +6 - [132] 
 Porcine (pig) PMAP-36 37 +13 - [133] 
 Porcine (pig) PMAP-37 37 +3 - [134] 
 Lupine (rabbit) CAP7 37 +12 - [135] 
 Murine (rat) rCRAMP 43 +8 - [136] 
 Rhesus monkey RL-37 37 +8 - [137] 
 Ovine (sheep) SMAP-29 29 +9 - [138] 
       
β-sheet (disulfide 
bond) Bovine (cow) Bac1 12 +4 - [86] 
 Porcine (pig) Protegrin-1 18 +6 α-amidation [139] 
 Porcine (pig) Protegrin-2 16 +5 α-amidation [139] 
 Porcine (pig) Protegrin-3 18 +5 α-amidation [139] 
 Porcine (pig) Protegrin-4 18 +4 α-amidation [140] 
 Porcine (pig) Protegrin-5 18 +5 α-amidation [91] 
 Ovine (sheep) Bac1 12 +4 - [141] 
       
Linear (Pro/Arg-rich) Bovine (cow) Bac5 43 +9 α-amidation [85] 
 Bovine (cow) Bac7 60 +17 - [85] 
 Porcine (pig) PR-39 39 +10 α-amidation [142] 
 Porcine (pig) Prophenin-2 79 +6 α-amidation [143] 
 Ovine (sheep) Bac5 43 +11 α-amidation [122] 
 Ovine (sheep) Bac7.5 60 +20 - [141] 
       
Linear (Trp-rich) Bovine (cow) Indolicidin 13 +3 α-amidation [121] 
Shaded rows designate examples from bovine. aa, amino acids. 
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Table 1.2 Bovine cathelicidin AMP properties 
Protein Name AMP Structure Weight (kDa) Feature 
Cathelicidin-1 Bac1 β-sheet (disulfide bond) 1.5 Disulfide bond 
Cathelicidin-2 Bac5 Linear/poly-proline helix 5.1 Proline and arginine rich  
Cathelicidin-3 Bac7 Linear/poly-proline helix 7.0 Proline and arginine rich 
Cathelicidin-4 Indolicidin Linear 1.9 Tryptophan rich 
Cathelicidin-5 BMAP-28 α-helical 3.1 Hydrophobic C-terminus 
Cathelicidin-6 BMAP-27 α-helical 3.2 Hydrophobic C-terminus 
Cathelicidin-7 BMAP-34 α-helical 4.2 Amphipathic 
 
1.4.6.2 Clinical applications of AMPs 
The relatively recent rise of antibiotic-resistant strains of bacteria has driven the search 
for alternative antibiotic therapies. AMPs have garnered much attention due to their 
rapid bactericidal activity, broad spectrum of activity and low incidence of resistance 
[144]. However, several drawbacks have hampered their release as approved therapies. 
Their limited stability, high cost and relatively unknown toxicology and pharmacology 
are often stumbling blocks to approval [144]. Despite this, many peptides are in various 
phases of clinical trials. For instance, Pexiganan is a topical cream containing magainin 
[145] that is being trialled in the treatment of diabetic foot ulcers [146]. Omiganan is 
also a topical treatment using a synthetic peptide derived from bovine indolicidin that is 
being trialled in the treatment of rosacea and catheter associated infections [147]. A 
final example is a synthetic peptide derived from LL-37, termed OP-145, that is being 
trialled in the treatment of chronic middle ear infection [148].  
 
The increasing recognition of AMPs as multifunctional mediators of immune responses 
has led to alternative methods of boosting endogenous AMPs to fight infection [149]. 
An alternative to direct AMP application has been proposed in the form of APEs. 
Examples of APEs include ultraviolet light, vitamin D, nucleic acids, endogenous 
interleukins, transcription factors or hormones, and bacterial, plant or fungal lysates 
[125]. These elicitors could act by upregulating expression of endogenous antimicrobial 
peptides to combat infection. However, this approach is still at the conceptual stage and 
may be more effective in treating disease associated with abnormal expression of 
AMPs.  
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1.4.6.3 Immunomodulatory activity 
The nature of the antimicrobial effects of cathelicidins revealed an important interaction 
with negatively charged molecules on bacterial cell walls. The ability of AMPs to bind 
free LPS led to investigations of their ability to attenuate LPS-induced effects on 
immune cells. Additionally, the realisation that antimicrobial peptides might be suitable 
substitutes for conventional antibiotics led to investigations of cytotoxicity in 
mammalian cells. These initial avenues of research have broadened to include specific 
interactions with different cell types. Several examples of the immunomodulatory 
effects of AMPs on neutrophils are provided in the following sections. General 
immunomodulatory effects are summarised in Table 1.3 and Table 1.4. 
 
The human cathelicidin AMP LL-37 induces several effects on human neutrophils via 
activation of fPRL1 and P2X7 receptors [150,151]. Activation induces intracellular 
calcium transients which mediate chemotaxis and ROS production. Other effects 
include induction of IL-8 expression [152] and induction of secondary necrosis in 
apoptotic neutrophils [153]. Multiple roles have also been identified for the porcine 
cathelicidin PR-39, including activation of neutrophil chemotaxis [154] and inhibition 
of respiratory burst [155]. Atlantic salmon cathelicidin AMPs can also induce 
expression of IL-8 in host neutrophils [156]. 
 
The effects of bovine cathelicidin AMPs on host defence have not been extensively 
studied. One minor study indicates that Bac5 and Bac7 are not able to induce bovine 
neutrophil or monocyte migration [117]. Another study found that BMAP-28 and 
BMAP-27 promote the secretion of TNFα from bovine MECs by an unknown 
mechanism [67]. In general, the remainder of the available research on the 
immunomodulatory properties of bovine cathelicidin AMPs has focused on their effects 
on non-bovine cells (Table 1.3), as a precursor to potential therapeutic antibiotic 
applications. This has left a large gap in the collective understanding of the roles that the 
different bovine cathelicidins carry out in host defence. 
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1.5 Aims  
The broad aim of this thesis was to investigate the role of bovine cathelicidins in host 
defence, in particular the effect of bovine cathelicidins on bovine neutrophil functions.  
 
The specific aims of this thesis were: 
 
1. To investigate the role of the bovine CLD in innate immune defence.  
 
2. To profile the immunomodulatory effects of the different bovine AMP domains 
on neutrophil function. 
 
3. To investigate the mechanism by which active bovine AMPs exert their 
immunomodulatory effects on neutrophils. 
 
 
 
Chapter 2: Materials and Methods 
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2.1 Peptide synthesis and preparation 
All peptides were synthesised by AusPep Proprietary Limited (Tullamarine, Australia) 
(Table 2.1). Mass and purity were determined by mass spectrometry (MS) and high 
performance liquid chromatography, respectively. The peptides were weighed and 
reconstituted to approximately 1 mM in endotoxin-free water. Serial dilutions of the 
1 mM stock were used to measure the actual concentration of peptide. For Bac1 and 
linear Bac1 a bicinchoninic acid (BCA) assay (section 2.3.3.3) was used to measure the 
actual concentrations of peptide serial dilutions. For all other peptides a NanoDrop ND-
1000 Spectrophotometer (Thermo Fisher Scientific New Zealand Ltd., North Shore 
City, New Zealand) was used to measure the concentration of serial dilutions based on 
extinction coefficients at 280 nm for peptides containing tryptophan or tyrosine (Bac5, 
indolicidin, BMAP-28, RITK), or 257 nm for peptides containing phenylalanine 
(BMAP-34 , LL-37) [190]. The 1 mM stock was then adjusted to approximately 
500 μM and retested. 
 
For fluorescein isothiocyanate (FITC)-conjugated Bac5 (Bac5-FITC) 
(excitation/emission 495 nm/519 nm), the peptide was reconstituted in dimethyl 
sulfoxide (Sigma-Aldrich, St Lewis, MO, USA) to approximately 5 mM. Serial 
dilutions of the 5 mM stock were measured for absorbance at 280 nm and 495 nm using 
a NanoDrop ND-1000 Spectrophotometer. Peptide concentration was determined using 
the equation given below [191], which takes into account FITC absorbance. The 5 mM 
stock was adjusted accordingly and retested. 
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Table 2.1 Synthetic peptide sequences 
Origin Peptide Sequence Weight (Da) 
Extinction 
coefficient 
(M-1cm-1) 
Bovine 
Cathelicidin-1 Bac1 
            ┌──────────┐ 
RLCRIVVIRVCR 1484 
125 
(280 nm) 
Bovine 
Cathelicidin-1 Linear Bac1 RLCRIVVIRVCR 1486 0 
Bovine 
Cathelicidin-2 Bac5 
RFRPPIRRPPIRPPFYPPFRPPIRPPIFPPIRPPF 
RPPLGPFP-NH2 5148 
1490 
(280 nm) 
Bovine 
Cathelicidin-2 Bac5-FITC 
FITC-RFRPPIRRPPIRPPFYPPFRPPIRPPIFPPIR 
PPFRPPLGPFP-NH2 5608 
1490 
(280 nm) 
Bovine 
Cathelicidin-4 Indolicidin ILPWKWPWWPWRR-NH2 1907 
27500 
(280 nm) 
Bovine 
Cathelicidin-5 BMAP-28 GGLRSLGRKILRAWKKYGPIIVPIIRI-NH2 3075 
6990 
(280 nm) 
Bovine 
Cathelicidin-7 BMAP-34 GLFRRLRDSIRRGQQKILEKARRIGERIKDIFR-NH2 4082 
390 
(257 nm) 
Human  
hCAP-18 LL-37 
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPR 
TES-OH 4493 
780 
(257 nm) 
Bovine 
Cathelicidin-1 RITK 
RITKQPWAPPQAA       
(putative 2nd cathelicidin-1 peptide) 1464 
5500 
(280 nm) 
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2.2 In-house antibody preparation 
2.2.1 Cathelicidin-specific A14 and A32 antibodies  
The A14 and A32 antibodies were prepared by Grant Smolenski (Food & Bio-based 
Products Group, AgResearch, New Zealand). Synthetic peptides (AusPep Proprietary 
Limited) were coupled to keyhole limpet haemocyanin (KLH) (Sigma-Aldrich). The 
peptide sequence for the A14 antibody was CNEQSSEPNIYRLLELDQ, which 
corresponds to a sequence which is conserved across all bovine CLDs. Hence the A14 
antibody binds to all bovine CLDs. The peptide sequence for the A32 antibody was 
CIRITKQPWAPPQAA, which corresponds to a specific sequence of bovine 
cathelicidin-1 CLD. Hence the A32 antibody only binds to the CLD of cathelicidin-1. 
Inoculation of rabbits and serum collection was carried out under animal ethics approval 
by Ric Broadhurst (Small Animal Colony, AgResearch, Ruakura, New Zealand). 
Purification of IgG antibody was carried out using a Protein A agarose column (Sigma-
Aldrich) and specificity for the target protein was verified by western blot. 
 
2.2.2 Transcobalamin II antibody 
Anti-transcobalamin II (TCII) antibody was prepared by Tanu Gupta (Food & Bio-
based Products Group, AgResearch, New Zealand). A synthetic peptide (AusPep 
Proprietary Limited) with the sequence SQLKRFLEDEKRAIGH, corresponding to a 
sequence within bovine transcobalamin II, was coupled to KLH. Inoculation of rabbits 
and serum collection was carried out under animal ethics approval by Ric Broadhurst. 
Purification of IgG antibody was carried out using a Protein A agarose column and 
specificity for the target protein was verified by western blot. 
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2.3 Molecular biology techniques 
2.3.1 Protein expression 
2.3.1.1 Open reading frame selection, PCR and cloning 
Cathelicidin-1 open reading frame PCR, PCR site-directed mutagenesis and cloning into 
Novagen pET-45b(+) vector (EMD Millipore, MA, USA) was previously carried out by 
Brendan Haigh (Food & Bio-based Products Group, AgResearch, New Zealand). This 
generated plasmid vectors encoding the CLD of cathelicidin-1 (pET_Cath1_15/13new5; 
Q30 to A143, P22226 [91]) to express recombinant bovine CLD (rbCLD), and a full 
length cathelicidin-1 protein containing an A143 to F143 mutation (pET_Cath1_NER2; 
Q30 to R155, P22226 [91]) to express recombinant bovine Cath1 (rbCath1). The 
mutation in rbCath1 was designed to prevent proteolytic cleavage of Bac1 AMP from 
the CLD. 
 
2.3.1.2 Transformation 
Novagen E. coli Origami (EMD Millipore) were transformed with 1 µl of each plasmid 
by incubating on ice for 5 minutes, incubating at 42 °C for 30 seconds and returning to 
ice for 2 minutes. Control transformations contained no plasmid. Cells were 
supplemented with 250 µl super optimal broth with catabolite repression media (SOC 
media, Life Technologies Inc., NY, USA) and incubated for 60 minutes at 37 °C. The 
cells were centrifuged and 50 µl suspensions were plated on Luria broth agar plates 
containing kanamycin, tetracycline and ampicillin antibiotics (LB/kan/tet/amp agar) 
(Appendix 2) and incubated overnight at 37 °C. 
 
2.3.1.3 Small scale expression test 
Colonies from each transformation were used to inoculate 2 ml LB/kan/tet/amp 
(Appendix 2) which were incubated overnight with shaking at 37 °C. Each overnight 
culture was added to 50 ml LB/kan/tet/amp in 250 ml flasks and incubated with shaking 
at 37 °C. The optical density at 600 nm (OD600) was measured using an Eppendorf 
Biophotometer (Eppendorf, Hamburg, Germany). Incubation was stopped when the 
OD600 reached 0.7 AU. A 2 ml sample of uninduced culture was removed for sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis 
(section 2.3.3.4). The remaining culture was induced with 62.5 µl 0.8 M isopropyl β-D-
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1-thiogalactopyranoside (IPTG) (Life Technologies Inc.) and incubated for 90 minutes 
or 180 minutes at 37 °C. A 2 ml sample of induced culture was removed for SDS-PAGE 
analysis. 
 
The pellets of samples for SDS-PAGE analysis were weighed and resuspended in 
5× Tris-ethylenediaminetetraacetic acid (EDTA) (5× TE) (Appendix 2) containing 
complete EDTA-free protease inhibitors (Roche Diagnostics N.Z., Ltd., Auckland, New 
Zealand). The cells were sonicated (Vibra Cell sonicator, Sonics & Materials Inc., CT, 
USA) on ice five times with 10 second bursts. The lysed cells were centrifuged at 
10,000 × g for 10 minutes at 4 °C. The supernatant was removed (soluble protein 
fraction) and 10 µl was prepared for SDS-PAGE. The pellet was resuspended in 5× TE 
at 10 ml/g of pellet (insoluble protein fraction) and 10 µl was prepared for SDS-PAGE. 
 
2.3.1.4 Glycerol stock 
Two aliquots of 0.5 ml uninduced culture were added to 0.5 ml 80% (v/v) glycerol 
(Thermo Fisher Scientific New Zealand Ltd.), rotated for 30 minutes at room 
temperature and stored at -80 °C. 
 
2.3.1.5 Large scale expression of rbCLD 
Two 5 ml overnight cultures inoculated from glycerol stock were added to two 2 L 
flasks containing 500 ml LB/kan/tet/amp, and incubated with shaking at 37 °C until the 
OD600 reached 0.7 AU. Samples were taken as described in section 2.3.1.3 and analysed 
by SDS-PAGE. The cultures were induced with 625 µl 0.8 M IPTG and incubated for 
3 hours at 37 °C. The cultures were centrifuged at 6000 rpm for 15 minutes at 4 °C. The 
supernatant was discarded and the pellets transferred into two 50 ml tubes and frozen at 
-80 °C until required. 
 
2.3.1.6 Large scale expression of rbCath1 
Two 3 ml overnight cultures inoculated from glycerol stock were added to two 1 L 
flasks containing 200 ml LB/kan/tet/amp and incubated with shaking at 37 °C until the 
OD600 reached 0.7 AU. Samples were taken as described in section 2.3.1.3 and analysed 
by SDS-PAGE. The cultures were induced with 250 µl 0.8 M IPTG and incubated for 
Chapter 2: Materials and Methods  37 
 
 
3 hours at 37 °C. The cultures were centrifuged at 6000 rpm for 15 minutes at 4 °C. The 
supernatant was discarded and the pellets transferred into two 50 ml tubes and frozen at 
-80° C until required. 
 
2.3.2 Protein purification 
2.3.2.1 Column preparation and storage 
A 1 ml HisTrap Fast Flow immobilised metal ion affinity chromatography (IMAC) 
column (GE Healthcare Ltd., Auckland, New Zealand) was prepared by flushing with 
3 column volumes (CV) of column stripping solution (Appendix 2) followed by 10 CV 
of milli-Q water (MQ.H2O). The column was loaded with Ni2+ by passing 1 CV of 
nickel loading solution (Appendix 2) through the column, followed by 10 CV of 
MQ.H2O to remove excess Ni2+. The column was then equilibrated with 6 CV of 
appropriate buffer. After use the column was cleaned by passing 10 CV of lysis buffer 
A (Appendix 2) through the column, followed by 10 CV MQ.H2O, then 3 CV of 
column storage solution (Appendix 2). 
 
2.3.2.2 IMAC purification of rbCLD 
The pellets from section 2.3.1.5 were resuspended in lysis buffer A containing 1 mg/ml 
lysozyme (Sigma-Aldrich) and complete EDTA-free protease inhibitors, and incubated 
on ice for 30 minutes. The cells were sonicated on ice five times with 30 second bursts. 
The lysed cells were centrifuged at 10,000 × g for 10 minutes at 4 °C. The pellet was 
retained for SDS-PAGE analysis. The supernatant was loaded onto a 1 ml HisTrap FF 
column, pre-equilibrated with lysis buffer A, through a 0.45 µm filter (Sartorius, 
Göttingen, Germany). The column was flushed with 10 CV wash buffer A 
(Appendix 2). The flow through was collected in 15 ml tubes. A second wash of 10 CV 
was performed and the flow through was collected. Six CV of elution buffer A 
(Appendix 2) was then passed through the column and the flow through was collected. 
The elution procedure was repeated and the flow through was collected in a separate 
tube. Aliquots of 20 µl were taken from each flow through collection for SDS-PAGE 
analysis. Imidazole was removed from the elution fractions by buffer exchange with 
dialysis buffer (Appendix 2) using a Vivaspin 6 centrifugal concentrator with 10 kDa 
molecular weight cut-off (GE Healthcare Ltd.). 
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2.3.2.3 IMAC purification and on-column refolding of rbCath1 
The pellets from section 2.3.1.6 were prepared as described in section 2.3.2.2 using lysis 
buffer B (Appendix 2). The supernatant was loaded onto a 1 ml HisTrap FF column, 
pre-equilibrated with lysis buffer B, through a 0.45 µm filter. The column was flushed 
with 6 CV wash buffer B (Appendix 2) and the flow through was collected. The column 
was then connected to an AKTA Explorer system (GE Healthcare Ltd.) equilibrated 
with wash buffer B. The system was then programmed (UNICORN software, GE 
Healthcare Ltd.) to run a gradient of 0% to 100% refold buffer B (Appendix 2) over 
4 hours. The flow through of the gradient was collected. The column was then removed 
from the system and refolded protein eluted with 10 CV elution buffer B (Appendix 2). 
Aliquots of 20 µl were taken from each flow through for SDS-PAGE analysis. 
Trichloroacetic acid (TCA) precipitation (section 2.3.3.1) was used to remove guanidine 
hydrochloride from samples prior to SDS-PAGE analysis. To remove imidazole and 
glycerol from the elution fraction, refolded rbCath1 was dialysed against dialysis buffer 
(Appendix 2) using Spectra/Por 6 dialysis membrane (3,500 Da, Spectrum Laboratories 
Inc., CA, USA). 
 
2.3.2.4 Concentration of purified protein 
Both recombinant proteins were concentrated using a Vivaspin 500 centrifugal 
concentrator with 10 kDa molecular weight cut-off (GE Healthcare Ltd.). Correct 
expression of rbCLD and rbCath1 was determined by western blot analysis 
(section 2.3.3.5). Primary antibody incubation was for 2 hours at room temperature 
using rabbit A32 antibody (section 2.2.1) diluted 1:10,000 in antibody diluent A 
(Appendix 2). Secondary antibody incubation was for 1 hour at room temperature using 
peroxidase-conjugated goat anti-rabbit antibody (A6154, Sigma-Aldrich) diluted 
1:10,000 in antibody diluent A. MS was also used to confirm rbCLD expression 
(section 2.8.1). 
 
2.3.2.5 His·Tag removal 
A Novagen recombinant enterokinase (rEK) cleavage-capture kit (EMD Millipore) was 
used to remove the His·Tag from recombinant protein according to the manufacturer’s 
instructions. Recombinant protein was dialysed with 1× rEK cleavage capture buffer 
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(Appendix 2) to prevent inhibition of rEK by elution buffer components. The system 
was then optimised for incubation time and enzyme to target protein ratio. Free His·Tag 
was removed from solution by passage through an IMAC column. The flow through 
containing the target protein was concentrated by centrifugation with buffer exchange as 
described in section 2.3.2.4. 
 
2.3.3 Protein detection 
2.3.3.1 TCA precipitation 
To precipitate protein from solution, one volume of 90% TCA (Riedel-de-Haën, Seelze, 
Germany) was added to four volumes of protein solution and incubated for 10 minutes 
on ice. Precipitated protein was centrifuged at 13,000 rpm for 5 minutes at 4 °C. The 
supernatant was discarded and the pellet was washed with 200 µl cold acetone (Thermo 
Fisher Scientific New Zealand Ltd.). The wash procedure was repeated and the pellet 
dried by heating at 95 °C for 10 minutes. The dried pellet was then prepared for SDS-
PAGE analysis (section 2.3.3.4). 
 
2.3.3.2 Bio-Rad Protein assay 
The Bio-Rad Protein assay (Bio-Rad, Richmond, CA, USA) is based on the colour 
change of Coomassie Brilliant Blue (CBB) G-250 when protein binding occurs. The 
following protocol is based on the manufacturer’s instructions. Bovine serum albumin 
(BSA) (Sigma-Aldrich) standards were made by diluting 2 mg/ml BSA stock in the 
unknown sample buffer to create six standards from 30 µg/ml to 180 µg/ml. Several 
dilutions of the unknown samples were also prepared in the same buffer. A Bio-Rad 
Protein assay working solution was made by diluting the assay dye concentrate 1:5 in 
MQ.H2O. In 1.5 ml tubes, 900 µl of assay working solution was added to 100 µl of 
standards and 100 µl of unknown samples and dilutions. Each solution was transferred 
to an Eppendorf UVette with 1 cm light path (Eppendorf, Hamburg, Germany) and the 
absorbance was measured at 595 nm in a Shimadzu UV-160A spectrophotometer 
(Shimadzu, Kyoto, Japan). 
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2.3.3.3 BCA assay 
The BCA assay is based on the formation of Cu2+-protein complexes under alkaline 
conditions, followed by reduction of Cu2+ to Cu1+. The following protocol is from the 
technical bulletin of the BCA protein assay kit (BCA1, Sigma-Aldrich) based on the 
method of Smith, et al. [192]. BSA standards were made by diluting a 2 mg/ml BSA 
stock in the unknown sample buffer to create eight standards from 25 µg/ml to 2 mg/ml. 
Several dilutions of the unknown samples were also prepared in the same buffer. The 
BCA working reagent was made by diluting 4% (w/v) copper (II) sulfate pentahydrate 
solution 1:8 in bicinchoninic acid solution. In 96-well flat bottom plates (Nunc, 
Denmark), 200 µl of BCA working reagent was added to 25 µl of standards in duplicate 
and 25 µl of unknown samples and dilutions in duplicate. The plate was incubated for 
30 minutes at 37 °C and the absorbance measured at 562 nm with a Synergy 2 multi-
mode microplate reader (BioTek Instruments Inc., VT, USA). Data were analysed with 
Gen5 software (BioTek Instruments Inc.). 
 
2.3.3.4 SDS-PAGE analysis 
2.3.3.4.1 Preparation of samples 
Samples for SDS-PAGE analysis were prepared by adding appropriate volumes of 
3× sample loading buffer (SLB) (Appendix 2) and MQ.H2O to protein solutions or 
precipitates. All samples were boiled for 10 minutes and allowed to cool before loading. 
Typical loading volumes were between 5 μl and 10 μl for mini polyacrylamide gels or 
between 10 μl and 20 μl for precast polyacrylamide gels. A range of protein molecular 
weight standards were used for each electrophoresis run depending on the procedures 
subsequent to electrophoresis. These standards were SeeBlue Plus2 Pre-Stained 
Standard (Life Technologies Inc.), Precision Plus Protein WesternC Standards (Bio-
Rad), and Natural Unstained Broad Range SDS-PAGE Standards (Bio-Rad). 
 
2.3.3.4.2 In-house mini polyacrylamide gels 
Mini gels were made using a Mini-Protean 3 Cell (Bio-Rad) according to the 
instructions provided. The compositions of mini gels are provided in Table 2.2. The gels 
were run in a mini tank using 1× running buffer (Appendix 2) at a constant voltage of 
200 V for 70 minutes. 
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Table 2.2 Mini polyacrylamide gel composition 
Reagent Stacking gel 10% Resolving gel 14% Resolving gel 
30% (w/v) Acrylamidea 0.66 ml 3.33 ml 4.67 ml 
4× stacking bufferb 1.23 ml - - 
4× resolving bufferb - 2.5 ml 2.5 ml 
MQ.H2O 3.08 ml 4.17 ml 2.33 ml 
10% (w/v) APSa 25 µl 30 µl 30 µl 
TEMEDa 10 µl 10 µl 10 µl 
afrom Bio-Rad; bsee Appendix 2. 
 
2.3.3.4.3 Precast polyacrylamide gels 
Criterion XT 12% Bis-Tris precast gels (Bio-Rad) were used prior to western blot or 
far-western blot procedures. The gels were run in a Criterion Cell buffer tank (Bio-Rad) 
using 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (Life Technologies Inc.) at 
a constant voltage of 160 V for 70 minutes. 
 
2.3.3.4.4 CBB R-250 stain 
Polyacrlyamide gels were fixed in fixative/destain solution (Appendix 2) for 30 minutes 
at room temperature, briefly rinsed in MQ.H2O and stained with CBB R-250 stain 
solution (Appendix 2) for 60 minutes at room temperature. The gels were destained with 
fix/destain solution at room temperature until the background was clear and analysed as 
described in section 2.3.3.9. 
 
2.3.3.5 Western blot procedure 
An electrotransfer cassette was prepared under N-cyclohexyl-3-aminopropanesulfonic 
acid (CAPS) transfer buffer (Appendix 2) by layering blotting pad, two sheets of pre-
soaked Whatman 3MM chromatography paper (GE Healthcare Ltd.), electrophoresed 
polyacrylamide gel, pre-soaked BioTrace NT nitrocellulose membrane (Pall 
Corporation, FL, USA), two sheets of pre-soaked 3MM and the top blotting pad. The 
stack was rolled to remove air bubbles and the cassette transferred to a blotting tank 
containing CAPS transfer buffer. The gel was transferred for 2 hours at 50 V.  
 
After transfer the cassette was disassembled and the membrane was stained for 
5 minutes in Ponceau S stain (Appendix 2) and analysed as described in section 2.3.3.9. 
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The membrane was then transferred to blocking solution A (Appendix 2) for 16 hours at 
4 °C. After blocking, and after primary and secondary antibody incubations, the 
membrane of each western blot was washed three times for 5 minutes in wash solution 
A (Appendix 2). Primary and secondary antibody incubation conditions were optimised 
for the detection of the specific protein. These conditions are stated in the sections 
where the western blot procedure was applied. Bound antibody was visualised using 
enzyme-linked chemiluminescence (ECL) (section 2.3.3.7). 
 
2.3.3.6 Dot blot procedure 
Dot blots were carried out using a Bio-Dot SF blotting apparatus (Bio-Rad). Samples 
were blotted onto BioTrace NT nitrocellulose membrane according to the instructions 
provided. The apparatus was disassembled and the membrane was stained for 5 minutes 
in Ponceau S stain and analysed as described in section 2.3.3.9. The membrane was then 
transferred to blocking solution A for 16 hours at 4 °C. After blocking, and after 
primary and secondary antibody incubations, the membrane of each dot blot was 
washed three times for 5 minutes in wash solution A (Appendix 2). Primary and 
secondary antibody incubation conditions were optimised for the detection of the 
specific protein. These conditions are stated in the section where the dot blot procedure 
was applied. Bound antibody was visualised using ECL. 
 
2.3.3.7 ECL detection 
For ECL detection of bound antibody, an ECL solution was made containing 220 μg/ml 
luminol (Sigma-Aldrich), 11.2 μg/ml p-coumaric acid (Sigma-Aldrich), and 0.01% (v/v) 
H2O2 (Thermo Fisher Scientific New Zealand Ltd.) in 100 mM Tris (pH 8.6) (Fisher 
BioReagents, NJ, USA). Following the final wash after secondary antibody incubation, 
the membrane was incubated in the ECL solution for 2 minutes. Photographic film 
(Kodak, Radiographic Supplies Ltd., New Zealand) was then exposed to the membrane 
in a light-free cassette (Kodak, Radiographic Supplies Ltd.). The developed 
photographic film was analysed as described in section 2.3.3.9. 
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2.3.3.8 Far-western blot procedure 
After SDS-PAGE, a transfer cassette was assembled with PVDF membrane (Bio-Rad) 
as described in section 2.3.3.5. After transfer the cassette was disassembled and the 
membrane was stained for 5 minutes in Ponceau S stain and analysed as described in 
section 2.3.3.9. The membrane was then transferred to blocking solution B 
(Appendix 2) for 16 hours at 4 °C. After blocking, and after probe incubations, the 
membrane of each far-western blot was washed three times for 5 minutes in wash 
solution B (Appendix 2). Probe incubation conditions were optimised to improve signal 
to noise ratio. These conditions are stated in the sections where the far-western blot 
procedure was applied. Bound probe was visualised and analysed as described in 
section 2.3.3.9. 
 
2.3.3.9 Semi-quantitative analysis of polyacrylamide gels and membranes 
Stained polyacrylamide gels, membranes stained with Ponceau S, and developed 
photographic film were scanned using a GS800 Calibrated Densitometer (Bio-Rad) and 
analysed using Quantity One 1-D analysis software (v4.5.2, Bio-Rad). 
 
Unstained polyacrylamide gels containing Bac5-FITC, and far-western blot membranes 
probed with Bac5-FITC were scanned using a Molecular Imager FX (Bio-Rad) with 
488 nm excitation laser. Images were analysed using Quantity One 1-D analysis 
software. 
  
Chapter 2: Materials and Methods  44 
 
 
2.4 LPS-binding assays 
2.4.1 Recombinant cathelicidin LPS-binding assay 
Purified rbCLD, rbCath1, native Cath1, LBP and casein were diluted to 10 µg/ml in 
phosphate buffered saline (PBS) (Appendix 2) and plated in 50 μl triplicates in flat-
bottomed 96-well microplates (MaxiSorp, Nunc). The microplates were incubated for 
16 hours at room temperature then washed three times with wash solution A 
(Appendix 2) between each step. Plates were blocked with 1% (w/v) casein in PBS for 
2 hours followed by 1 µg/ml biotin-conjugated LPS (Sigma-Aldrich) for 1 hour. Bound 
LPS was visualised with streptavidin-conjugated horseradish peroxidase (HRP) 
(Biogenex, CA, USA) diluted 1:3000 and 3,3',5,5'-tetramethylbenzidine (TMB) 
substrate (Life Technologies Inc.). The reaction was stopped with 1 M H2SO4 and the 
absorbance measured at 450 nm using a Synergy2 multi-mode microplate reader and 
Gen5 software. 
 
2.4.2 Cathelicidin AMP LPS-binding assay 
The bovine cathelicidin AMPs Bac1, linear Bac1, Bac5, indolicidin, BMAP-28 and 
BMAP-34 were tested in this assay. The human cathelicidin AMP LL-37 was also 
tested. A chromogenic Limulus amoebocyte lysate assay kit (Kinetic-QCL assay kit, 
Lonza, MD, USA) was used to measure cathelicidin AMP-LPS binding. LPS-binding 
assays were carried out in 5 ml glass tubes, sterilised by heating at 250 °C for 1 hour. 
Duplicate titrations of AMP were prepared in endotoxin-free water at a final volume of 
54 µl. LPS (from E. coli strain 055:B5) was reconstituted at 50 EU/ml in endotoxin-free 
water and an LPS working dilution of 5 EU/ml prepared. Each AMP titration was then 
mixed with 6 µl LPS working dilution, giving a final LPS concentration of 0.5 EU/ml. 
Standards containing 0.5 EU/ml LPS alone, and negative controls containing endotoxin-
free water were also prepared. Tubes were incubated with continuous shaking for 
30 minutes at 37 °C. After incubation, 50 µl of controls and samples were dispensed 
into a sterile 96-well tissue culture plate (Nunc) and 50 µl of Kinetic-QCL reagent was 
added. Absorbance was measured at 405 nm every 90 seconds for 1 hour using a 
Synergy 2 multi-mode microplate reader and Gen5 software. Free LPS was calculated 
from absorbance curves for each sample and compared to the 0.5 EU/ml LPS standards 
to determine the proportion of LPS bound to AMP. 
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2.5 Microbial assays 
2.5.1 Microbe preparation 
Preparation of microbe titres was carried out by Megan Callaghan (Food & Bio-based 
Products Group, AgResearch, New Zealand). The bacteria Escherichia coli (DNZ-1 
isolate, DairyNZ, Newstead, Hamilton), Streptococcus uberis (strain ATCC BAA-854 / 
0140J, American Type Culture Collection, VA, USA), Staphylococcus aureus (isolate 
2057, isolated in-house, AgResearch, Food & Bio-based Products Group, New 
Zealand), Salmonella enterica subspecies enterica (strain ATCC 14028, American Type 
Culture Collection), were cultured in Mueller-Hinton broth (Fort Richard Laboratories 
Ltd., Auckland, New Zealand) overnight at 37 °C. The fungus Candida albicans (strain 
ATCC 10231, American Type Culture Collection) was cultured in either RPMI 1640 
medium (Life Technologies Inc.) or Sabouraud B media (Fort Richard Laboratories 
Ltd.) overnight at 37 °C. A 1 ml aliquot was removed from each strain and centrifuged 
at 5,000 rpm for 10 minutes. The pellet was washed with 1 ml PBS. 
 
2.5.2 Microbial agglutination 
Microbes were prepared as described in section 2.5.1 and resuspended in 1 ml PBS 
containing 0.1% (w/v) Crystal Violet (BDH Chemicals, Poole, England). Recombinant 
rbCLD, rbCath1 and native Cath1 protein were titrated 2-fold from 20 µg/ml to 5 µg/ml 
in 100 µl PBS containing 0.1% Crystal Violet. Control wells contained either no protein 
or equal amounts of A32 antibody (section 2.2.1) which was used to purify native 
Cath1. An equal volume of microbe solution was added and agglutination assessed 
visually after incubating for 1 hour or 3 hours at room temperature using an Olympus 
CK2 inverted microscope (Olympus America Inc., NY, USA). Agglutination was 
subjectively judged as absent (0%), minimal (<25%), moderate (25-75%), or severe 
(>75%). 
 
2.5.3 Minimal inhibitory concentration determination 
The minimal inhibitory concentration (MIC) of a synthetic version of a putative second 
AMP generated from bovine cathelicidin-1 was investigated in this assay (see section 
2.7.1 and 2.7.2). The peptide was tentatively called RITK after the first four amino acids 
of its sequence (Table 2.1). The MIC assay was based on a standard modified microtitre 
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broth dilution method [193]. Microbes were prepared as described in section 2.5.1. 
S. enterica was omitted from this assay. The microbial cultures were diluted in fresh 
culture media to give 0.4-1.4 × 106 cfu/ml. The RITK peptide was diluted in fresh 
culture media to give two-fold serial dilutions from 200 µM to 16 µM. The microbial 
dilutions were dispensed into sterile 96-well polypropylene microplates (Nunc) in 50 µl 
duplicates, and 50 µl of the peptide serial dilutions were added. Wells containing 
microbes without peptide served as negative controls and wells containing media alone 
served as sterility controls. The plates were incubated for 24 hours at 37 °C. After 
incubation, 1 µl from each well was diluted in 1 ml fresh media and plated on Mueller-
Hinton agar plates (Fort Richard Laboratories Ltd.) or Sabouraud dextrose agar plates 
(Fort Richard Laboratories Ltd.) and incubated for 18 hours at 37 °C. The MIC was 
determined as the lowest concentration of peptide that prevented any residual colony 
formation. 
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2.6 Neutrophil function assays 
The method for each neutrophil function assay is provided in this section. Where 
indicated by italics, each method is subdivided into recombinant protein assays, primary 
screening assays, or dose-response assays to describe assay modifications. In general, 
the recombinant protein assays examined rbCLD and rbCath1 activity. As an initial 
means of identifying bovine cathelicidin AMPs that modify neutrophil function, the 
primary screening assays examined Bac1, linear Bac1, Bac5, indolicidin, BMAP-28 and 
BMAP-34 at a fixed concentration of 5 µM. The peptides which exhibited a significant 
ability to modify neutrophil function were examined in the dose-response assays. These 
peptides were linear Bac1, Bac5 and BMAP-34, which were assayed in two-fold 
titrations from 10 µM to 0.16 µM unless otherwise indicated. 
 
2.6.1 Preparation of neutrophils from bovine blood 
Bovine neutrophils were isolated based on a previously described method [194]. Whole 
bovine blood was obtained from freshly killed cattle at a local abattoir (Ruakura 
Abattoir, Ruakura Road, Hamilton, New Zealand or Taylor Preston Limited, 131 
Centennial Highway, Ngauranga, Wellington, New Zealand) using 10% (w/v) EDTA as 
anticoagulant.  
 
Blood was centrifuged at 860 × g for 30 minutes at 4°C. Plasma, buffy coat and one-
third of the red blood cell (RBC) pellet were removed by aspiration. An equal part ice-
cold sterile MQ.H2O was added to the RBC pellet and inverted for 30 seconds to lyse 
RBCs, followed by an equal part ice-cold 3 RPMI 1640 media to restore tonicity. This 
procedure was repeated and the cell pellet was washed with ice-cold Hank’s Balanced 
Salt Solution (HBSS) (Life Technologies Inc.) before layering 7 ml of cell suspension 
over 5 ml Lymphoprep (Medica Limited, Auckland, New Zealand). The density 
gradient was centrifuged at 800 × g for 10 minutes at 4 °C. The supernatant containing 
peripheral blood mononuclear cells was discarded and the granulocyte pellet was 
washed with ice-cold HBSS and resuspended in appropriate media for experiments.  
 
The concentration of granulocytes was determined by haemocytometer (Neubauer 
Improved Chamber, Blau Brand, Germany) and the viability was determined by trypan 
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blue exclusion (0.4% trypan blue stain, Life Technologies Inc.). To determine purity, 
cell preparations were stained using a Kwik Diff Stain kit (Thermo Fisher Scientific) 
and cell types counted using an Olympus BH2 microscope (Olympus America Inc.) and 
Image-Pro plus v7.0.0.591 software (Media Cybernetics, Inc., USA). 
 
2.6.2 Detection of apoptotic and necrotic cells 
Neutrophils were plated in duplicate in sterile 2-methacryloxyethyl phosphorylcholine 
(MCP)-treated 96-well round-bottom plates (Nunc) at 5 × 105 cells/well in RPMI 1640 
medium (Appendix 2). The cells were left inactivated (naïve) or were activated with 
100 ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) at the same time as 
AMP treatment.  
 
Primary screening assays 
Neutrophils were treated with 5 μM AMP for 1 hour at 37 °C. The cells were then 
washed with excess RPMI 1640 medium followed by 1× annexin-V binding buffer 
(Appendix 2). The cells were stained with FITC-annexin-V (BD Biosciences, CA, 
USA) diluted 1:100 in 1× annexin-V binding buffer for 30 minutes on ice. The cells 
were then washed with PBS and incubated with 1 μg/ml propidium iodide (PI) (Sigma-
Aldrich) for 15 minutes on ice. The cells were washed with ice-cold PBS and kept at 
4 °C until flow cytometry analysis (section 2.6.10). 
 
Dose-response assays 
Neutrophils were treated with titrations of AMP for 1 hour or 6 hours at 37 °C. The 
cells were then washed with excess RPMI 1640 medium followed by PBS containing 
2 mM EDTA to prevent cell clumping. The cells were stained with LIVE/DEAD 
Fixable Red Dead Cell stain (Life Technologies Inc.) diluted 1:1000 in PBS containing 
2 mM EDTA for 30 minutes on ice. The cells were washed with excess 1× annexin-V 
binding buffer and incubated with Pacific Blue-annexin-V (BioLegend, CA, USA) 
diluted 1:200 in annexin-V binding buffer for 30 minutes on ice. The cells were washed 
with PBS and fixed in PBS containing 4% (w/v) paraformaldehyde (Fisher 
BioReagents, NJ, USA) and kept at 4° C before preparation for analysis by flow 
cytometry. 
 
Chapter 2: Materials and Methods  49 
 
 
2.6.3 Detection of membrane permeabilisation 
Recombinant protein assays 
Neutrophils suspended at 1  107 cells/ml in PBS were dispensed in duplicate in sterile 
5 ml tubes (BD Biosciences) at 1  106 cells/tube. For measurement of rbCLD, rbCath1 
and native Cath1 membrane permeabilisation, cells were treated with 70 nM or 700 nM 
rbCLD, rbCath1 or native Cath1 for 30 minutes at room temperature. The cells were 
stained with 2 μg/ml PI in PBS for 5 minutes at room temperature and placed on ice 
until analysis by flow cytometry. 
 
Primary screening assays 
Neutrophils were plated in triplicate in sterile 96-well black-wall fluorescence plates 
(Nunc) at 5 × 105 cells/well in RPMI 1640 medium. The cells were left inactivated 
(naïve) or were activated with 100 ng/ml PMA at the same time as AMP treatment. The 
cells were treated with 5 μM AMP and 5 μM of the cell impermeant fluorescent dye 
SYTOX Orange (excitation/emission 547 nm/570 nm) (Life Technologies Inc.) for 
1 hour at 37 °C. Fluorescence was measured with a Synergy 2 multi-mode microplate 
reader every 20 seconds for 1 hour with excitation and emission filters set at 528/20 nm 
and 590/20 nm, respectively. Data were analysed with Gen5 software. 
 
2.6.4 Migration 
A modified 48-well Boyden chamber kit (Neuro Probe Inc., Gaithersburg, MD, USA) 
was used for all migration assays. Neutrophils were diluted to 5  106 cells/ml in Hank’s 
Balanced Salt Solution containing Ca2+ and Mg2+ (HBSS2+) (Life Technologies Inc.) 
with 1% (w/v) BSA (referred to as assay media). Recombinant human IL-8 (R&D 
Systems, Inc., Minneapolis, MN, USA) diluted to 5 ng/ml in assay media served as a 
positive control for migration [40]. Wells containing assay media alone served as 
negative controls. 
 
Primary screen assays 
Lower wells of the chamber were loaded in duplicate with 5 μM AMP in assay media. 
The chamber was assembled with 3 µm pore polycarbonate membrane, gasket and top 
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plate as per the instructions provided. The wells of the top plate were loaded with 50 μl 
neutrophil suspension and the chamber was incubated for 45 minutes at 37 °C.  
 
Dose-response assays 
Lower wells of the chamber were loaded in duplicate with titrations of AMP in assay 
media. The 3 µm pore polycarbonate membranes were coated in type I collagen (Sigma-
Aldrich) for 2 hours at 37 °C, rinsed with assay media, and sterilised by UV light 
exposure for 30 minutes. The chamber was assembled with membrane, gasket and top 
plate as per the instructions provided. The wells of the top plate were loaded with 50 μl 
neutrophil suspension and the complete chamber was incubated for 1 hour at 37 °C. 
 
After incubation the chamber was disassembled. The top side of the membrane was 
scraped to remove non-migrated cells and left to air dry. Migrated cells left on the 
bottom side of the membrane were fixed in 100% methanol (Fisher Scientific, 
Loughborough, UK) and stained with Kwik Diff Stain Kit. Stained membranes were 
mounted under glass coverslips with microscopy immersion oil (Sigma-Aldrich) and the 
edges were sealed with DPX mountant (BDH Chemicals). Five random microscope 
fields were counted for each well using a 20 objective on an Olympus BH-2 (Olympus 
America Inc.) microscope. The mean of duplicates was used to calculate the migration 
index, defined as the number of migrating cells in response to treatment divided by the 
number of migrating cells in the absence of treatment. 
 
2.6.5 Degranulation 
Neutrophils were plated in triplicate in sterile 96-well tissue culture plates at 
1  106 cells/well in HBSS2+. The cells were left inactivated (naïve) or were activated 
with 100 ng/ml PMA at the same time as AMP treatment.  
 
Primary screening assays 
Neutrophils were treated with 5 μM AMP for 1 hour at 37 °C. The cells were 
centrifuged at 1500 rpm for 5 minutes. The supernatant was removed for analysis of 
primary (section 2.6.5.1) and large (section 2.6.5.3) granule release, and secretory 
vesicle release (section 2.6.5.4). 
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Dose-response assays 
Neutrophils were treated with titrations of AMP for 1 hour or 6 hours at 37 °C. The 
cells were centrifuged at 1500 rpm for 5 minutes. The supernatant was removed for 
analysis of primary, secondary (section 2.6.5.2) and large granule release. 
 
2.6.5.1 Measurement of primary granule release 
Primary granule release was measured by myeloperoxidase (MPO) activity in 
supernatants [195]. To determine total MPO activity 1  106 neutrophils were 
suspended in an equal volume of 50 mM KH2PO4 with 0.5% (v/v) hexadecyltrimethyl 
ammonium bromide, sonicated on ice and centrifuged to remove insoluble material. The 
supernatant was removed and used to form a standard curve of total MPO activity. MPO 
activity was measured by adding 100 μl TMB substrate to 50 μl supernatant and 
incubating for 30 minutes at room temperature. The reaction was stopped by adding 
50 μl 1 M H2SO4. Absorbance was measured at 450 nm using a Synergy 2 multi-mode 
microplate reader and Gen5 software. 
 
2.6.5.2 Measurement of secondary granule release 
Dose-response assays 
Secondary granule release was measured by release of transcobalamin II [47,196] into 
culture supernatants. Triplicate supernatants were pooled and the protein was 
concentrated by TCA precipitation (section 2.3.3.1). The precipitated protein was 
resuspended in 20 μl 3× SLB (Appendix 2), boiled for 10 minutes, and analysed by 
western blot (section 2.3.3.5). Primary antibody incubation was for 3 hours at room 
temperature using rabbit anti-transcobalamin II antibody (section 2.2.2) diluted 1:10,000 
in antibody diluent A (Appendix 2). Secondary antibody incubation was for 1 hour at 
room temperature using peroxidase-conjugated goat anti-rabbit antibody diluted 
1:10,000 in antibody diluent A. 
 
2.6.5.3 Measurement of large granule release 
Primary screening assays 
Large granule release was measured by release of CLD [45] into culture supernatants. 
Triplicate supernatants were pooled and 5 μl supernatant was mixed with 10 μl 3× SLB, 
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boiled for 10 minutes and analysed by western blot (section 2.3.3.5). Primary antibody 
incubation was for 2 hours at room temperature using rabbit A14 antibody 
(section 2.2.1) diluted 1:20,000 in antibody diluent A. Secondary antibody incubation 
was for 1 hour at room temperature using peroxidase-conjugated goat anti-rabbit 
antibody diluted 1:20,000 in antibody diluent A. 
 
Dose-response assays 
Large granule release was measured by release of CLD [45] into culture supernatants. 
Triplicate supernatants were pooled and 5 μl supernatant was diluted 20-fold and 
analysed by dot blot (section 2.3.3.6). Primary antibody incubation was for 2 hours at 
room temperature using rabbit A14 antibody diluted 1:20,000 in antibody diluent A. 
Secondary antibody incubation was for 1 hour at room temperature using peroxidase-
conjugated goat anti-rabbit antibody diluted 1:20,000 in antibody diluent A. 
 
2.6.5.4 Measurement of secretory vesicle release 
Primary screen assays 
Secretory vesicle release was measured by alkaline phosphatase [47] activity in culture 
supernatants based on a previously described method [197]. Triplicate supernatants 
were pooled and 33 μl supernatant was mixed with 100 μl p-nitrophenyl phosphate 
liquid (Sigma-Aldrich) in 96-well plates. The plates were incubated for 40 minutes at 
37 °C. The reaction was stopped by adding 50 μl 3 M NaOH and the absorbance was 
measured at 410 nm using a Synergy 2 multi-mode microplate reader and Gen5 
software. 
 
2.6.6 Respiratory burst 
2.6.6.1 Measurement of extracellular ROS production 
Extracellular superoxide production was measured by reduction of the water-soluble 
tetrazolium salt, WST-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), to a 
coloured formazan product [198]. Neutrophils were plated in triplicate in 96-well plates 
at 2 × 106 cells/ml in RPMI 1640 medium. The cells were left inactivated (naïve) or 
were activated with 100 ng/ml PMA at the same time as AMP treatment.  
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Primary screen assays 
The cells were treated with 5 μM AMP for 1 hour at 37°C.  
 
Dose-response assays 
The cells were treated with titrations of AMP for 1 hour at 37°C. 
 
Absorbance was measured at 450 nm using a Synergy 2 multi-mode microplate reader 
and Gen5 software. 
 
2.6.6.2 Measurement of intracellular ROS production 
The fixable intracellular ROS indicator CellROX Deep Red (excitation/emission 
644 nm/665 nm) (Life Technologies Inc.) was used to measure intracellular ROS 
production. Neutrophils were plated in duplicate in MCP-treated 96-well round-bottom 
plates at 5 × 105 cells/well in RPMI 1640 medium. The cells were left inactivated 
(naïve) or were activated with 100 ng/ml PMA at the same time as AMP treatment. The 
cells were treated with titrations of Bac5-FITC for 5, 15, 30 or 60 minutes in the 
presence of 1 µM CellROX Deep Red. After each time point the cells were washed 
three times with PBS containing 1% (w/v) BSA and then fixed in PBS containing 
4% (w/v) paraformaldehyde and kept at 4 °C before preparation for analysis by flow 
cytometry (section 2.6.10). 
 
2.6.7 Phagocytosis 
Phagocytosis was assessed by the uptake of Molecular Probes FluoSpheres 
(carboxylate-modified microspheres, 0.5 µm, yellow-green fluorescent 
(excitation/emission 505 nm/515 nm), 2% solids, Life Technologies Inc.). Fluospheres 
were opsonised by diluting 1:500 in fetal bovine serum (FBS) (Sigma-Aldrich) and 
incubating for 1 hour with continuous shaking at 37 °C. Cells treated with 100 ng/ml 
PMA served as positive controls for phagocytosis as activated cells have enhanced 
phagocytic capacity [199]. Cells pre-incubated with 10 μM cytochalasin D or B (Sigma-
Aldrich) for 30 minutes at 37 °C served as negative controls for phagocytosis, as 
cytochalasin binds to actin and inhibits actin polymerisation [200]. 
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Primary screening assays 
Neutrophils were plated in duplicate in 24-well tissue culture plates (Nunc) at 
5 × 105 cells/well in RPMI 1640 medium. The cells were left to adhere for 30 minutes at 
37 °C. The cells were then pre-incubated for 45 minutes with 5 µM AMP. FluoSpheres 
in FBS were added to the cells at a final dilution of 1:50,000 (5.82 spheres/cell) and the 
cells were incubated for 1 hour at 37 °C. After incubation the cells were fixed in PBS 
containing 4% (w/v) paraformaldehyde and kept at 4° C before preparation for analysis 
by flow cytometry (section 2.6.10). 
 
Dose-response assays 
Neutrophils were plated in duplicate in 96-well MCP-treated round-bottom plates at 
5 × 105 cells/well in RPMI 1640 medium. The FluoSpheres were washed in RPMI 1640 
medium and added to the cells at a final dilution of 1:50,000 (5.82 spheres/cell). The 
cells were treated with titrations of AMP for 1 hour at 37 °C. After incubation, the cells 
were washed with ice-cold PBS and incubated for 2 minutes with ice-cold 0.08% (w/v) 
trypan blue in PBS to quench the fluorescence of surface-bound FluoSpheres. The cells 
were then washed with PBS to remove excess trypan blue, fixed in PBS containing 
4% (w/v) paraformaldehyde and kept at 4 °C before preparation for analysis by flow 
cytometry. Cells were also analysed by confocal microscopy (section 2.9). 
 
2.6.8 Intracellular calcium mobilisation 
The fluorescent calcium ion indicator Fluo-4/acetoxymethyl ester (Fluo-4 AM, 
excitation/emission 494 nm/506 nm) (Life Technologies Inc.) was used to measure 
changes in intracellular calcium. Neutrophils were diluted to 2.5 × 106 cells/ml in 
HBSS2+ containing 3 μM Fluo-4 AM and mixed for 45 minutes at room temperature. 
The cells were washed twice in HBSS2+ and incubated for a further 30 minutes at room 
temperature. The Fluo-4 loaded neutrophils were plated in triplicate in 96-well black-
walled fluorescence plates and pre-warmed to 37 °C. Baseline fluorescence was 
measured with a Synergy 2 multimode microplate reader with excitation and emission 
filters set to 485/20 nm and 528/20 nm, respectively. The cells were left inactivated 
(naïve) or were activated with 100 ng/ml PMA at the same time as AMP treatment. 
Cells treated with 10 μM calcium ionophore A23187 (Sigma-Aldrich) or 10% zymosan-
activated serum (section 2.6.8.1) served as positive controls for calcium mobilisation. 
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Primary screen assays 
Cells were treated with 5 μM AMP and the fluorescence was measured every 
20 seconds for 1 hour at 37 °C. 
 
Dose-response assays 
Cells were treated the titrations of AMP and the fluorescence was measured every 
20 seconds for 10 minutes at 37 °C and an endpoint reading was taken after 1 hour at 
37 °C. 
 
2.6.8.1 Preparation of zymosan-activated serum 
Whole bovine blood was obtained from freshly killed cattle at a local abattoir and 
collected in 50 ml tubes without anticoagulant. Blood from at least three different cows 
was collected. The blood was incubated for 1 hour at 37 °C and then for 1 hour at 20 °C 
to allow complete clotting. The tubes were centrifuged at 1500 × g for 15 minutes at 4 
°C. The serum supernatant was removed, pooled and centrifuged at 13,000 × g for 
10 minutes at 4 °C. Aliquots of 1 ml were stored at -80 °C until use. 
 
Preparation of activated serum was based on the method described by Rainard, et al. 
[61]. Zymosan A from Saccharomyces cerevisiae (Sigma-Aldrich) was prepared at 
2 mg/ml in HBSS and boiled for 1 hour. The zymosan was washed three times by 
centrifugation at 1,000 × g for 2 minutes and resuspended in HBSS. After the third wash 
the zymosan was resuspended at 2 mg/ml in pooled serum and incubated with 
continuous shaking for 2 hours at 37 °C. The zymosan was pelleted by centrifugation at 
1,000 × g for 2 minutes. Activated serum was removed and stored in 1 ml aliquots at  
-80 °C until use. 
 
2.6.9 Peptide internalisation 
Neutrophils were plated in duplicate in MCP-treated 96-well round-bottom plates at 
5 × 105 cells/well in RPMI 1640 medium. The cells were treated with titrations of Bac5-
FITC for 5, 15, 30 or 60 minutes. After each time point the cells were washed with ice-
cold PBS and incubated for 2 minutes with ice-cold 0.08% (w/v) trypan blue in PBS. 
The cells were then washed with PBS to remove excess trypan blue, fixed in PBS 
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containing 4% (w/v) paraformaldehyde and kept at 4°C before preparation for analysis 
by flow cytometry (section 2.6.10). 
 
2.6.10 Flow cytometry analysis 
Neutrophils were gated according to forward scatter and side scatter properties. Where 
dual staining was applied, positive and negative controls were singly stained and 
compensation for spectral overlap adjusted accordingly. Generally 10,000 events were 
collected. However, where a loss of cells occurred due to cytotoxicity, the sample was 
run until the maximum possible volume was utilised, and the data were analysed 
according to the number of events collected. 
 
Primary screening assays 
Prior to analysis, the cells were resuspended in IsoFlow Sheath Fluid (Beckman Coulter 
New Zealand Ltd., North Shore City, New Zealand). For detection of apoptotic and 
necrotic cells, membrane permeabilisation assays and phagocytosis assays, the cells 
were analysed using a FACS Scan or FACS Calibre flow cytometer with BD CellQuest 
software v5.2.1 (BD Biosciences Immunocytometry Systems, USA).  
 
Dose-response assays and Bac5 analysis 
Prior to analysis, the cells were resuspended in BD FACSFlow Sheath Fluid (BD 
Biosciences). For detection of apoptotic and necrotic cells, phagocytosis, Bac5-FITC 
internalisation and intracellular ROS production, the cells were analysed using a 
FACSVerse flow cytometer and BD FACSuite software v1.0.3 (BD Biosciences 
Immunocytometry Systems).  
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2.7 Protein interaction assays 
2.7.1 Protease digestion of rbCath1 
Recombinant cathelicidin-4 (produced by Robert Wieliczko, Food & Bio-based 
Products Group, AgResearch, New Zealand) and rbCath1 were concentrated in 100 mM 
HEPES (pH 7.5) (BDH Chemicals), using Vivaspin 500 centrifugal concentrators with 
10 kDa molecular weight cut off. Elastase from human leukocytes (Sigma-Aldrich) was 
reconstituted in 100 mM HEPES, pH 7.5. Recombinant protein and elastase were mixed 
in a ratio of 50 µg recombinant protein:1 µg elastase, in a total volume of 50 µl, and 
incubated for 30, 60 or 90 minutes at 37 °C. A 2 µl sample from each digestion was 
analysed by western blot (section 2.3.3.5). The predicted sequence of the cleavage 
product contained the epitope for recognition by the cathelicidin-1 CLD-specific A32 
antibody (section 2.2.1). Therefore in western blot analysis the primary antibody 
incubation was for 2 hours at room temperature using rabbit A32 antibody diluted 
1:10,000 in antibody diluent A. Secondary antibody incubation was for 1 hour at room 
temperature using peroxidase-conjugated goat anti-rabbit antibody diluted 1:10,000 in 
antibody diluent A. The 3 kDa band identified by western blot was also analysed by MS 
(section 2.8.1) to confirm the peptide sequence. 
 
2.7.2 Ex vivo production of cathelicidin-1 peptides 
Neutrophils were plated in 12-well tissue culture plates (Nunc) at 5 × 107 cells/well in 
HBSS2+. The cells were treated with 100 ng/ml PMA or 10 µM calcium ionophore 
A23187 and incubated with gentle shaking for 1, 2, 4 or 8 hours at 37 °C. The culture 
media was removed and centrifuged at 800 × g for 5 minutes at 4 °C. The supernatant 
was removed and frozen at -80 °C until liquid chromatography-MS/MS (LC-MS/MS) 
analysis (section 2.8.2.2). 
 
2.7.3 Membrane fractionation for p47phox analysis 
Neutrophils were suspended at 5  106 cells/ml in RPMI 1640 medium and were 
dispensed in 15 ml tubes (BD Biosciences) at 2  107 cells/tube. The cells were left 
inactivated (naïve) or were activated with 100 ng/ml PMA at the same time as AMP 
treatment. Naïve cells treated with 2.5 µM Bac5 showed significant enhancement of 
respiratory burst, therefore this concentration was used to treat neutrophils for this 
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analysis. Conversely, activated cells treated with 10 µM Bac5 showed significantly 
inhibited respiratory burst, therefore this concentration was used to treat activated 
neutrophils for this analysis. The cells were incubated for 0, 30, or 60 minutes at 37 °C. 
At each time point the cells were pelleted by centrifugation at 800 × g for 5 minutes.  
 
The supernatant was discarded and the cells resuspended in 400 ml fractionation buffer 
(Appendix 2) and lysed by sonication on ice with two 10 second bursts. The lysates 
were clarified by centrifugation at 13,000 × g for 10 minutes at 4 °C and transferred to 
Nalgene UltraPlus tubes (Nalge Company, NY, USA). Cleared lysates were centrifuged 
at 35,000 rpm for 60 minutes at 4 °C using a Type 70.1 Ti rotor (Beckman Coulter) in a 
Sorvall Discovery 90 SE ultracentrifuge (Hitachi, Japan). The supernatant was removed 
(cytosolic fraction) and protein concentration was determined by Bio-Rad protein assay 
(section 2.3.3.2). Cytosolic fractions were stored at -80 °C until use.  
 
The membrane pellet was resuspended in 50 µl 3× SLB (Appendix 2) and stored at  
-80 °C until use. Membrane protein concentration was determined by SDS-PAGE 
analysis (section 2.3.3.4). Each lysate was then analysed by western blot (section 
2.3.3.5). Primary antibody incubation was for 2 hours at room temperature using rabbit 
anti-p47phox antibody (sc-7660-R, Santa Cruz Biotechnology) diluted 1:10,000 in 
antibody diluent A. Secondary antibody incubation was for 1 hour at room temperature 
using peroxidase-conjugated goat anti-rabbit antibody diluted 1:10,000 in antibody 
diluent A. 
 
2.7.4 Preparation of whole neutrophil lysate 
Neutrophil lysates were prepared by reconstituting untreated cells at 2 × 107 cells/ml in 
hypotonic buffer (Appendix 2). The cells were lysed by sonication on ice with three 
10 second bursts, followed by two freeze-thaw cycles. The lysates were clarified by 
centrifugation for 10 minutes at 13,000 × g, 4 °C. Protein concentration was determined 
by Bio-Rad protein assay. The supernatant was stored at -80 °C until use.  
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2.7.5 Analysis of Bac5 protein interactions 
Neutrophil lysates prepared in section 2.7.4 were separated by SDS-PAGE in triplicate. 
Two of the three replicates were analysed in parallel by far-western blot (section 
2.3.3.8). For Blot 1, no primary probe was used. Instead, incubation was for 2 hours at 
room temperature using reagent diluent B (Appendix 2). Secondary probe incubation 
was for 2 hours at room temperature using Bac5-FITC peptide diluted to 0.5 µM in 
antibody diluent B. For Blot 2, primary probe incubation was for 2 hours at room 
temperature using unlabelled Bac5 peptide diluted to 2.5 µM in antibody diluent B. 
Secondary probe incubation was for 2 hours at room temperature using Bac5-FITC 
peptide diluted to 0.5 µM in antibody diluent B. The third SDS-PAGE replicate was 
analysed by LC-MS/MS (section 2.8.2.1) to identify the proteins interacting with Bac5-
FITC. 
 
2.7.6 Immunopurification of cellular β-actin 
The immunopurification method was based on a method developed in-house 
(AgResearch, Ruakura, New Zealand). A 50% slurry of Protein A-agarose beads 
(Sigma-Aldrich) was prepared in hypotonic buffer. The neutrophil lysate was diluted to 
0.8 mg/ml in hypotonic buffer and pre-cleared by adding 50% slurry at 10 µl/ml of 
protein dilution and mixing for 30 minutes at room temperature. The beads were 
pelleted by centrifugation at 2,000 rpm for 1 minute. The supernatant was transferred to 
a new tube and 1 ml mixed with 1 µg anti-actin antibody (A2066, Sigma-Aldrich) for 
16 hours at room temperature. Slurry, freshly washed in hypotonic buffer, was added at 
15 µl/ml of protein and mixed for 2 hours. The beads were pelleted as before and the 
supernatant retained for SDS-PAGE analysis. The beads were washed twice with 
hypotonic buffer and three times with PBS containing protease inhibitors. The beads 
were pelleted and resuspended in 20 µl 3× SLB, boiled for 3 minutes and stored at  
-20 °C until SDS-PAGE and far-western blot analysis (section 2.3.3.8). For far-western 
blot analysis, primary probe incubation was for 2 hours at room temperature using 
Bac5-FITC peptide diluted to 0.5 µM in antibody diluent B. 
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2.7.7 Co-immunopurification of β-actin and Bac5-FITC 
The method for co-immunopurification of cellular or purified β-actin and Bac5-FITC 
was similar to the method described in section 2.7.6. Exogenous Bac5-FITC was added 
at a final concentration of 26.1 µg/ml to combinations of neutrophil lysate and antibody 
(Table 2.3), or purified β-actin (Huntingtree Bioscience Supplies, Auckland, New 
Zealand) and antibody (Table 2.4). Combinations were mixed overnight at room 
temperature and prepared for analysis as in section 2.7.6. Supernatants from the purified 
β-actin co-immunoprecipitation were concentrated by TCA precipitation 
(section 2.3.3.1). Supernatants, TCA precipitates and co-immunopurified protein were 
separated by SDS-PAGE and analysed as described in section 2.3.3.9. 
 
Table 2.3 Combinations of cellular β-actin and Bac5-FITC co-immunopurification 
Standard No lysate No antibody No Bac5-FITC 
0.8 mg lysate - 0.8 mg lysate 0.8 mg lysate 
1 µg antibody 1 µg antibody - 1 µg antibody 
26.1 µg Bac5-FITC 26.1 µg Bac5-FITC 26.1 µg Bac5-FITC  - 
15 µl 50% slurry 15 µl 50% slurry 15 µl 50% slurry 15 µl 50% slurry 
 
 
Table 2.4 Combinations of purified β-actin and Bac5-FITC co-immunopurification 
Standard No β-actin No antibody No Bac5-FITC 
1 µg β-actin - 1 µg β-actin 1 µg β-actin 
1 µg antibody 1 µg antibody - 1 µg antibody 
26.1 µg Bac5-FITC 26.1 µg Bac5-FITC 26.1 µg Bac5-FITC  - 
15 µl 50% slurry 15 µl 50% slurry 15 µl 50% slurry 15 µl 50% slurry 
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2.8 Mass spectrometry 
2.8.1 MALDI TOF/TOF  
In preparation for MS analysis, polyacrlyamide gels were fixed in MS gel fixative 
solution (Appendix 2) for 16 hours at room temperature, with two to three changes of 
fixative solution during this time. Fixed gels were then stained with CBB G-250 stain 
solution (Appendix 2) for 16 hours at room temperature. The gels were destained with 
MS gel destain solution (Appendix 2) at room temperature until the background was 
clear. 
 
After CBB G-250 staining the particular protein band required for analysis was excised. 
The gel plug was destained overnight at 4 °C with gel destain solution (Appendix 2), 
washed for 1 hour with fresh destain wash solution (Appendix 2) and incubated in 
25 mM DTT (Roche Diagnostics N.Z., Ltd.) for 30 minutes at 60 °C. After cooling, the 
gel plug was incubated in 100 mM iodoacetamide (Sigma-Aldrich) in the dark for 
1 hour at room temperature. The gel piece was then washed twice for 30 minutes in 
destain wash solution and dehydrated in pure acetonitrile (Merck, Darmstadt, 
Germany). The acetonitrile was removed and the gel piece dried by vacuum 
centrifugation (Savant SpeedVac, Thermo Fisher Scientific New Zealand Ltd.) for 
15 minutes.  
 
The dried gel piece was incubated in trypsin digest solution (Appendix 2) for 16 hours 
at 37 °C followed by incubation in a sonicating water bath (Fisher Scientific) for 
10 minutes. The gel piece was centrifuged and the supernatant removed to a new tube. 
The pipette tip was retained. The gel plug was resuspended in acetonitrile/TFA solution 
(Appendix 2) and sonicated for 10 minutes. The supernatant was removed to the new 
tube using the retained pipette tip. This process was repeated once more, and then 
repeated again using pure acetonitrile. The pooled supernatant was frozen for 
20 minutes at -80 °C and lyophilised by vacuum centrifugation. The lyophilised 
peptides were reconstituted in matrix solution (Appendix 2), spotted onto the MALDI 
plate and washed with spot wash solution (Appendix 2). Samples from section 2.3.2.4 
were analysed by Grant Smolenski (Food & Bio-based Products Group, AgResearch, 
New Zealand) using a Bruker Autoflex TOF/TOF mass spectrometer (Bruker Daltonics, 
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Bremen, Germany). Samples from section 2.7.1 were analysed by Grant Smolenski 
using an ABI Q-Star Pulsar i mass spectrometer (Applied Biosystems, MA, USA). Data 
were analysed using ProteinScape 3.0 (Bruker). 
 
2.8.2 LC-MS/MS 
2.8.2.1 Preparation of Bac5 protein interaction samples 
Samples from the analysis of Bac5 protein interactions (section 2.7.5) were prepared as 
described in section 2.8.1. The lyophilised peptides were reconstituted in 0.1% (v/v) 
formic acid (Fluka Analytical, Sigma-Aldrich) before analysis. LC-MS/MS analysis 
was carried out by Irina Boggs (Food & Bio-based Products Group, AgResearch, New 
Zealand). 
 
2.8.2.2 Preparation of ex vivo produced cathelicidin-1 peptides 
Preparation and analysis by LC-MS/MS was carried out by Ancy Thomas and Stefan 
Clerens (Food & Bio-based Products Group, AgResearch, New Zealand). The culture 
media from stimulated neutrophils (section 2.7.2) was diluted two-fold in 0.1% (v/v) 
formic acid. The solution was transferred to a preconditioned centrifugal filter unit with 
10 kDa nominal molecular weight limit (Ultrafree-MC, EMD Millipore). The unit was 
centrifuged at 14,000 × g for 30 minutes at 4 °C and the filtrate retained. A 2 M 
ammonium formate solution (pH 3.0) (Fluka Analytical, Sigma-Aldrich) was added and 
the unit was centrifuged again. The filtrate was discarded and a solution containing 
75% (v/v) acetonitrile with 0.1% (v/v) formic acid was used to elute bound peptides. 
The total filtrate was lyophilised in a vacuum centrifuge and reconstituted in 0.1% (v/v) 
formic acid.  
 
2.8.2.3 LC-MS/MS analysis 
For each sample, 5 µL was loaded at a flow rate of 5000 nl/min on a Magic C18AQ 
Nano trap column (100 μm internal diameter × 100 mm, 5μ, 200Å) (Bruker Daltonics) 
connected to a Bruker nano-Advance UHPLC equipped with nano-Advance 
Autosampler. The trap column was then switched in line with a Magic C18AQ 
analytical column (100 μm internal diameter × 150 mm, 3μ, 200Å) (Bruker Daltonics) 
and peptides were eluted with a gradient from 2-45% (v/v) acetonitrile in 0.1% (v/v) 
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formic acid at a flow rate of 800 nl/minute. The analytical column outlet was directly 
connected to a Bruker Daltonics maXis impact mass spectrometer (Bruker Daltonics) 
equipped with a CaptiveSpray ion source. Data were analysed using ProteinScape 3.0. 
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2.9 Confocal laser scanning microscopy 
Where indicated, Bac5-FITC was used to visualise internalised Bac5, CellROX Deep 
Red was used to visualise intracellular ROS production, phalloidin-conjugated 
tetramethylrhodamine isothiocyanate (TRITC) was used to visualise cellular actin, and 
4',6-diamidino-2-phenylindole (DAPI) was used to visualise cell nuclei.  
 
2.9.1 Slide preparation for phagocytosis analysis 
Aliquots of PMA-treated cells incubated with opsonised FluoSpheres for 1 hour at 
37 °C were dried on microscopy slides. The cells were fixed in PBS containing 
4% (w/v) paraformaldehyde for 30 minutes at room temperature. The cells were washed 
three times with PBS and mounted using ProLong Gold Antifade Reagent with DAPI 
(excitation/emission 358 nm/461 nm) (Life Technologies Inc.) using #1.5 coverslips 
(Warner Instruments, CT, USA). After mounting, the coverslips were sealed with DPX 
mountant and stored at -20 °C until confocal microscopy analysis. 
 
2.9.2 Slide preparation for colocalisation analysis 
Neutrophils were seeded onto 12 mm #1.5 coverslips in 12-well flat-bottom tissue 
culture plates at 2 × 105 cells/well in RPMI 1640 medium. The cells were allowed to 
adhere for 15 minutes at 37 °C. For naïve cells, the cells were treated with 2.5 μM 
Bac5-FITC and 5 μM CellROX Deep Red for 60 minutes at 37 °C. For activated cells, 
the cells were treated with 10 μM Bac5-FITC, 100 ng/ml PMA and 5 μM CellROX 
Deep Red for 60 minutes at 37 °C. 
 
After treatment the coverslips were washed four times with excess PBS containing 
1% (w/v) BSA and fixed in PBS containing 4% (w/v) paraformaldehyde for 30 minutes 
at room temperature. The coverslips were washed with excess PBS and fixed in acetone 
for 30 seconds. The cells were then permeabilised for 5 minutes with 0.1% Triton  
X-100 (Sigma-Aldrich), washed in excess PBS, and blocked with PBS containing 
1% (w/v) BSA for 1 hour at room temperature. The coverslips were then incubated with 
5 µg/ml phalloidin-TRITC (excitation/emission 547 nm/572 nm) (Sigma-Aldrich) for 
1 hour at room temperature. The coverslips were washed three times with PBS and 
mounted on slides using ProLong Gold Antifade Reagent with DAPI to identify nuclei. 
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After mounting, the coverslips were sealed with DPX mountant and stored at -20 °C 
until confocal microscopy analysis. 
 
2.9.3 Slide and image analysis 
Slides were analysed using an Olympus Fluoview FV1000 confocal laser scanning 
biological microscope and Olympus Fluoview v1.7a software (Olympus America Inc.). 
Spectral based detection was used to image DAPI, FITC/FluoSpheres and TRITC 
fluorescence and filter based detection was used to image CellROX Deep Red 
fluorescence (Table 2.5). This approach prevented overlap in the emission spectrums of 
different fluorophores. Images were analysed using Image-Pro plus v7.0.0.591 and 
Corel Paint Shop Pro Photo XI v11.20 (Corel Corporation, ON, Canada). 
 
Table 2.5 Confocal microscopy excitation and emission settings 
Fluorophore Excitation laser Emission range Detection type 
DAPI 405 nm 425 nm - 475 nm Spectral 
FITC 488 nm 500 nm - 540 nm Spectral 
TRITC 561 nm 570 nm - 630 nm Spectral 
CellROX Deep Red 633 nm >650 nm Filter 
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2.10 Statistical analysis 
All data were analysed using Minitab v15.1.0.0 (Minitab Inc., State College, PA, USA) 
or Prism v5.0 (GraphPad Software, Inc., CA, USA). One-way analysis of variance 
(ANOVA) was conducted using Fisher’s post hoc test or Tukey’s post-test, where 
appropriate, to compare treatments with controls, or Student’s t-test to compare two 
treatments. 
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3.1 Introduction 
The Food & Bio-based Products Group (AgResearch) initially investigated cathelicidins 
as an early indicator of mastitis in cattle. Data indicated cathelicidins could be detected 
prior to the onset of clinical symptoms and the concentration demonstrated a high 
correlation with SCC [108]. Subsequently, native cathelicidin-1 protein (native Cath1) 
was prepared by immunopurification of the CLD from mastitic milk for further analysis. 
The purified protein was able to bind LPS, aggregate several mastitis causing species of 
microorganism and was cytotoxic toward bovine neutrophils (unpublished data, Food & 
Bio-based Products Group, AgResearch). These findings were significant as a defined 
function for this protein has not been clarified. To produce more Cath1 protein for 
further studies, two expression constructs were created. Firstly, the CLD from bovine 
cathelicidin-1 was produced (rbCLD) and secondly a full-length cathelicidin-1 was 
produced with mutation A143 to F143, rendering the C-terminal peptide resistant to 
neutrophil elastase cleavage (rbCath1). The activity of the purified protein led to the 
hypothesis that: the rbCLD and rbCath1 proteins will have similar activity to native 
Cath1 protein. 
 
The recombinant proteins would also be useful tools in further functional studies to 
determine the full role of the CLD during infection. In this chapter, rbCath1 was used to 
investigate the production of a second peptide from the CLD of cathelicidin-1. The 
potential secondary cleavage of cathelicidin-1 is of significant interest as this process 
would generate a novel undescribed bovine cathelicidin AMP. Interestingly, the elastase 
cleavage site of cathelicidin-1 is 13 amino acids down-stream of the classical aligned 
cleavage site of the other six bovine cathelicidins (Table 3.1). Therefore it was 
hypothesised that: further proteolytic processing of cathelicidin-1 occurs, producing 
a second antimicrobial peptide. 
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Table 3.1 Multiple C-terminal sequence alignment of bovine cathelicidins. 
Protein Name UniProt Entry [91] C-terminal AMP sequence alignment 
CLD 
Length 
    
Cathelicidin-1 P22226 ...FDITCNNHQSI ? RITKQPWAPPQAA > RLCRIVVIRVCR 114 aa 
Cathelicidin-2 P19660 ...FDINCNELQSV > RFRPPIRRPPIRPPFYPPFRPPIRPPIFPPIRP... 101 aa 
Cathelicidin-3 P19661 ...FDLNCNELQSV > RRIRPRPPRLPRPRPRPLPFPRPGPRPIP... 101 aa 
Cathelicidin-4 P33046 ...FDLNCNELQSV > ILPWKWPWWPWRRG 101 aa 
Cathelicidin-5 P54229 ...FDITCAVPQSV > GGLRSLGRKILRAWKKYGPIIVPIIRIG 102 aa 
Cathelicidin-6 P54228 ...INVTCEELQSV > GRFKRFRKKFKKLFKKLSPVIPLLHLG 102 aa 
Cathelicidin-7 P56425 ...FDITCNNIQSA > GLFRRLRDSIRRGQQKILEKARRIGERIKDIFRG 102 aa 
    
The classical neutrophil elastase cleavage sites are indicated by the ‘>’ symbol. The predicted alternate 
cleavage site for cathelicidin-1 is indicated with the ‘?’ symbol. aa, amino acids.  
 
3.2 Aims 
 Transform, express and purify rbCLD and rbCath1 from E. coli. 
 Assess the LPS-binding activity, microbial agglutinating activity and 
cytotoxicity of rbCLD and rbCath1. 
 Investigate whether cathelicidin-1 can produce a second AMP. 
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3.3 Results 
3.3.1 Expression and purification of rbCLD and rbCath1 
3.3.1.1 Bacterial expression constructs 
A bacterial expression system was used due to the ease of use, fast culture generation 
and high yield of protein. The pET-45b(+) vector was used as the expression construct 
which contains a N-terminal His·Tag coding sequence allowing easy purification, a 
strong T7lac promoter, an enterokinase cleavage site and a multiple cloning site 
producing minimal vector-encoded residues at the target sequence fusion site  
(Figure 3.1 A, B). 
 
The Cath1_15/13new5 (Figure 3.1 C) and Cath1_NER2 (Figure 3.1 D) expression 
constructs had been previously prepared by another researcher. The nucleotide sequence 
for the 114 amino acids of the CLD and 126 amino acids for the full length bovine 
cathelicidin-1 coding sequence were cloned into the pET-45b(+) vector. The plasmid 
was sequenced and the insert was confirmed to be correct. In this plasmid vector protein 
expression is induced by IPTG via the T7lac promoter. Following EK cleavage, the 
resulting protein will contain an extra Ser-Pro-Asp-Pro sequence at the N-termini of the 
rbCLD and rbCath1 protein sequences.  
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ATGGCACATCACCACCACCATCACGTGGGTACCGGTTCGAATGATGACGACGACAAGAGTCCGGATCCCCAGGCCCTCAGCTAC...
MetAlaHisHisHisHisHisHisValGlyThrGlySerAsnAspAspAspAspLysSerProAspProGlnAlaLeuSerTyr...
...GCACCACCACAGGCAGCCTTAAAGCTT
...AlaProProGlnAlaAlaStop
...GCACCACCACAGGCATTCCGATTATGTCGCATTGTAGTGATAAGGGTTTGCAGATAAAAGCTT
...AlaProProGlnAlaPheArgLeuCysArgIleValValIleArgValCysArgStop
Hind III
Hind III
BamH IHis·Tag
enterokinase
Cath1_15/13new5 
construct
Cath1
Cath1_NER2 construct
A
B
C
D
F143 Bac1 AMP
*
*
*
Produces
rbCLD
Produces
rbCath1
 
 
Figure 3.1 Protein coding regions of the constructs expressed in E. coli 
(A) Plasmid pET-45b(+) map. (B) Nucleotide and amino acid sequences of the expression region of the 
pET-45b(+) plasmid. (C) C-terminal of Cath1_15/13new5 construct to express rbCLD. (D) C-terminal of 
Cath1_NER2 construct to express rbCath1 showing A143 to F143 amino acid substitution to prevent 
neutrophil elastase cleavage of the AMP domain (Bac1). 
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3.3.1.2 Small scale expression test for rbCLD and rbCath1 
To ensure the correct protein was translated by each expression construct, a small scale 
expression test was conducted before scaling up recombinant protein production. 
Because the CLD contains disulfide bonds, the Origami E. coli strain was used for 
transformation. This strain contains mutations in the thioredoxin reductase (trxB) and 
glutathione reductase (gor) genes, allowing disulfide bond formation to occur in the 
bacterial cytoplasm [201]. The trxB and gor mutations were selected for by culturing in 
the presence of kanamycin and tetracycline antibiotics, while the pET-45b(+) plasmid 
vector was maintained by the presence of ampicillin antibiotic.  
 
The Origami strain was transformed with each plasmid and grew numerous colonies on 
antibiotic agar plates, whilst control transformation plates showed no growth, indicating 
a successful transformation. Expression of both plasmids in Origami was induced with 
IPTG for 90 and 180 minutes (Figure 3.2 A). SDS-PAGE analysis of the expression test 
indicated induction of significant protein, producing gel bands at approximately 
15.5 kDa and 17 kDa. This matched the predicted molecular weight of rbCLD and 
rbCath1 proteins (15.61 kDa and 17.15 kDa, respectively). The bands were confirmed to 
contain cathelicidin protein by western blot analysis using a cathelicidin-1 specific 
antibody (Figure 3.2 E, lanes 2 and 3). The rbCLD was mostly soluble after 90 minutes, 
whereas almost a quarter of total expressed protein was insoluble after 180 minutes of 
induction. The rbCath1 protein was mostly expressed as insoluble inclusion bodies at 
both time points. The inclusion bodies were soluble in buffer containing 6 M guanidine 
hydrochloride. 
 
3.3.1.3 Large scale expression and purification of rbCLD 
To yield more recombinant protein, the culture conditions were scaled up to produce 
two separate batches of 500 ml culture for rbCLD. An expression test using 2 ml of this 
culture showed minimal ‘leaky’ expression before induction with IPTG. Nearly all of 
the induced recombinant protein was soluble (Figure 3.2 B, lane 5) and a negligible 
amount was insoluble. The recombinant protein was then purified from other bacterial 
proteins using IMAC.  
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The majority of E. coli proteins did not bind to the column during loading and were 
eluted with the flow through (Figure 3.2 B, lane 9). Minimal recombinant protein was 
observed in the loading flow through. The first wash removed remaining bacterial 
proteins with a minor loss of rbCLD. The second wash was virtually clear of bacterial 
proteins however some high molecular weight protein remained. The yield of rbCLD 
was high (4.67 mg/ml) and relatively pure (~80% monomeric) but also contained high 
molecular weight contaminants. The flow through from the first elution was then 
subjected to a second round of IMAC to determine if the high molecular weight 
contaminants could be removed (Figure 3.2 C). However, the persistence of these bands 
in both purifications and their predicted molecular mass indicated these proteins were 
most likely multimeric forms of the recombinant protein. Western blot analysis 
confirmed that the bands at approximately 30 kDa were recombinant protein  
(Figure 3.2 E). The higher molecular weight protein could not be identified. 
 
3.3.1.4 Large scale expression and purification of rbCath1 
Culture conditions for rbCath1 were scaled up to 200 ml. Due to the formation of 
inclusion bodies in the small scale test the culture pellet was resuspended in lysis buffer 
containing 6 M guanidine hydrochloride. Less E. coli protein was present in the 
inclusion bodies and was mostly removed in the flow through of the protein load during 
IMAC purification (Figure 3.2 D, lane 7). A small amount of recombinant protein was 
present in the flow through from the protein load and the wash, and no bacterial proteins 
were visible by CBB R-250 stain after the wash step.  
 
Inclusion bodies are generally considered as aggregated and misfolded protein [202]. 
On-column refolding was employed to obtain correctly folded protein and remove 
guanidine hydrochloride from the buffer. This was achieved by immobilising rbCath1 
on an IMAC column and slowly replacing the guanidine hydrochloride buffer for buffer 
without guanidine hydrochloride. No recombinant protein was eluted while the gradient 
progressed from 0% to 100% refold buffer B. The elution step gave a high yield of 
soluble monomeric rbCath1 (1.34 mg/ml) with minimal high molecular weight 
contamination (~84% monomeric). Western blot analysis confirmed the presence of a 
dimer of approximately 34 kDa (Figure 3.2 E, lane 3), similar to that observed for the 
rbCLD purification. 
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Figure 3.2 SDS-PAGE analysis of the expression and purification of rbCLD and 
rbCath1 
Arrows indicate recombinant protein. (A) Transformed Origami expression test. Cultures were induced 
with 1 mM IPTG for the indicated time. (B) IMAC purification of rbCLD scaled up to 500 ml culture. 
Cultures were induced with 1 mM IPTG for 3 hours. (C) Second IMAC purification of rbCLD.  
(D) IMAC purification of rbCath1 scaled up to 200 ml culture with on-column refolding analysis. 
Cultures were induced with 1 mM IPTG for 3 hours. (E) Western blot analysis of recombinant and native 
cathelicidin-1 protein using the cathelicidin-1-specific A32 antibody. 
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3.3.1.5 Mass spectrometry analysis of rbCLD 
As antibodies only recognise a small antigen sequence, the purified rbCLD was also 
subjected to MS analysis to ensure the whole protein sequence was translated correctly. 
An SDS-PAGE of purified rbCLD was stained with colloidal CBB G250. The rbCLD 
bands were removed and prepared in duplicate for analysis by MALDI LIFT-TOF/TOF 
[203] (performed by Grant Smolenski, Food & Bio-based Products Group, 
AgResearch). Five tryptic peptides were identified for each replicate with statistically 
significant molecular weight search (MOWSE) probability scores [204] of 67 and 80 
respectively. Both samples generated 42% coverage of the accession sequence, 
corresponding to 57% actual coverage (Table 3.2). This confirmed the recombinant 
protein had the correct sequence. 
 
Table 3.2 Summary of mass spectrometry analysis of rbCLD 
Sample Identification Accession Weight (Da) 
MOWSE 
score Expect Peptides Coverage 
Actual 
Coverage 
BP-01 Cathelicidin-1 [Bos taurus] gi|27807341 17931 67 
7.210-
3 5 42% 57% 
BP-02 Cathelicidin-1 [Bos taurus] gi|27807341 17931 80 
3.410-
4 5 42% 57% 
 
3.3.1.6 Removal of the His·Tag 
The N-terminal His·Tag was removed in order to minimise any differences between the 
recombinant proteins and native Cath1. This was achieved using an EK cleavage-
capture kit. A 48 hour time-course analysis of EK cleavage showed the optimal 
incubation time was 24 hours at 37 °C at an enzyme:protein ratio of 1 unit EK:20 μg 
protein. Although multiple bands of different molecular weight were present, the 
approximate shift in molecular weight (~2 kDa) corresponded to the expected size of 
the purification tag (Figure 3.3, lanes 3 and 8). Removal of the cleaved His·Tag by 
IMAC excessively diluted the target protein, therefore spin-column centrifugation was 
used to concentrate the flow through containing the target protein. The final purity of 
cleaved product was approximately 46% for both recombinant proteins, with yields of 
40% and 9% of starting protein for rbCLD and rbCath1, respectively. Microdialysis was 
used to exchange the buffer in preparation for activity assays.  
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Figure 3.3 Removal of His·Tag from rbCLD and rbCath1 
The His·Tag of rbCLD and rbCath1 were removed using a Novagen recombinant enterokinase cleavage-
capture kit (EMD Millipore). After removal of the tags the recombinant proteins were concentrated with 
Vivaspin 6 centrifugal concentrators (Vivaproducts, Inc., USA). 
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3.3.2 Activity and cytotoxicity of rbCLD and rbCath1 
3.3.2.1 LPS-binding 
Many immune defence proteins are able to bind LPS, either enhancing or inhibiting its 
effect on immune cells and tissues [205,206]. An enzyme-linked immunosorbent-based 
assay was used to test the ability of rbCLD and rbCath1 to bind LPS. Purified bovine 
LBP served as a positive control, while purified casein served as a negative control. 
Both recombinant proteins showed comparable LPS-binding capacity at about 20% of 
LBP binding (Figure 3.4). This was significantly greater than the casein control. 
However, the extent to which both recombinants bound LPS was significantly less than 
that of native Cath1 protein. 
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Figure 3.4 LPS-binding activity of rbCLD and rbCath1 
High protein-binding plates (MaxiSorp, Nunc) were coated with 10 µg/ml protein overnight and blocked 
with 1% (w/v) casein in PBS. LPS-conjugated biotin was added for 1 hour. Streptavidin-HRP and TMB 
substrate were used to indicate LPS-binding. Data are expressed as proportion of LPS bound compared to 
LPS-binding protein (100%) and represent the mean ± SEM for three independent experiments performed 
in triplicate. Statistical significance was determined by one-way ANOVA using Tukey’s post-test. 
* P < 0.05, ** P < 0.01, *** P < 0.001. 
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3.3.2.2 Microbial agglutination 
An important feature of innate immune defence is the aggregation and agglutination of 
microbes. This process prevents the spread of infection and aids clearance by 
phagocytes. Unpublished data (Food & Bio-based Products Group, AgResearch) 
indicates native Cath1 efficiently agglutinates several species of microbe. As far as can 
be discerned, the agglutinating activity of the bovine CLD has not been reported 
previously. Several concentrations of rbCLD and rbCath1 were tested against five 
species of microbe for agglutination activity after 1 hour or 3 hours exposure. In these 
assays native Cath1 served as a positive control for agglutination. The antibody used to 
immunopurify native Cath1 (A32 antibody) was also tested as a control for native Cath1 
agglutination activity. 
 
Spontaneous agglutination was observed after 1 hour (Table 3.3) and 3 hours  
(Table 3.4) in all E. coli (Gram-negative) samples. S. typhimurium (Gram-negative) also 
spontaneously agglutinated after 3 hours. Native Cath1 efficiently agglutinated S. uberis 
(Gram-positive), S. aureus (Gram-positive) and C. albicans (yeast) after 1 hour, which 
was not attributable to the presence of the A32 purification antibody (control IgG). 
However, neither rbCLD nor rbCath1 was able to agglutinate any of these microbes, 
even after 3 hours exposure (Table 3.3 and Table 3.4, Figure 3.5 and Figure 3.6). 
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Table 3.3 Microbial agglutination scores after 1 hour treatment 
  E. coli S. uberis S. aureus S. typhimurium C. albicans 
Control ++ - - - - 
10 μg/ml rbCLD ++ - - - - 
5 μg/ml rbCLD ++ - - - - 
2.5 μg/ml rbCLD ++ - - - - 
10 μg/ml rbCath1 ++ - - - - 
5 μg/ml rbCath1 ++ - - - - 
2.5 μg/ml rbCath1 ++ - - - - 
10 μg/ml native Cath1 ++ + +++ - +++ 
5 μg/ml native Cath1 ++ + +++ - +++ 
2.5 μg/ml native Cath1 ++ + +++ - +++ 
10 μg/ml control IgG ++ - - - - 
5 μg/ml control IgG ++ - - - - 
2.5 μg/ml control IgG ++ - - - - 
(-) no agglutination; (+) minimal agglutination; (++) moderate agglutination; (+++) severe agglutination 
 
Table 3.4 Microbial agglutination scores after 3 hours treatment 
  E. coli S. uberis S. aureus S. typhimurium C. albicans 
Control +++ - - + - 
10 μg/ml rbCLD +++ - - + + 
5 μg/ml rbCLD +++ - - + - 
2.5 μg/ml rbCLD +++ - - + - 
10 μg/ml rbCath1 +++ - - + - 
5 μg/ml rbCath1 +++ - - + - 
2.5 μg/ml rbCath1 +++ - - + - 
10 μg/ml native Cath1 +++ +++ +++ + +++ 
5 μg/ml native Cath1 +++ +++ +++ + +++ 
2.5 μg/ml native Cath1 +++ +++ +++ + +++ 
10 μg/ml control IgG +++ - - + - 
5 μg/ml control IgG +++ - - + - 
2.5 μg/ml control IgG +++ - - + + 
(-) no agglutination; (+) minimal agglutination; (++) moderate agglutination; (+++) severe agglutination  
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Figure 3.5 Photomicrographs of microbial agglutination after 1 hour treatment 
All treatments contain 10 μg/ml protein. Photomicrographs were taken with 40× objective. 
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Figure 3.6 Photomicrographs of microbial agglutination after 3 hours treatment 
All treatments contain 10 μg/ml protein. Photomicrographs were taken with 40× objective. 
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3.3.2.3 Neutrophil cytotoxicity 
Because cathelicidins are constituents of neutrophil granules and released by neutrophils 
during infection, rbCLD and rbCath1 were tested for cytotoxicity in a neutrophil 
membrane permeabilisation assay. Unpublished data (Food & Bio-based Products 
Group, AgResearch) indicates native Cath1 is cytotoxic to bovine neutrophils at greater 
than 100 nM. Therefore naïve neutrophils were exposed to 70 nM (~0.91 µg/ml) and 
700 nM (~9.1 µg/ml) concentrations of rbCLD, rbCath1 and native Cath1 for 
30 minutes and stained with PI prior to flow cytometry analysis. The data showed 
neutrophils were not permeabilised by either rbCLD or rbCath1 at either of the 
concentrations tested (Figure 3.7). In contrast, native Cath1 was able to permeabilise 
neutrophil membranes at 700 nM inducing death in nearly all of the cells analysed. 
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Figure 3.7 Neutrophil membrane permeabilisation 
Bovine neutrophils were exposed to rbCLD, rbCath1 and native Cath1 at the indicated concentrations for 
30 minutes at room temperature, stained with PI, and analysed by flow cytometry. Data represent the 
mean ± SEM for at least two independent experiments performed in duplicate. Statistical significance was 
determined by one-way ANOVA using Tukey’s post-test comparing treatments with control. 
*** P < 0.001. 
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3.3.3 Investigation of a second AMP produced by cathelicidin-1 
3.3.3.1 Digestion of rbCath1 with neutrophil elastase 
The bovine cathelicidins are proteolytically cleaved by neutrophil elastase (NE) to 
release the AMP domain. The cleavage site is conserved for all expressed bovine 
cathelicidins except cathelicidin-1. Here the cleavage site is distal to the conserved 
cleavage site, leaving 13 amino acids at the C-terminus of the CLD (see Table 3.1). This 
suggested that an alternate cleavage site might exist which could generate an additional 
novel bovine AMP. Using the MEROPS database [207], this second potential cleavage 
site was assessed for compatibility with known NE cleavage sites. The most preferential 
substrates for NE in the P1 position of the scissile bond were valine, isoleucine and 
alanine (in order). Therefore NE was used to determine whether rbCath1 would be 
cleaved between I130 (P1) and R131 (P1’), in alignment with the site at which the other 
bovine cathelicidins are processed. Due to the NE resistant mutation (A143 to F143) the 
predicted cleavage product would also contain the Bac1 peptide and have an 
approximate molecular weight of 3 kDa. The CLD of bovine cathelicidin-4 (rbCLD4) 
was produced as a recombinant protein in E. coli (by Robert Wieliczko, Food & Bio-
based Products Group, AgResearch) and was used as a negative control for non-specific 
CLD cleavage.  
 
NE cleavage of rbCath1 revealed a time dependent increase in a low molecular weight 
product over 90 minutes (Figure 3.8 A). No cleavage products of rbCLD4 were visible 
after Ponceau S stain, indicating cleavage was specific for rbCath1. Western blot 
analysis using the epitope specific A32 antibody revealed robust production of a 3 kDa 
peptide from rbCath1 (Figure 3.8 B). CBB G-250 stain was able to resolve the 3 kDa 
band after SDS-PAGE analysis (Figure 3.8 C), but also revealed several other major 
products of neutrophil elastase cleavage. The 3 kDa band was removed and subjected to 
MS analysis. 
 
Chapter 3: Expression and Activity of Recombinant Cathelicidin-1 84 
 
 
kDa
rbCLD4 + NE
17 -
14 -
6 -
3 -
0 min     30 min    60 min     90 min      0 min      30 min    60 min      90 min
rbCath1 + NE
A
17 -
14 -
6 -
3 -
B
kDa
17 -
14 -
6 -
3 -
C
kDa
rbCLD4 + NE
0 min     30 min    60 min     90 min      0 min      30 min    60 min      90 min
rbCath1 + NE
0 min       90 min
rbCath1 + NE
 
Figure 3.8 Cleavage of rbCath1 by neutrophil elastase 
Recombinant rbCath1 was incubated with NE at 37 °C for the indicated times and cleavage products were 
analysed by western blot. Recombinant rbCLD4 served as a negative control for non-specific CLD 
cleavage. Arrows indicate the predicted 3 kDa product. (A) PVDF transfer membrane stained with 
Ponceau S. (B) PVDF transfer membrane probed with cathelicidin-1-specific A32 antibody.  
(C) CBB G-250 stain of SDS-PAGE.  
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3.3.3.2 MS analysis of the 3 kDa band 
The trypsin-derived peptide fragments of the 3 kDa cleavage product of rbCath1 were 
used to generate a peptide mass fingerprint mass spectrum using MALDI LIFT-
TOF/TOF MS analysis [203] (performed by Grant Smolenski, Food & Bio-based 
Products Group, AgResearch). Two peptides were identified in the spectrum with 
MOWSE probability scores of 43.8 and 52.4. Further fragmentation of the peptides 
using post-source decay produced spectra with good sequence coverage of the mutation 
site of rbCath1 (Figure 3.9 A, B). This confirmed the 3 kDa cleavage product had the 
predicted sequence of R131 to R155. The putative second cathelicidin-1 peptide (with 
sequence RITKQPWAPPQAA) was hereafter referred to as the RITK peptide. 
 
3.3.3.3 MS analysis of stimulated neutrophil culture media 
Having confirmed that the RITK peptide could be produced in vitro, it was then 
necessary to establish whether the peptide could be produced by bovine neutrophils ex 
vivo. Isolated neutrophils were stimulated in culture with PMA or calcium ionophore for 
up to eight hours to promote release of granule contents and maturation of AMPs. 
Supernatants were removed for analysis by LC-MS/MS (performed by Stefan Clarens 
and Ancy Thomas, Food & Bio-based Products Group, AgResearch) to identify the 
RITK peptide (Figure 3.10 A, B). Synthetic versions of the RITK peptide and Bac1 
were used to calibrate the instrument. Bac1 was detected in greater concentrations as 
treatment time progressed, indicating that endogenous neutrophil elastase processing 
does occur ex vivo. However, the RITK peptide could not be detected after either 
treatment at any of the time points measured. 
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m/z measured 476.258
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Figure 3.9 Peptide mass fingerprint data after post-source decay for the 3 kDa 
cleavage product  
Fragmentation mass spectra generated from MALDI LIFT-TOF/TOF analysis. (A) and (B) represent two 
peptides identified after post-source decay which cover the A to F mutation in the expected 3 kDa 
cleavage product. 
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Figure 3.10 LC chromatograms of stimulated neutrophil culture media 
Neutrophils were stimulated with (A) 10 µM calcium ionophore (CI A23187) or (B) 100 ng/ml PMA for 
the indicated times. Culture plates were centrifuged and the supernatants were removed and analysed by 
LC-MS/MS. No signal for the RITK peptide (dark blue) was observed after either type of stimulation. 
False positives have either the wrong charge state or different actual mass and charge. 
Chapter 3: Expression and Activity of Recombinant Cathelicidin-1 88 
 
 
3.3.4 Investigation of RITK peptide activity 
3.3.4.1 MIC determination 
As AMPs generally have strong antimicrobial activity, a synthetic version of the 
potentially novel RITK peptide was tested in a standard MIC assay. Several species of 
microbe were exposed to titrations of the peptide for 24 hours to determine the MIC of 
the RITK peptide for each microbe. 
 
The RITK peptide was tested at two-fold titrations from 100 µM but was unable to 
inhibit the growth of either E. coli or S. aureus after 24 hours at any concentration (data 
not shown). The growth of C. albicans was also uninhibited in Sabouraud B medium 
and RPMI 1640 medium. 
 
3.3.4.2 Neutrophil respiratory burst 
Some AMPs have no intrinsic antimicrobial activity but may have the ability to bind 
specific receptors and illicit immune responses in certain cell types. For example fMLP 
[32] can activate human neutrophils via the fPRL-1 receptor, inducing ROS production 
and chemotaxis [150,152]. Therefore the RITK peptide was tested for modulation of 
respiratory burst in naïve or activated bovine neutrophils but was unable to modify the 
respiratory burst of cells in either state (Figure 3.11 A, B).  
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Figure 3.11 The effect of the RITK peptide on bovine neutrophil respiratory burst 
Extracellular superoxide production was tested using the colourimetric dye WST-1 and the absorbance 
was measured after 1 hour. (A) Naïve cells and (B) cells activated with 100 ng/ml PMA. Data represent 
the mean WST-1 reduction relative to naïve controls ± SEM for two independent experiments performed 
in triplicate. No statistical significance was found using a one-way ANOVA with Tukey’s post-test 
comparing treatments with untreated controls (0 µM AMP). 
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3.4 Discussion 
The aims of the experiments in this chapter were to produce rbCLD and rbCath1 and 
compare the humoral activity and cytotoxicity to a native purification of Cath1. 
Additionally, rbCath1 was used to investigate whether cathelicidin-1 could produce a 
second AMP through cleavage by neutrophil elastase.  
 
3.4.1 Expression and activity of rbCLD and rbCath1 
A high yield of predominantly soluble monomeric rbCLD was produced in E. coli. 
However, rbCath1 was expressed as insoluble inclusion bodies which required 
solubilisation with a strong chaotropic agent and subsequent refolding. The CLD 
contains two conserved disulfide bonds (C56-C67 and C78-C95). These require the 
correct pairing and orientation when overexpressed in E. coli in order for the protein to 
fold correctly. As rbCLD was produced as soluble protein when overexpressed, the 
presence of a third disulfide bond (C117-C125) in the AMP domain of rbCath1 is likely 
to have caused the inclusion bodies to form. Several methods are available to attempt to 
overcome inclusion body formation [208], however in this case adequate soluble protein 
was produced by refolding rbCath1. 
 
Native Cath1, rbCLD and rbCath1 were able to bind LPS with significantly greater 
affinity than the casein control, but with only 20-30% of the capacity of LBP. Despite 
this comparatively low binding capacity, cathelicidin is relatively abundant during 
infection [108] which could translate into a large overall capacity to sequester LPS 
during infection. Binding of LPS and other pathogen associated molecular patterns 
(PAMPs) can also aid agglutination of microbes. However, rbCLD and rbCath1 were 
unable to aggregate any microbe tested, whereas native Cath1 was able to efficiently 
aggregate C. albicans and the Gram-positive bacteria S. uberis and S. aureus. This 
suggests that native Cath1, at least, may have affinity for peptidoglycans such as 
lipotechoic acid, a major constituent of Gram-positive bacterial cell walls. Gram-
negative bacteria appeared to be unaffected by any treatment, consistent with the LPS-
binding data, although E. coli could not be adequately tested due to spontaneous 
agglutination. Further binding assays with alternate types of PAMPs would clarify these 
observations.  
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As agglutination of microbes can aid clearance by phagocytes it is interesting to observe 
the cytotoxic nature of native Cath1 toward bovine neutrophils. This may indicate a 
non-specific mode of action such as aggregation at the membrane [209] leading to 
membrane permeabilisation. As CLD concentration can reach 100 µg/ml (~10 µM) 
[108] in an inflammatory environment this may serve to regulate excessive neutrophil 
activity and prevent the spread of pathogens.  
 
A question remains as to why rbCLD and rbCath1 were not able to exhibit the same 
activity as the native Cath1 preparation. Western blot analysis revealed a high molecular 
weight A32-positive band in the native Cath1 preparation at approximately 50 kDa (see 
Figure 3.2 E). Preparation of proteins for SDS-PAGE involves boiling protein solutions 
in denaturing buffer. The presence of this high molecular weight CLD indicates that 
tetrameric forms or aggregates of the protein may be produced in vivo, which have 
strong intermolecular bonds inaccessible to the denaturants in sample loading buffer. 
Only dimeric structures appeared to be formed during recombinant overexpression, and 
none of these higher molecular weight structures were present in neutrophil lysates. 
This indicates a structural rearrangement may occur in vivo, after cathelicidin is released 
during infection. Structural analysis of the porcine protegrin-3 CLD indicates domain-
swapped dimers can be formed [97] and high molecular weight forms, either multimers 
or aggregates of cathelicidins, have been observed previously [58,110]. No post-
translational modifications have been reported for the CLD therefore it is possible that 
the activity observed with the native form is due to the formation of multimeric 
complexes of the CLD that for some unforeseen reason do not occur with the 
recombinant proteins. Further analysis of the different molecular weights of native 
Cath1 protein would clarify if this activity is specific to certain multimers. 
 
3.4.2 The RITK peptide 
The use of rbCath1 in the investigation of a second peptide of cathelicidin-1 generated a 
3 kDa fragment which was resolved by SDS-PAGE and identified by Western blot. MS 
analysis confirmed the peptide had the predicted sequence indicating the RITK peptide 
might be produced in vivo. Neutrophils were stimulated to release cathelicidins and the 
culture media was analysed by LC-MS/MS. However, the RITK peptide could not be 
identified in this ex vivo experiment.  
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There are many factors that may have contributed to this outcome. In particular, the in 
vitro activity of the bovine neutrophil elastase is reported to have 50 times less activity 
compared to the human protease when cleaving the synthetic substrate peptidyl-7-
amino-4-methylcoumarin [210]. A BLAST sequence alignment shows 67% homology 
between bovine and human neutrophil elastase with identical catalytic residues but 
altered active site residues [211]. This might explain why the bovine protease has less 
activity on synthetic substrates compared to the human protease, and why production of 
the RITK peptide was not observed ex vivo. However, Bac1 was able to be detected in 
culture media, demonstrating neutrophil elastase activity was present. If the RITK 
peptide is actually produced at all, it may be possible that it is only generated within the 
phagosome and is not produced extracellularly. Further methods toward clarifying the 
existence of the RITK peptide are discussed in Chapter 6, section 6.2.2. 
 
While the existence of a secondary peptide from cathelicidin-1 was not confirmed, the 
inability of the synthetic peptide to inhibit microbial growth was not unexpected. 
Multiple peptide fractions of similar molecular weight were separated when Bac1 was 
first identified [86] which may have included the RITK peptide. The fraction later found 
to contain Bac1 was of particular interest because of the strong antimicrobial activity it 
exhibited. Other peptide fractions were overlooked due to their inability to inhibit 
microbial growth. Some AMPs have also been identified which lack intrinsic 
antimicrobial activity but are able to modify innate immunity [212,213]. Despite this, 
the RITK peptide was unable to modify neutrophil respiratory burst, however this was 
only one assay of one cell type, therefore possible functions for this peptide remain 
open. Clarification of the existence of the peptide in vivo will validate whether further 
functional research is practical. 
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3.5 Conclusions 
Two recombinant versions of the cathelicidin-1 host defence protein were produced by 
over expression in E. coli. The recombinants bound less LPS, were unable to agglutinate 
microbes, and were unable to permeabilise neutrophil membranes when compared to 
native Cath1. A possible explanation for this is the existence of a high molecular weight 
multimer of cathelicidin in the native Cath1 preparation which was not observed in the 
recombinant protein preparations. 
 
A second peptide was generated by in vitro proteolytic cleavage of the C-terminal of 
rbCath1. Stimulation of neutrophils ex vivo produced detectable Bac1 peptide but did 
not produce detectable RITK peptide. Different approaches to this experiment, such as 
isolating and recombining the protease- and cathelicidin-containing granule subsets may 
yield evidence to the contrary. A synthetic version of the putative 13 amino acid RITK 
peptide was not able to inhibit microbial growth, nor was it able to modulate neutrophil 
respiratory burst. However, this does not rule out other immunomodulatory functions 
for the peptide. The established bovine cathelicidin AMPs do have antimicrobial 
activity and cathelicidin AMPs from other species are able to modulate immune cell 
function. The possibility that the bovine cathelicidin AMPs modulate key bovine 
neutrophil functions was investigated in Chapter 4. 
 
 
 
Chapter 4: Modulation of Bovine Neutrophil 
Function by Cathelicidin AMPs
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4.1 Introduction 
4.1.1 Neutrophil functions 
Neutrophil recruitment and activation is a vital part of the first line of defence against 
invading pathogens. Upon activation, neutrophils engage a number of methods for 
effective host defence, including migration, respiratory burst, phagocytosis, and the 
release of granules containing cathelicidin AMPs and other humoral components [214]. 
Cathelicidin peptides are considered to act primarily as antimicrobial components. 
However, there is evidence that AMPs can also regulate inflammation [215], immune 
cell function [102,154,155], and elicit different effects on naïve and activated cells 
[160,216]. These peptides are from a range of species, each having different structures 
and unique sequences. Bovine express seven cathelicidin AMPs and each have 
significantly different sequences and structures. The ability of AMPs from other species 
to regulate immune cell function and the existence of seven different bovine AMPs led 
to the hypothesis that: bovine cathelicidin AMPs differentially modulate naïve and 
activated bovine neutrophil functions. 
 
4.1.2 LPS-binding activity 
Principal investigations of cathelicidin AMPs have focused on their antimicrobial 
activity, a component of which involves binding PAMPs. The most common PAMP 
associated with Gram-negative bacteria is LPS. The LPS-binding capacity of host 
defence peptides and proteins can vary significantly within and between species due to 
hydrophobicity, charge and structure [217-220]. LPS sequestration can translate into 
immune modulation through prevention of TLR activation [178] and inhibition of 
downstream intracellular signalling. Results from Chapter 3 indicated the CLD was able 
to weakly bind LPS. However, due to the variation in structure, sequence and net charge 
of the different bovine AMPs, the ability to bind LPS might be different for each 
peptide, leading to the hypothesis that: bovine cathelicidin AMPs vary in their ability 
to bind LPS. 
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4.2 Aims 
 Investigate the modulatory effects of bovine AMPs on neutrophil innate immune 
function. 
 Measure LPS-binding capacity of a representative selection of bovine 
cathelicidin AMPs. 
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4.3 Results 
4.3.1 Neutrophil isolation 
Neutrophils were isolated by hypotonic lysis of RBCs and density gradient 
centrifugation to separate granular cells from peripheral blood mononuclear cells. This 
technique reliably isolated neutrophils with >95% viability as determined by trypan blue 
exclusion. On average, isolated cells were 96% neutrophils and 4% eosinophils. 
 
4.3.2 Primary screen of neutrophil function 
4.3.2.1 Cathelicidin AMP selection 
Five representative bovine cathelicidins, as well as a linear variant of the Bac1 β-turn 
peptide, were selected for initial testing based on their difference in structure and 
composition (Table 4.1). Bac1 is the smallest AMP identified to date and may exist in a 
linear conformation in vivo [86,221,222], therefore both Bac1 variations were selected 
to identify effects attributable to either structure. Bac5 contains a repeating proline-rich 
motif (PPXX, where X indicates any amino acid) found in other cathelicidins [223] and 
has a relatively high net positive charge. Conversely, the linear peptide indolicidin is 
unique across species, containing an unusually high content of tryptophan [69].  
BMAP-28 has an α-helical structure with an unstructured hydrophobic C-terminus, 
while BMAP-34 is larger, contains negatively charged amino acids and forms an 
amphipathic α-helix. 
  
Table 4.1 Properties of the selected bovine cathelicidin AMPs 
Protein AMP Structure Sequence Weight (kDa) 
Net 
charge Feature 
Cathelicidin-1 Bac1 β-turn 
      ┌────────┐ 
RLCRIVVIRVCR 1.5 +4 
Disulfide 
bond 
Cathelicidin-1 Bac1 Linear RLCRIVVIRVCR 1.5 +4 Free cysteines 
Cathelicidin-2 Bac5 Linear/poly-proline helix 
RFRPPIRRPPIRPPFYPPFR
PPIRPPIFPPIRPPFRPPLG
PFP-NH2 
5.1 +9 Proline and arginine rich  
Cathelicidin-4 Indolicidin Linear ILPWKWPWWPWRR-NH2 1.9 +3 
Tryptophan 
rich 
Cathelicidin-5 BMAP-28 α-helical GGLRSLGRKILRAWKKYGPIIVPIIRI-NH2 
3.1 +7 Hydrophobic C-terminus 
Cathelicidin-7 BMAP-34 α-helical GLFRRLRDSIRRGQQKILEKARRIGERIKDIFR-NH2 
4.2 +8 Amphipathic 
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The physiological concentration of bovine AMPs during infection has not been 
reported. Therefore the bovine cathelicidin peptides were first tested at a concentration 
of 5 M, consistent with the concentrations at which human LL-37 [150] and porcine 
PR-39 [154] are reported to exhibit immune activity. Neutrophils recruited to sites of 
inflammation are readily activated therefore the response of both naïve and PMA-
activated neutrophils in the presence of AMP was measured in this study. The survival, 
migration, degranulation, respiratory burst, phagocytosis and intracellular calcium 
mobilisation of naïve and activated cells were tested to determine the effect of the 
bovine AMPs on these functions. As neutrophils are one of the first types of immune 
cell to respond to infection and inflammation, their key functions were measured after 
1 hour exposure.  
 
4.3.2.2 Bovine α-helical peptides induce cytotoxicity 
The cytotoxic effects of the different AMPs were measured by flow cytometry to 
determine the proportion of viable (annexin-V-negative/PI-negative), apoptotic 
(annexin-V-positive/PI-negative) and necrotic (PI-positive) cells. Analysis of the flow 
cytometry data showed that only BMAP-28-treated cells were significantly stained with 
PI, indicating that cell death was primarily the result of necrosis (Figure 4.1 A). After 
stimulation with PMA, only BMAP-34 induced a significant drop in neutrophil 
viability, also via the induction of necrosis (Figure 4.1 B). A trend towards increased 
cytotoxicity in PMA-stimulated neutrophils was also observed for BMAP-28. The 
remaining peptides had no effect on naïve or activated neutrophil survival. 
 
4.3.2.3 BMAP-28 induces membrane permeabilisation 
BMAP-28 is known to be cytotoxic [127,224], driven by its ability to increase cell 
membrane permeability through pore formation [160]. To determine whether BMAP-28 
and BMAP-34 were able to permeabilise the neutrophil membrane, peptide treated cells 
were incubated with the cell impermeable dye SYTOX Orange. As shown in  
Figure 4.1 C, neutrophils treated with PMA alone did not stain for SYTOX Orange 
indicating that the membrane was intact. Naïve neutrophils treated with BMAP-28 
showed significant levels of intracellular staining. Activated cells were more susceptible 
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to BMAP-28 permeabilisation, while BMAP-34 treatment only induced moderate 
staining of PMA-activated cells. 
 
4.3.2.4 Multiple bovine AMPs induce neutrophil migration 
Cathelicidin peptides LL-37 and PR-39 are reported to induce neutrophil migration at 
micromolar concentrations [102,196]. As these physically contrasting peptides were 
able to induce migration in their respective species, the bovine AMPs were each tested 
for their ability to induce bovine neutrophil migration. A modified Boyden chamber 
with a polycarbonate membrane containing 3 µm pores was used to assess migration 
toward 5 µM solutions of AMP. Bac1, linear Bac1, Bac5 and BMAP-28 each induced 
significant neutrophil migration (Figure 4.1 D). Weak migration was observed in 
response to BMAP-34, whereas indolicidin had no effect. 
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Figure 4.1 Primary screen of neutrophil function 1 
Neutrophil functions were assessed after incubation in the presence of 5 μM AMP for 1 hour. 
Cytotoxicity of AMPs toward (A) naïve cells and (B) cells activated with 100 ng/ml PMA was measured 
by flow cytometry. Annexin-V and PI were used to distinguish viable (annexin-V-negative/PI-negative), 
apoptotic (annexin-V-positive/PI-negative) and necrotic (PI-positive) cells. (C) Permeabilisation of 
neutrophils by BMAP-28 and BMAP-34 was measured using the cell-impermeant fluorescent dye 
SYTOX Orange. (D) Migration of naive neutrophils in response to 5 μM AMP was assessed using a 
Boyden chamber. All data represent the mean ± SEM for three independent experiments. Statistical 
significance was determined by one-way ANOVA with Tukey’s post-test comparing treatments with 
control or Student’s t-test comparing treatments. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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4.3.2.5 Degranulation is only affected by BMAP-28 treatment 
The process of neutrophil migration to inflammatory foci and activation commonly 
triggers neutrophil secretory granule release [42]. After 1 hour exposure to AMPs, 
granule contents released into the culture media from naïve and activated cells were 
measured by activity assays and immunoblotting. MPO activity was used as a measure 
of primary granule release. Western blot of CLD content was used as a measure of large 
granule release. Alkaline phosphatase activity was used as a measure of secretory 
vesicle release. Degranulation in response to the peptides was only observed following 
BMAP-28 treatment where both naïve and activated cells released significant amounts 
of secretory vesicles and large granules (Figure 4.2 A, B).  
 
4.3.2.6 Bovine AMPs have different effects on respiratory burst 
Respiratory burst is one of the methods by which neutrophils orchestrate bacterial 
killing. It is characterised by the activation of NADPH oxidase leading to production of 
superoxide radical and ROS [48]. Extracellular superoxide production by naïve and 
activated neutrophils exposed to AMP was measured via the reduction of WST-1 to a 
yellow formazan salt. As shown in Figure 4.2 C, a trend for increasing stimulation by 
Bac5 was observed in naïve neutrophils. Linear Bac1 and indolicidin induced 
significant superoxide production in naïve neutrophils. BMAP-28 and BMAP-34 
suppressed basal levels of respiratory burst in naïve cells and also suppressed 
respiratory burst in activated cells (Figure 4.2 D). 
 
4.3.2.7 Bac5 enhances phagocytosis 
Neutrophils are phagocytes. To investigate whether the AMPs affected phagocytosis, 
AMP-treated neutrophils were incubated with opsonised fluorescent beads and analysed 
by flow cytometry to identify fluorescence-positive cells. Bac5 induced a significant 
increase in neutrophil phagocytosis compared to untreated controls  
(Figure 4.2 E, F). None of the other peptides significantly altered bead uptake. 
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Figure 4.2 Primary screen of neutrophil function 2 
Neutrophil functions were assessed after incubation in the presence of 5 μM AMP for 1 hour. 
Degranulation was assessed by measuring the release of protein markers of primary granules, large 
granules, and secretory vesicles in (A) naïve cells and (B) cells activated with 100 ng/ml PMA, after 
incubation with AMP. Respiratory burst was measured in (C) naïve cells and (D) cells activated with 
100 ng/ml PMA by reduction of WST-1. Phagocytosis was assessed by the uptake of opsonised 
fluorescent beads using flow cytometry. (E) Representative histogram analysis of phagocytosis. (F) 
Combined phagocytosis histogram data. All data represent the mean ± SEM for three independent 
experiments. Statistical significance was determined by one-way ANOVA with Tukey’s post-test 
comparing treatments with control. * P < 0.05, ** P < 0.01, *** P < 0.001.  
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4.3.2.8 Intracellular calcium mobilisation is not affected by AMP treatment 
Neutrophil innate immune functions are commonly induced by changes in intracellular 
calcium concentrations [225,226]. To measure intracellular calcium mobilisation, 
neutrophils were loaded with the fluorescent calcium ion indicator Fluo-4 AM. Naïve or 
activated neutrophils were then treated with AMP and changes in fluorescence were 
monitored over 1 hour. Treatment with zymosan-activated serum served as a positive 
control which induced a characteristic transitory increase in fluorescence, indicating the 
cells were correctly loaded with Fluo-4 AM. None of the peptides affected intracellular 
calcium flux in either naïve (Figure 4.3 A) or activated (Figure 4.3 B) cells except for 
BMAP-28. BMAP-28 induced a gradual increase in fluorescence in naïve and activated 
cells, which was similar to that induced by 10 μM calcium ionophore A23187. This 
indicated a steady flux of calcium, and is consistent with cell permeabilisation induced 
by this peptide. These results are also consistent with the fact that activation with PMA 
does not induce calcium flux in bovine (or human) neutrophils [210]. It is also 
interesting to note that cytotoxicity induced in activated cells by BMAP-34 is not 
accompanied by changes in intracellular calcium and indicates BMAP-34 induces a 
controlled mode of cell death. 
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Figure 4.3 Primary screen of neutrophil function 3 
Intracellular calcium mobilisation of (A) naïve cells and (B) cells activated with 100 ng/ml PMA was 
monitored in the presence of AMP over 1 hour. Neutrophils were loaded with Fluo-4 AM before exposure 
to treatments. BMAP-28-induced calcium mobilisation was significant (arbitrary fluorescence units, 
P < 0.001) after 10 minutes in both naïve and PMA-activated neutrophils. Note the change in time scale 
indicated by the break. Data represent the mean ± SEM for at least three independent experiments 
performed in triplicate. Statistical significance was determined by one-way ANOVA with Tukey’s post-
test comparing treatments with control. CI A23187, calcium ionophore A23187; ZAS, zymosan-activated 
serum. 
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4.3.2.9 Summary of the primary screen analysis of neutrophil function 
A summary of the results from the primary screen is provided in Table 4.2 and  
Table 4.3. Due to the ability to induce or inhibit key neutrophil functions in the absence 
of cytotoxic effects (with the caveat of BMAP-34 only inducing cell death in PMA-
activated neutrophils), linear Bac1, Bac5 and BMAP-34 were selected for further 
analysis in dose-response assays. BMAP-28 was excluded because significant cell death 
was induced in naïve and activated cells, suggesting the pro-inflammatory effects were 
primarily due to non-specific cell death. Indolicidin and the β-turn form of Bac1 were 
excluded as they were only able to respectively induce migration or respiratory burst. 
However, the selective nature of these two peptides is worthy of future investigation. 
 
Table 4.2 Primary screen summary 1 
 Neutrophil response 
  Cell death  Migration  Granule release 
Peptide Naïve Activated  Naïve  Naïve Activated 
Bac1     +    
Linear Bac1     +    
Bac5    +    
Indolicidin        
BMAP-28 +   +  + + 
BMAP-34  +      
(+) indicates induction or enhancement; (-) indicates inhibition  
 
Table 4.3 Primary screen summary 2 
 Neutrophil response 
  Respiratory burst   Phagocytosis   Calcium flux 
Peptide Naïve Activated   Naïve   Naïve Activated 
Bac1          
Linear Bac1  +       
Bac5    +    
Indolicidin +       
BMAP-28 - -    + + 
BMAP-34 - -           
(+) indicates induction or enhancement; (-) indicates inhibition  
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4.3.3 Dose-response analysis of neutrophil function 
In this section the functional assays were adjusted to a dose-response format, and where 
appropriate, optimised to better mimic the in vivo conditions neutrophils encounter 
during inflammation. Starting at a maximum concentration of 10 µM, a two-fold 
titration of each peptide was tested to determine dose-response effects. For migration 
assays a ten-fold titration was tested. 
 
4.3.3.1 Cytotoxicity 
To determine the effect of bovine cathelicidins on neutrophil survival, naïve and 
activated neutrophils were incubated with the selected AMPs for 1 hour. Because 
minimal cytotoxicity was observed after 1 hour, cytotoxicity was also measured after 
6 hours, before the time at which neutrophils undergo spontaneous apoptosis [55]. 
Pacific Blue-conjugated annexin-V was used to distinguish apoptosis. Due to the large 
number of samples to be analysed by flow cytometry, a fixable necrotic cell dye 
(LIVE/DEAD Fixable Red Dead Cell Stain) was used, as propidium iodide has the 
propensity to leach out of dead cells that are not analysed soon after staining.  
 
Consistent with the results of the preliminary assays, the AMPs had little effect on naïve 
neutrophil viability within the first hour except for BMAP-34 which induced significant 
cell death at 10 µM, primarily by necrosis (Figure 4.4 A). After 6 hours, Bac5 treatment 
increased cell viability over the full concentration range whereas linear Bac1 and 
BMAP-34 each improved cell survival at lower concentrations (Figure 4.4 B). 
 
A significant loss of cells from analysis occurred after neutrophils were treated with 
PMA. It is likely that activation caused a majority of cells to tightly adhere to culture 
plates despite the plates being treated to prevent adherence, and unintentional damage to 
cells is likely to have ensued during the staining and wash procedures. Consequently, 
the results probably do not accurately reflect the true proportions of viable, apoptotic 
and necrotic cells. However, in the activated neutrophils that could be analysed, all three 
AMPs showed a trend toward inducing necrotic cell death as the concentration 
increased (BMAP-34 > Bac5 > linear Bac1) (Figure 4.5 A, B). 
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Figure 4.4 Survival of naïve neutrophils after linear Bac1, Bac5 or BMAP-34 
treatment 
Survival of naïve cells after (A) 1 hour or (B) 6 hours of AMP treatment was measured by flow 
cytometry. Pacific Blue-annexin-V and LIVE/DEAD Fixable Red Dead Cell Stain were used to 
distinguish viable (annexin-V-negative, LIVE/DEAD-negative), apoptotic (annexin-V-positive, 
LIVE/DEAD-negative) and necrotic (LIVE/DEAD-positive) cells. The cells were fixed with 
4% (w/v) paraformaldehyde in PBS, washed, and resuspended in sheath fluid before analysis. Data 
represent the mean ± SEM for three independent experiments performed in duplicate. Statistical 
significance was determined by one-way ANOVA with Fisher’s post hoc test comparing AMP treatments 
with untreated controls (0 µM AMP). * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 4.5 Survival of activated neutrophils after linear Bac1, Bac5 or BMAP-34 
treatment 
Survival of cells activated with 100 ng/ml PMA after (A) 1 hour or (B) 6 hours of AMP treatment was 
measured by flow cytometry. Pacific Blue-annexin-V and LIVE/DEAD Fixable Red Dead Cell Stain 
were used to distinguish viable (annexin-V-negative, LIVE/DEAD-negative), apoptotic (annexin-V-
positive, LIVE/DEAD-negative) and necrotic (LIVE/DEAD-positive) cells. The cells were fixed with 
4% (w/v) paraformaldehyde in PBS, washed, and resuspended in sheath fluid before analysis. Data 
represent the mean ± SEM for three independent experiments performed in duplicate. Statistical 
significance was determined by one-way ANOVA with Fisher’s post hoc test comparing AMP treatments 
with untreated controls (0 µM AMP). * P < 0.05, ** P < 0.01, *** P < 0.001. 
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4.3.3.2 Migration 
Neutrophil chemoattractants commonly induce their effects at nanomolar 
concentrations. Therefore the ability of linear Bac1, Bac5 or BMAP-34 to induce the 
migration of naïve neutrophils was assessed at ten-fold concentrations between 10 µM 
and 1 nM. Recombinant human IL-8 was used as a positive control at 5 ng/ml. The 
polycarbonate membranes were coated in Type I collagen to better mimic tissues 
through which neutrophils migrate in response to inflammatory signals. As shown in 
Figure 4.6, all of the AMPs exhibited notably different migration profiles as the AMP 
concentration increased. Linear Bac1 was able to induce significant migration at 1 nM 
which decreased at higher concentrations. The Bac5 migration index increased with 
concentration to a maximum comparable to the positive control (5 ng/ml recombinant 
human interleukin-8, migration index = 6.84 ± 2.82). The maximal response to  
BMAP-34 peaked at 100 nM then dropped significantly. This was consistent with the 
decrease in cell survival observed at higher concentrations of BMAP-34  
(see Figure 4.4 A). 
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Figure 4.6 Neutrophil migration induced by linear Bac1, Bac5 or BMAP-34 
(A) Neutrophil migration was assessed using a Boyden chamber. Polycarbonate membranes were coated 
in collagen (Type I) and migration proceeded for 1 hour. (B) From left to right: representative Boyden 
chamber well at 1  objective, 20  objective and 100  objective (oil immersion). Data represent the 
mean ± SEM for two independent experiments (linear Bac1) or four independent experiments (Bac5, 
BMAP-34) performed in duplicate. Statistical significance was determined by one-way ANOVA with 
Tukey’s post-test comparing AMP treatments with untreated controls. * P < 0.05, ** P < 0.01.  
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4.3.3.3 Degranulation 
Significant degranulation for linear Bac1, Bac5 and BMAP-34 was not observed in the 
primary screen assays, therefore the dose-response assays were extended out to 6 hours. 
A trend toward increasing primary granule release was observed after 6 hours treatment 
with linear Bac1, which peaked at 1.25 μM (Figure 4.7 A). Bac5 and BMAP-34 were 
unable to significantly alter primary granule release in naïve neutrophils. Activated 
neutrophils did not release as much MPO as naïve neutrophils. Even when treated with 
peptide the response remained suppressed, with linear Bac1 and BMAP-34 inducing 
minor increases at the lowest concentration tested. Bac5 produced a similar increase at 
2.5 μM only. Overall, primary granule release was minor, with less than 10% of the 
total cellular MPO released at any time. 
 
The secondary granules of bovine neutrophils contain humoral mediators of the innate 
immune response which are bacteriostatic and bactericidal in nature. These mediators 
include lysozyme, lactoferrin and TCII (vitamin B12 binding protein) [227]. Therefore, 
in the dose-response assays, secondary granule release was measured instead of 
secretory vesicle release. Western blot was used to measure TCII as an indicator of 
secondary granule release (Figure 4.7 B) and dot blot was used to measure CLD as an 
indicator of large granule release (Figure 4.7 C). All three peptides appeared to suppress 
secondary granule release by naive neutrophils whereas Bac5 dose-dependently 
increased secondary granule release in activated cells (Figure 4.7 B). Linear Bac1 also 
appeared to enhance secondary granule release in activated cells but not to a significant 
degree.  
 
Neither linear Bac1 nor Bac5 had a significant effect on large granule release by naive 
or activated cells (Figure 4.7 C). However, naïve neutrophils treated with BMAP-34 
exhibited a dose-dependent increase in large granule release that then dropped away at 
higher concentrations. A similar effect was observed in activated cells, where the 
amount of CLD released reached a maximum at 0.63 µM BMAP-34, which dropped 
below background levels at higher concentrations. 
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Figure 4.7 Neutrophil granule release after 6 hours of linear Bac1, Bac5 or  
BMAP-34 treatment 
Naïve cells and cells activated with 100 ng/ml PMA were treated with AMP for 6 hours. MPO activity in 
neutrophil culture supernatants was used as an indicator of (A) primary granule release. The percentage of 
primary granule release was determined from the total MPO activity of an equivalent number of cells. 
Data represent the mean ± SEM for two independent experiments performed in triplicate. Western blot 
and dot blot of the granule markers TCII and CLD in neutrophil culture supernatants were used as an 
indicator of (B) secondary and (C) large granule release, respectively. Data represent the mean ± SEM for 
three independent experiments performed in triplicate. Statistical significance was determined by one-
way ANOVA with Fisher’s post hoc test comparing AMP treatments with untreated controls 
(0 µM AMP). * P < 0.05, ** P < 0.01. 
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4.3.3.4 Respiratory burst 
Measurement of superoxide production induced by linear Bac1, Bac5 and BMAP-34 
gave similar results to the screening assays. As shown in Figure 4.8 A, linear Bac1 and 
Bac5 induced a dose-dependent increase in superoxide production in naïve neutrophils. 
The approximate EC50 values were 1.66 ± 0.24 µM and 0.39 ± 0.17 µM, respectively. 
As seen in the primary screen assay, BMAP-34 inhibited superoxide production 
compared to untreated controls. The strong production of superoxide elicited by PMA 
(PMA-treated controls = 16.63 ± 1.70) was not affected by either linear Bac1 or  
BMAP-34 (Figure 4.8 B). However, 10 µM Bac5 was able to significantly inhibit PMA-
induced superoxide production.  
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Figure 4.8 Neutrophil respiratory burst after linear Bac1, Bac5 or BMAP-34 
treatment 
Extracellular superoxide production was measured using the colourimetric dye WST-1. Absorbance was 
measured after 1 hour exposure to AMP for (A) naïve cells and (B) cells activated with 100 ng/ml PMA. 
Data represent the mean WST-1 reduction relative to naïve controls ± SEM for three independent 
experiments performed in triplicate. Statistical significance was determined by one-way ANOVA with 
Fisher’s post hoc test comparing AMP treatments with untreated controls (0 µM AMP). * P < 0.05, 
** P < 0.01, *** P < 0.001.  
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4.3.3.5 Phagocytosis 
Assays of neutrophil phagocytosis in the presence of linear Bac1, Bac5 and BMAP-34 
were modified so that the cells were not pretreated with AMP. Instead, peptide was 
added along with the opsonised beads. Additionally, the opsonised beads were washed 
in media prior to their addition to the assay to remove traces of activated serum. 
Cytochalasin B inhibits phagocytosis by interfering with actin filament formation and 
was used as a negative control of phagocytosis in these assays, while PMA was used as 
a positive control. All three peptides enhanced phagocytosis in a dose-dependent 
manner (Figure 4.9). 
 
4.3.3.6 Intracellular calcium mobilisation 
The assays for calcium mobilisation remained unchanged from the primary screen 
assays. None of the AMPs induced a change in fluorescence in either naïve  
(Figure 4.10 A) or activated (Figure 4.10 B) neutrophils at any of the concentrations 
tested. The same result was observed after 1 hour (Figure 4.10 C, D). These data 
indicated calcium mobilisation within neutrophils remained unchanged throughout 
treatment. 
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Figure 4.9 Phagocytosis during linear Bac1, Bac5 or BMAP-34 treatment 
Neutrophils were incubated in the presence of AMP and opsonised FluoSpheres for 1 hour before analysis 
by flow cytometry. (A) Representative histogram analysis. (B) Proportion of cells that had completely 
phagocytosed beads during AMP treatment. (C) Representative fluorescence photomicrograph of a 
phagocytosing neutrophil showing internal FluoSpheres (arrows). Control values: 10 µM cytochalasin B, 
1.66 ± 0.38%; 100 ng/ml PMA, 6.72 ± 1.49%, P < 0.05. Data represent the mean ± SEM for three 
independent experiments performed in duplicate. Statistical significance was determined by one-way 
ANOVA with Fisher’s post hoc test comparing AMP treatments with untreated controls (1.15 ± 0.18%). 
* P < 0.05, *** P < 0.001.  
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Figure 4.10 Calcium mobilisation during linear Bac1, Bac5 or BMAP-34 treatment 
Neutrophils were loaded with Fluo-4 AM and changes in intracellular calcium of (A) naïve cells and (B) 
cells activated with 100 ng/ml PMA were monitored in the presence of AMP for 3 minutes. AMP alone or 
AMP and PMA were added at 0 minutes. After 1 hour exposure the fluorescence of Fluo-4 AM was also 
measured for (C) naïve cells and (D) cells activated with 100 ng/ml PMA. Data represent the mean 
± SEM for three independent experiments performed in triplicate. Statistical significance was determined 
by one-way ANOVA with Fisher’s post hoc test comparing AMP treatments with untreated controls 
(0 µM AMP). ** P < 0.01. CI A23187, calcium ionophore A23187; ZAS, zymosan-activated serum. 
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4.3.3.7 Summary of the dose-response analysis of neutrophil function 
A summary of the dose-response analysis is provided in Table 4.4 and Table 4.5. 
Differences in relation to the primary screen assays generally occur due to modification 
of the experimental approach. However, it should be noted that variation in results 
between the primary screen analysis and the dose-response analysis could result in part 
from seasonal variation in cattle immune responses. This is a well reported phenomenon 
in several species including humans [228-230]. This is particularly relevant considering 
the primary screen data were collected in autumn and winter, and the dose-response data 
were collected in spring and summer. 
 
Table 4.4 Dose-response summary 1 
 Neutrophil response 
 Cell death   Granule release 
  1 hour   6 hours   1 hour   6 hours 
Peptide Naïve Activated   Naïve Activated   Naïve Activated   Naïve Activated 
Linear Bac1     - -     + + 
Bac5    -       + 
BMAP-34 +     -/+ +          + + 
(+) indicates induction or enhancement; (-) indicates inhibition  
 
Table 4.5 Dose-response summary 2 
 Neutrophil response 
 Migration   Respiratory burst   Phagocytosis   Calcium flux 
Peptide Naïve  Naïve Activated  Naïve  Naïve Activated 
Linear Bac1  +  +   +    
Bac5 +  + -  +    
BMAP-34 +   -    +       
(+) indicates induction or enhancement; (-) indicates inhibition  
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4.3.4 LPS-binding activity 
To test the hypothesis of LPS-binding, a standard chromogenic Limulus amoebocyte 
lysate assay was modified so that serial dilutions of peptide were spiked with a known 
concentration of LPS. Measurement of free LPS in solution permitted AMP binding 
parameters to be calculated (Figure 4.11, Table 4.6). All peptides demonstrated LPS-
binding activity. Linear Bac1 and BMAP-34 had the greatest LPS-binding capacity with 
EC50 values of 0.1 µM. BMAP-28 also had a similarly low EC50 value of 0.2 µM 
contrary to a previous report (cf. 4.2 μM [161]). Bac1 and Bac5 had EC50 values of 
0.4 µM and 0.5 µM, respectively. Indolicidin had the least LPS-binding capacity with 
an EC50 value of 1.1 µM. The LPS-binding capacity of LL-37 was also tested to allow 
these data to be compared with previous reports. LL-37 bound LPS with an EC50 of 
0.3 µM which was similar to previous reports (cf. 0.36 µM [231] and 0.42 μM [137]). 
 
4.3.5 AMP-induced cytokine release from bovine neutrophils 
Neutrophils have a role in cytokine-mediated signalling during the inflammatory 
response [232]. The strong LPS-binding activity of the bovine peptides led to the 
hypothesis that the bovine AMPs would augment the release of cytokines from LPS-
stimulated neutrophils. Culture media from unstimulated or LPS-stimulated neutrophils 
treated with AMP were tested for the bovine cytokines TNFα, IL-1β, IL-6, IL-8 and  
IL-10 by enzyme-linked immunosorbent assay (ELISA). However, control samples 
without cells, containing only media and AMP gave false positive readings in several of 
the ELISAs tested. Control samples containing media alone were negative. This 
strongly indicated that the bovine AMPs were non-specifically binding antibody 
molecules leading to false-positive readings. This technical problem is discussed further 
in Appendix 1. Subsequently, investigation into cytokine release by neutrophils was not 
further pursued. 
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Figure 4.11 LPS-binding activity of bovine cathelicidin AMPs 
Serial dilutions of peptide were spiked with 0.5 EU and incubated for 30 minutes at 37 °C. Free LPS was 
measured with a chromogenic Limulus amoebocyte lysate assay kit. Data represent the mean ± SEM for 
at least two independent experiments performed in duplicate. 
 
Table 4.6 LPS-binding statistics 
 
 Best-fit values  95% Confidence Intervals  Goodness of Fit 
Peptide  EC50 (μM)  EC50 (μM)  R² 
Bac1  0.4  0.15 to 1.08  0.16 
Linear Bac1  0.1  0.07 to 0.17  0.61 
Bac5  0.5  0.35 to 0.68  0.89 
Indolicidin  1.1  0.68 to 1.70  0.87 
BMAP-28  0.2  0.12 to 0.19  0.93 
BMAP-34  0.1  0.07 to 0.18  0.80 
LL37  0.3  0.19 to 0.49  0.81 
Values and statistics were calculated from non-linear regression analysis carried out using Prism v5.0 
(GraphPad Software, Inc.). 
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4.4 Discussion 
The focus of this chapter was to determine the effects of selected bovine cathelicidin 
AMPs on neutrophil function and LPS-binding capacity, testing the hypothesis that 
cathelicidin peptides have differential activities, dependent on AMP structure and 
neutrophil activation status.  
 
4.4.1 The effects of bovine cathelicidin AMPs on neutrophil function 
The six bovine cathelicidin AMPs selected for the primary screen of neutrophil specific 
activity include peptides with different sequence and structure properties (Table 4.1). 
The results of these studies show that individual bovine cathelicidin peptides have the 
ability to exert different effects on naïve and activated neutrophils in a sequence and 
structure dependent manner (Table 4.2, Table 4.3, Table 4.4 and Table 4.5). 
 
The β-turn form of Bac1, indolicidin and BMAP-28 were eliminated from further 
analysis in dose-response assays. In the primary screen analysis these peptides exhibited 
minimal ability to modify neutrophil function or induced cell death. Indolicidin and the 
β-turn form of Bac1 are cytotoxic to rat and human T lymphocytes [159] but were not 
cytotoxic to bovine neutrophils in this study. The only significant activity identified 
with the β-turn form of Bac1 was an ability to enhance the migration rate of naïve 
neutrophils. An increase in migration rate stimulated by Bac1 would serve to enhance 
directed neutrophil infiltration to sites of infection, in a similar manner to 
chemoattractants such as leukotriene B4, C5a and IL-8 [233]. At inflammatory foci, the 
combined antimicrobial effects and enhancement of neutrophil migration by Bac1 
would also indirectly aid phagocytic clearance of bacteria.  
 
Indolicidin is structurally unique in that it contains an unusually high content of 
tryptophan [121]. This unique structure is very divergent from the other bovine AMPs 
and may explain the ability of indolicidin to trigger neutrophil respiratory burst without 
affecting other AMP sensitive neutrophil activities. A possible mechanism for this 
selective activity is unclear although indolicidin has been shown to cross biological 
membranes [234], and may therefore exert its effects intracellularly. 
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Of all the AMPs tested, the α-helical peptide BMAP-28 exhibited the most striking 
‘activity’ profile, and induced significant changes in all of the pro-inflammatory 
neutrophil functions tested in the primary screen assays. However, BMAP-28 is highly 
cytotoxic, a property which has also been observed in cell lines from non-bovine species 
[158,160], and induced significant cell death in both naïve and activated bovine 
neutrophils. This suggests the BMAP-28-induced modulation of neutrophil function is 
primarily the result of cell death. Interestingly, bovine RBCs are tolerant to BMAP-28 
toxicity [127] which suggests BMAP-28-induced neutrophil death may be a specific 
function to promote clearance of spent neutrophils from inflammatory foci. 
 
The in-depth analysis of linear Bac1, Bac5 and BMAP-34 produced interesting results 
(Figure 4.12). With slight modifications to several of the assays to better mimic 
conditions found in vivo, these peptides exhibited dose-dependent effects on neutrophil 
function. Both linear and cyclic structural variants of the Bac1 peptide were able to 
enhance migration indicating amino acid composition, rather than structure, is a 
defining factor for Bac1 enhanced migration. However, the dose-response analysis 
showed the linear form was able to enhance migration at much lower concentrations 
than the β-turn form, suggesting some structural aspect of the linear configuration, as 
well as composition, results in a more potent chemokinetic effect. Linear Bac1 also 
produced a dose-dependent increase in neutrophil respiratory burst, which conversely 
did not occur in the presence of the β-turn form. Similar to indolicidin, liposome 
interaction studies indicate the linear form of Bac1 is effective at penetrating lipid 
bilayers [235]. Therefore linear Bac1 may activate ROS production in a similar manner 
to indolicidin via a cytosolic mechanism. The enhancement of phagocytosis observed in 
the dose-response analysis may likewise occur via an intracellular mechanism.  
 
Bac5 was able to dose-dependently enhance migration, phagocytosis and ROS 
production in naïve neutrophils. In activated neutrophils Bac5 inhibited ROS 
production, enhanced cell survival and promoted secondary granule release. Taken 
together, these results indicate a pro-inflammatory effect which regulates the production 
of ROS to ensure neutrophils remain viable, active and capable of functioning 
appropriately during an immune response. Migration, degranulation and respiratory 
burst induced via intracellular calcium mobilisation is a hallmark of receptor mediated 
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activation [236,237]. The absence of detectable calcium flux in Bac5-stimulated 
neutrophils indicates a receptor-independent mode of action. The opposing inhibitory 
effect of Bac5 on PMA-induced ROS production, which occurs via intracellular 
signalling, also supports a receptor-independent mode of action. The inhibition of PMA-
induced ROS production is similar to that reported for the structurally related proline-
rich porcine cathelicidin PR-39 [154,155], suggesting a common mechanism of 
inhibition by proline-rich peptides. Further studies of this potential mode of action are 
covered in Chapter 5. 
 
The α-helical peptides BMAP-34 and BMAP-28 have similar structure, however 
BMAP-34 is amphipathic, containing positively and negatively charged amino acids 
and hydrophobic amino acids along opposite sides of the α-helical axis [196]. In 
contrast BMAP-28 has an unstructured hydrophobic C-terminal region and lacks 
negative amino acids [127]. Interestingly, in the primary screen assays BMAP-34 
induced membrane permeabilisation and cytotoxicity only in activated neutrophils. The 
difference in structure and the extensive reorganisation of membrane components 
during cellular activation [238] may contribute to the differential effects observed for 
these α-helical peptides. This suggests evolution of the BMAP-34 gene has led to a 
peptide sequence which specifically ‘targets’ activated or spent neutrophils, inducing 
cell death and promoting clearance in a more refined manner compared to BMAP-28.  
 
Like linear Bac1 and Bac5, BMAP-34 also enhanced migration and phagocytosis. 
However, a mild inhibitory effect on naïve cell ROS production was also observed at 
low concentrations. As ROS production can be a mediator of programmed cell death 
[239], inhibition of ROS at low BMAP-34 concentrations correlates with enhanced 
survival of naïve cells after 6 hours exposure to the peptide. At low concentrations 
BMAP-34 also promoted large granule release. Large granules in bovine neutrophils 
contain the pro-forms of cathelicidin [45], therefore this response may represent a 
mechanism of self-regulating cathelicidin release. Together, these results indicate 
BMAP-34 may have a regulatory role to maintain naïve cells and promote inflammatory 
functions at low concentrations while aiding removal of dead cells and debris at high 
concentrations. 
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Previous studies with other AMPs link their biological activities with cell 
permeabilisation, an event that triggers non-specific calcium influx [152,160]. LL-37 
and the bovine peptides BMAP-27 and BMAP-28 have all been shown to elevate 
intracellular calcium levels in conjunction with ROS production and cell death in 
proliferating human lymphocytes [152,160]. Interestingly, linear Bac1, Bac5 and 
BMAP-34 were unable to induce changes in neutrophil intracellular calcium levels 
indicating that these peptides orchestrate their effects via calcium-independent 
signalling pathways. It also indicates that these AMPs are unlikely to be causing non-
specific membrane permeabilisation. 
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Figure 4.12 Summary of the effects of linear Bac1, Bac5 and BMAP-34 on 
neutrophil function in vitro 
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4.4.2 LPS-binding activity 
The ability to bind LPS is a common feature of cathelicidin AMPs (Table 4.7). 
Electrostatic interactions occur between the cationic AMPs and negatively charged LPS 
molecules. Therefore the presence of positive amino acids, and the absence of negative 
amino acids are the main determinants of the AMP binding affinity [240]. Also, the 
relevance of structure is demonstrated by the different binding affinities of the linear 
and β-turn forms of Bac1, and the generally higher but differential binding affinity of 
the α-helical peptides. AMPs with low LPS-binding EC50 values correlate with an 
ability to alter host cell responses to LPS in vitro, or protection against endotoxic shock 
in vivo [169,177,241,242]. This has been demonstrated for many cathelicidin AMPs 
(see Chapter 1, Table 1.3 and Table 1.4), indicating the bovine cathelicidin AMPs used 
in these studies may have comparable activity. Measurement of cytokine release by 
LPS-stimulated neutrophils in the presence of AMPs may have supported this 
hypothesis. Unfortunately cytokine release could not be measured accurately. This was 
due to non-specific binding of the peptides to either capture or detection antibodies of 
several different bovine-specific ELISAs. The non-specific binding was robust enough 
to produce consistently significant false positive readings making measurement of 
actual cytokines impossible. Measurement of cytokine mRNA changes may have been a 
viable alternative, although not a direct measure of release per se. The non-specific 
peptide-antibody interaction is discussed further in Appendix 1. 
 
Table 4.7 Examples of cathelicidin AMPs that bind LPS  
Peptide Species Structure Method EC50 (μM) Reference 
Bac5 Caprine (goat) Linear Quantitative LAL assay 4.0 [122] 
Bac7 Bovine (cow) Linear Quantitative LAL assay ~1.5 [241] 
Indolicidin Bovine (cow) Linear Polymyxin B displacement assay 8.5 [243] 
Indolicidin Bovine (cow) Linear Polymyxin B displacement assay 18 [244] 
BMAP-28 Bovine (cow) α-helical Quantitative LAL assay 4.2 [161] 
LL-37 Human α-helical Quantitative LAL assay 0.36 [231] 
LL-37 Human α-helical Quantitative LAL assay 0.42 [137] 
CAP-11 Guinea Pig α-helical FITC-LPS binding to RAW 264.7 cells 0.053 [245] 
RL-37 Rhesus monkey α-helical Quantitative LAL assay 4.44 [137] 
SMAP-29 Ovine (sheep) α-helical Quantitative LAL assay 2.56 [138] 
SMAP-29 Ovine (sheep) α-helical Quantitative LAL assay 3.2 [242] 
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4.5 Conclusions 
The results of this chapter demonstrate that bovine cathelicidin AMPs have differential 
effects on neutrophil innate immune function and that these activities are dependent on 
neutrophil activation state and peptide structure. This suggests the peptides have a range 
of different immunomodulatory roles during infection and inflammation. Furthermore, 
all the peptides have the ability to bind LPS. This ability of each peptide to bind LPS 
with relatively high affinity may alter recognition of PAMPs by immune cells, although 
it is unclear whether this function would be facilitative or preventative. Measurement of 
cytokine release by LPS-stimulated neutrophils in the presence of AMPs may have 
clarified this observation but unfortunately cytokine release could not be measured 
accurately. 
 
Interestingly, the selected AMPs were able to modify a number of neutrophil functions. 
While the effects of BMAP-28 were attributable to toxicity, other functions were altered 
by AMPs in the absence of toxic effects. Migration and ROS production were enhanced 
by several peptides while ROS production was inhibited by others. When investigated 
in further detail, linear Bac1, Bac5 and BMAP-34 were able to dose-dependently induce 
or inhibit several key neutrophil functions including migration, degranulation, 
respiratory burst and phagocytosis, indicating significant roles in differential modulation 
of immune responses. The results of this chapter also suggest some bovine cathelicidins 
are able to cross neutrophil membranes without significant disruption to cellular 
homeostasis, possibly eliciting their effects intracellularly. Due to the ability of Bac5 to 
differentially modify neutrophil respiratory burst, the potential of Bac5 to act via an 
intracellular mechanism to alter ROS production was investigated in Chapter 5. 
 
 
 
 
Chapter 5: The Mechanism of Bac5 Regulation of 
the Respiratory Burst 
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5.1 Introduction 
Cathelicidin AMPs are able to penetrate eukaryotic membranes. In most cases these 
peptides have amphipathic α-helical structures and cause a membranolytic effect which 
induces cell death [157-160,173]. However, amphipathicity and flexibility of peptides 
are determinants of their ability to translocate across membranes [246]. Linear peptides 
rich in proline and arginine have been shown to be internalised by eukaryotic cells, 
either by passive diffusion or by endocytosis, without causing lysis [247,248]. 
Examples of these peptides include bovine Bac5 and Bac7, and porcine PR-39. 
 
Bac5 has been shown to efficiently translocate into murine fibroblasts [247], and Bac7 
into murine fibroblasts and human lymphoma cells [247,248] where they promote 
cellular proliferation. Porcine PR-39 has been studied in more detail. The intracellular 
effects of this peptide include modulation of gene expression [183] and promotion of 
angiogenesis by inhibiting degradation of hypoxia-inducible factor 1-α [184]. PR-39 
also inhibits apoptosis by down-regulating caspase-3 and inducing inhibitor of 
apoptosis-2 [185,186], and inhibits ROS production by binding to p47phox [154,155]. 
 
The proline-rich nature of bovine Bac5 and Bac7, and porcine PR-39 allow them to 
mediate protein-protein interactions that rely on consecutive proline repeat motifs for 
signalling [249,250]. For example, PR-39 binds to the Src homology domain of the 
p47phox subunit, a domain that recognises proline-rich ligand motifs. In Chapter 4, Bac5 
was shown to inhibit PMA-induced ROS production. PMA acts via an intracellular 
mechanism to induce ROS production. Bac5 is known to translocate into eukaryotic cell 
lines, and shares structural similarities with PR-39, which directly interacts with 
components of the NADPH oxidase complex. This led to the hypothesis that: Bac5 acts 
via an intracellular mechanism to regulate neutrophil respiratory burst. 
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5.2 Aims 
 Determine whether Bac5 crosses the neutrophil membrane and accumulates 
intracellularly. 
 Assess the effect of Bac5 on intracellular ROS production in neutrophils. 
 Identify intracellular Bac5-protein interactions that might contribute to the 
mechanism of Bac5-mediated regulation of neutrophil respiratory burst. 
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5.3 Results  
5.3.1 Assessment of Bac5 internalisation 
A synthetic Bac5 peptide conjugated to FITC was used to investigate Bac5 
internalisation. Naïve neutrophils were exposed to Bac5-FITC for up to 60 minutes then 
analysed by confocal microscopy. To obtain semi-quantitative data on the rate of 
internalisation of the peptide, neutrophil uptake was assessed at different times by flow 
cytometry. Confocal microscopy showed Bac5-FITC was internalised by naïve 
neutrophils (Figure 5.1). The extent of internalisation varied, with some neutrophils 
internalising more peptide than others. The peptide was localised to the cytoplasm of 
most cells in a diffuse, non-specific pattern and did not appear to enter the nuclei. In a 
minority of cells Bac5-FITC appeared to be localised to vesicles, suggesting an active 
uptake mechanism of peptide internalisation. 
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Figure 5.1  Confocal microscopy of Bac5-FITC-treated neutrophils 
Bovine neutrophils were seeded onto coverslips and treated with 2.5 μM Bac5-FITC for 60 minutes. 
Bac5-FITC signal was confined to the cytoplasm of most cells. In some cells Bac5-FITC appeared to be 
confined to vesicles (arrow). Images are representative of two independent experiments. 
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Flow cytometry analysis showed peptide internalisation occurred in a time and dose-
dependent manner (Figure 5.2). At 5 µM or greater, significant amounts of peptide were 
present after five minutes. At 2.5 µM or greater, significant internalisation occurred 
after 30 minutes. After five minutes, there appeared to be a linear relationship of 
internalisation with respect to time, indicating a constant rate of internalisation of Bac5-
FITC, either by passive diffusion, active uptake, or both processes simultaneously 
(Figure 5.2 B). 
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Figure 5.2 Flow cytometry analysis of Bac5-FITC-treated neutrophils 
Neutrophils were exposed to increasing concentrations of Bac5-FITC for 5, 15, 30 and 60 minutes. 
Extracellular FITC fluorescence was quenched with trypan blue. Cells were washed and fixed before flow 
cytometry analysis. (A) Representative histogram analysis. (B) Dose-time-response analysis. Data 
represent the mean ± SEM for three independent experiments performed in duplicate. Statistical 
significance was determined by one-way ANOVA with Tukey’s post-test comparing treatments with 
control. ** P < 0.01, *** P < 0.001.  
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5.3.2 Bac5 induces intracellular ROS production 
Because Bac5 was able to induce extracellular ROS production (Chapter 4, 
section 4.3.3.4) and was readily found in the cytoplasm of neutrophils, intracellular 
ROS production was also assessed. Naïve neutrophils were treated with the intracellular 
fluorescent ROS indicator CellROX Deep Red and Bac5-FITC. The cells were analysed 
by flow cytometry to determine whether Bac5 induced intracellular ROS production. 
For flow cytometry analysis, neutrophils were gated by forward and side scatter 
properties (Figure 5.3 A, P1) and Bac5-FITC-positive cells gated (P2) according to 
FITC-negative cells in untreated controls. Histograms of Bac5-FITC-positive cells 
displaying the median fluorescence intensity (MFI) of CellROX Deep Red fluorescence 
were used for dose-response analysis (Figure 5.3 B). The analysis of Bac5-FITC 
positive cells showed naïve neutrophils treated with Bac5 produced a dose and time-
dependent increase in intracellular ROS production (Figure 5.3 C). The increase was 
significant after 30 minutes with cells treated with at least 5 µM Bac5-FITC, and after 
60 minutes with at least 2.5 µM. The flow cytometry analysis also affirmed that cells 
positive for intracellular ROS production were also positive for Bac5-FITC, indicating 
that internalisation of Bac5 was associated with intracellular ROS production.  
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Figure 5.3 Flow cytometry analysis of Bac5-induced intracellular ROS production 
The fluorescent intracellular ROS indicator CellROX Deep Red was used to measure intracellular ROS 
induced by Bac5-FITC using flow cytometry. (A) Dotplots, histograms and contour plots representing the 
gating strategy for Bac5-FITC-positive/CellROX-positive neutrophils after 60 minutes. (B) Stacked 
histograms of Bac5-FITC-positive/CellROX-positive neutrophils at 30 and 60 minutes. (C) Dose-
response curves for intracellular ROS production induced by Bac5-FITC. Data represent the mean ± SEM 
for three independent experiments performed in duplicate. Statistical significance was determined by one-
way ANOVA with Tukey’s post-test comparing treatments with control. * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
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5.3.3 Bac5 colocalises with intracellular ROS 
Confocal microscopy of Bac5-FITC and CellROX Deep Red-treated cells showed that 
intracellular ROS production was diffuse throughout the cytoplasm but also appeared to 
be localised in vesicles (Figure 5.4). The CellROX Deep Red signal was constantly 
localised with a strong Bac5-FITC signal in either cytoplasmic or vesicular locations. 
Untreated cells showed minor background CellROX Deep Red fluorescence. Together 
these observations supported the data from the flow cytometry analysis.  
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Figure 5.4 Confocal microscopy of Bac5 and intracellular ROS colocalisation 
Neutrophils were seeded onto glass coverslips and incubated with 2.5 µM Bac5-FITC (green) for 60 
minutes in the presence of CellROX Deep Red (blue). White arrows indicate vesicular colocalisation 
(cyan) of Bac5-FITC and ROS production. Images are representative of two independent experiments. 
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5.3.4 Intracellular targets of Bac5 
The internalisation of Bac5-FITC suggested that Bac5 was acting intracellularly to 
modulate neutrophil function. Extracellular and intracellular ROS production induced 
by Bac5 also suggested Bac5 was interacting with the NADPH oxidase complex or 
proteins associated with oxidase activation. For active ROS production, cytosolic 
subunits of the oxidase assembly must translocate to the membrane bound subunits 
which are subsequently phosphorylated by kinases to form an active NADPH oxidase 
complex. The cytosolic subunit p47phox is essential for oxidase activity in response to 
agonists [251,252]. To investigate the role of Bac5 in ROS production, measurement of 
the translocation of p47phox was used to assess whether Bac5 upregulates membrane 
expression of active NADPH oxidase. Far-western blotting of neutrophil lysate and MS 
analysis was then used to assess which intracellular proteins Bac5 associates with. 
 
5.3.4.1 Bac5-induced ROS production does not involve p47phox translocation 
Bac5 was able to consistently induce ROS production at 2.5 µM, therefore this 
concentration was used to stimulate naïve neutrophils to produce ROS for 30 or 
60 minutes. The cells were then lysed and separated into membrane and cytosol protein 
fractions and p47phox content assessed by western blot. After adjusting for protein 
loading (Figure 5.5 A) and p47phox signal (Figure 5.5 B), localisation of p47phox was 
compared (Figure 5.5 C). A significant change in the translocation of cytosolic p47phox 
to the membrane was not observed at either 30 or 60 minutes compared to untreated 
neutrophils. Oddly, a trend toward increased cytosolic p47phox was observed 30 minutes 
after Bac5 treatment, which dissipated after 60 minutes. How this translates into 
increased NADPH oxidase activity is unclear, although despite contrasting with the 
expected outcome, there may be the potential for Bac5 to modulate NADPH oxidase 
assembly or disassembly. 
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Figure 5.5 Western blot analysis of p47phox translocation 
Naïve neutrophils were treated with 2.5 µM Bac5 for 30 or 60 minutes. The cells were lysed, separated 
into cytosol and membrane fractions and 30 µg protein probed by western blot using anti-p47phox 
antibody. (A) Representative Ponceau S stain for loading controls. (B) Representative anti-p47phox 
antibody probe. (C) Semi-quantitative analysis of the relative abundance of p47phox in cytosol and 
membrane fractions. Data represent the mean ± SEM for three independent experiments. No statistical 
significance was found using a one-way ANOVA and Tukey’s post-test. C, cytosol; M, membrane. 
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5.3.4.2 Bac5 binds to several intracellular neutrophil proteins 
To investigate potential intracellular Bac5-protein interactions, untreated naïve 
neutrophils were lysed in the presence of protease inhibitors and the insoluble material 
removed. Cleared lysate was separated by SDS-PAGE and Bac5-FITC used as the 
probe in far-western blot analysis. Two membranes were analysed in parallel. 
Ponceau S stain indicated equivalent loading of neutrophil lysate for each membrane 
(Figure 5.6 A). After 2 hours incubation, Bac5-FITC had bound with a strong signal 
corresponding to a protein at approximately 43 kDa (Figure 5.6 B, Blot 1). Minor 
signals from bands at around 21 kDa were also present. To determine if the interaction 
was Bac5-specific, a duplicate blot was analysed in parallel and initially blocked with 
unlabelled Bac5 prior to probing with Bac5-FITC. This produced a reduction in signal 
from the 43 kDa band as well as a visible reduction in signal from a band at 22 kDa 
(Figure 5.6 B, Blot 2). The remaining bands at approximately 21 kDa did not appear to 
have a reduced Bac5-FITC signal and therefore were not analysed by LC-MS/MS. 
 
5.3.4.3 β-actin is an intracellular target of Bac5 
To identify the proteins to which Bac5-FITC bound to in the far-western blot analysis, a 
replicate of neutrophil lysate was electrophoresed on the same polyacrylamide gel and 
stained with CBB G-250 (Figure 5.6 C). The corresponding bands at 43 kDa (MS1) and 
22 kDa (MS2) were removed and prepared for analysis by LC-MS/MS. A peptide mass 
fingerprint mass spectrum was generated and database searches against this mass 
spectrum showed several hits to neutrophil proteins (Table 5.1).  
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Figure 5.6 Far-western blot of neutrophil lysate 
Untreated naïve neutrophils were lysed in the presence of protease inhibitors. The protein was separated 
by electrophoresis and analysed by far-western blot using Bac5-FITC. (A) Ponceau S stain for protein 
loading. (B) Blot 1 was incubated with reagent diluent for 2 hours, washed and probed with Bac5-FITC. 
Blot 2 was probed with a five-fold excess of unlabelled Bac5 for 2 hours, washed and probed with  
Bac5-FITC. (C) CBB G-250 stain for LC-MS/MS analysis. MS1 and MS2 indicate bands removed for  
LC-MS/MS analysis.  
 
Table 5.1 Summary of the LC-MS/MS data for the Bac5-FITC far-western blot 
Sample  Protein Peptides MOWSE score 
Accession 
number Activity 
MW 
(kDa) 
MS1 Beta actin 26 1762 gi|313507212 Cell motility 41.7 
 Serpin B1 23 1483.9 gi|331028727 
Regulates neutrophil 
protease activity 42.2 
 
Serpin B3  
(predicted) 6 368.5 gi|119916473 
Regulates neutrophil 
protease activity 44 
 Haptoglobin 6 240.9 gi|94966763 Acute-phase protein 44.9 
MS2 Serpin B1 24 1581.1 gi|331028727 Regulates neutrophil protease activity 42.2 
 Beta actin 23 1804.2 gi|313507212 Cell motility 41.7 
 S100 A9 17 1290.2 gi|296489689 
Regulation of inflammatory 
and immune responses 17.1 
 Haptoglobin 6 286.9 gi|94966763 Acute-phase protein 44.9 
 Serpin B4 5 345.1 gi|151557009 
Regulates neutrophil 
protease activity 44.4 
  Peptidoglycan recognition protein 1 3 143.4 gi|223635600 
Gram-positive bactericidal 
protein 21 
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Sample MS1 produced multiple peptides indicating the presence of serpin B1, 
serpin B3, haptoglobin and β-actin, which all had predicted molecular weights of the 
correct size for the excised band [91]. In sample MS2, serpin B1, haptoglobin and  
β-actin were also identified, as well as serpin B4. These peptides are likely to be 
contaminants from the first sample that were inadvertently retained by the LC column 
during analysis of MS1. Serpin B1 and serpin B3 are cytoplasmic serine protease 
inhibitors [253] which have additional roles in inflammation, complement activation, 
apoptosis, and host defence during microbial infection [254]. Considering these roles, 
and the effects of Bac5 on neutrophils, the potential interaction of Bac5 and serpins 
warrants further investigation. However, Bac5 was able to modulate migration, ROS 
production and phagocytosis, suggesting a target protein other than the serpins may be 
involved. 
 
Haptoglobin is a hepatocyte derived plasma protein involved in the acute phase 
response but is also synthesised and stored in the secondary granules of neutrophils 
[255]. Haptoglobin primarily serves in the removal of free haemoglobin and can thereby 
reduce ROS production [256]. β-actin is a structural protein involved in neutrophil 
motility [257,258], degranulation [43], phagocytosis [259] and the regulation of 
NADPH oxidase activity [260,261]. In sample MS2, multiple peptides were identified 
for S100A9, a cytosolic 17.1 kDa acute-phase protein [262] which enhances neutrophil 
migration and phagocytosis, and along with S100A8 (collectively called calprotectin), 
induces ROS production via transfer of arachidonic acid and via direct interaction with 
NADPH oxidase subunits p67phox and Rac [263]. 
 
Taken together, haptoglobin, β-actin and S100A9 each have a role in modulation of 
ROS production. Bac5 may interact with all three of these proteins to induce ROS 
production. However, the high peptide sequence coverage and MOWSE score in the 
LC-MS/MS analysis, as well as the strong localisation of Bac5-FITC signal in the far-
western blot indicated β-actin was the best candidate protein for interaction with Bac5. 
Therefore β-actin was investigated in further detail. Nevertheless, the potential for Bac5 
to interact with haptoglobin and S100A9 warrants future investigation.  
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5.3.5 Confirmation of the Bac5-β-actin interaction 
5.3.5.1 Bac5 binds immunopurified cellular β-actin 
Of the proteins identified by MS, β-actin was considered the most likely candidate for 
mediating Bac5 ROS production. To confirm the Bac5-β-actin interaction, β-actin was 
purified from neutrophil lysate by immunopurification, and duplicate purifications were 
separated by SDS-PAGE. One duplicate was stained with CBB R-250 (Figure 5.7 A) 
which indicated a significant amount of β-actin was obtained from the purification 
procedure. The second duplicate was transferred to PVDF membrane and stained with 
Ponceau S (Figure 5.7 B) which indicated a successful transfer of β-actin to the 
membrane. Using Bac5-FITC to probe the membrane (Figure 5.7 C), a distinct FITC 
signal was obtained corresponding to β-actin in the lysate start material, the supernatant, 
and in the immunopurified protein sample, confirming the specificity of Bac5 for  
β-actin.
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Figure 5.7  Immunopurification of cellular β-actin and far-western blot 
Neutrophil lysate was mixed with 1 µg rabbit anti-actin IgG antibody overnight and precipitated with 
protein A-conjugated sepharose beads for two hours. Beads were isolated by centrifugation and prepared 
for SDS-PAGE and far-western blot using Bac5-FITC as the probe. (A) CBB R-250 stain. (B) Ponceau S 
stain. (C) The PVDF membrane was probed by far-western blot using 0.5 µM Bac5-FITC. Arrows from 
top to bottom indicate IgG heavy chain, β-actin and IgG light chain. 
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5.3.5.2 Bac5 does not readily co-purify with cellular β-actin 
The far-western blot technique identifies interactions between a denatured protein 
immobilised on a membrane, and a native protein used as the probe. To determine if the 
interaction between Bac5 and β-actin occurred when β-actin was in the native folded 
state, a co-immunoprecipitation procedure was used. Exogenous Bac5-FITC was added 
to the neutrophil lysate prior to the purification procedure. Parallel samples were also 
processed in which the neutrophil lysate, purification antibody or exogenous Bac5-FITC 
were omitted. This allowed non-specific interactions between Bac5-FITC and antibody, 
or Bac5-FITC and Protein A agarose beads to be measured. 
 
The electrophoresed samples were stained with CBB R-250 (Figure 5.8 A) after a FITC 
fluorescence image was taken (Figure 5.8 B). A successful immunopurification 
occurred either in the presence or absence of exogenous Bac5-FITC (Figure 5.8 A, lanes 
5 and 11, respectively). However, omission of either the lysate or the antibody resulted 
in an unsuccessful immunopurification of β-actin, as expected (Figure 5.8 A, lanes 7 
and 9, respectively). The fluorescence image of co-immunopurified Bac5-FITC showed 
that some Bac5-FITC was associated with each co-immunopurification except where 
Bac5-FITC was omitted (Figure 5.8 B, lanes 10 and 11). This indicated that Bac5-FITC 
was non-specifically binding to the antibody or the purification beads, as well as  
β-actin. Semi-quantitative analysis allowed the relative density of co-immunopurified 
Bac5-FITC in each sample to be measured (Figure 5.8 C). Due to the omission of either 
lysate or antibody, the amount of non-specific binding of Bac5-FITC to antibody, or of 
Bac5-FITC to the purification beads, could be taken into account. These allowed 
estimates to be calculated for the proportion of Bac5-FITC bound to each component of 
the standard co-immunopurification procedure (where no component was omitted) 
(Figure 5.8 D). These estimates were: 14.85 ± 1.89% of Bac5 bound to native β-actin, 
29.30 ± 11.31% bound to antibody, and 55.85 ± 9.55% bound to the purification beads. 
This is assuming that the pre-clearance step (Chapter 2, section 2.7.6) removed any non-
specific binding of protein in the neutrophil lysate. 
 
The occurrence of cathelicidin AMPs binding to antibody was encountered in Chapter 4 
(section 4.3.5) and is discussed in Appendix 1. Binding of Bac5-FITC to the agarose 
purification beads was unexpected. However, the beads are conjugated to protein A, a 
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secreted and membrane associated 42 kDa S. aureus cell wall protein with a low pI 
[264]. Due to the opposing high pI of Bac5, electrostatic interactions probably occur 
between the protein and the peptide resulting in non-specific binding.  
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Figure 5.8 Co-immunopurification of cellular β-actin and Bac5 
Neutrophils were treated with protease inhibitors before lysis. As indicated, 800 µg lysate was mixed with 
1 µg rabbit anti-actin IgG antibody and 10 µg Bac5-FITC overnight. Bac5-FITC-β-actin complexes were 
precipitated with protein A-conjugated sepharose beads for 2 hours. The sepharose beads were isolated by 
centrifugation and prepared for SDS-PAGE analysis along with supernatant samples. (A) CBB R-250 
stain. (B) Molecular Imager FX scan at 488 nm excitation and 540 nm emission for FITC fluorescence 
(495 nm excitation, 519 nm peak emission). (C) Semi-quantitative analysis of co-immunopurified Bac5-
FITC. (D) Calculation of the estimated proportions of Bac5-FITC binding to immunopurification 
components. Data represent the mean ± SEM for three independent experiments. Normalisation to control 
and calculations were performed for each experiment before calculating means. S, supernatant sample; IP, 
immunopurified protein. 
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5.3.5.3 Co-immunopurification of Bac5 and purified β-actin 
To investigate whether endogenous protein in the neutrophil lysate was potentially 
altering the Bac5-β-actin interaction, an identical co-immunopurification procedure was 
performed with purified non-muscle actin in place of the neutrophil lysate. As in the 
previous section, the electrophoresed samples were stained with CBB R-250  
(Figure 5.9) after a FITC fluorescence image was taken (Figure 5.9 B).  
 
Successful immunopurifications occurred in either the presence or absence of 
exogenous Bac5-FITC (Figure 5.9 A, lanes 5 and 11, respectively). As expected, 
omission of purified β-actin resulted in an unsuccessful immunopurification  
(Figure 5.9 A, lane 7). However, omission of the antibody still resulted in some β-actin 
being purified (Figure 5.9 A, lane 9). This could be explained by the fact that  
Bac5-FITC binds both β-actin and the purification beads, and in this case may be acting 
in a similar manner to the antibody. This would also explain why more β-actin was 
immunopurified in the presence of Bac5 compared to when Bac5 was omitted  
(Figure 5.9 A, lanes 5 and 11). The presence of excess protein in the neutrophil lysate 
co-immunopurification potentially acted to block this effect. This anomaly subsequently 
affected the co-immunopurification analysis (Figure 5.9 B, C) which may have 
contributed to the large errors in the estimates of Bac5-FITC binding in the standard co-
immunopurification procedure (Figure 5.9 D). These estimates were 21.55 ± 23.27% for 
Bac5-FITC bound to β-actin, 34.73 ± 32.98% bound to antibody and 43.72 ± 15.04% 
bound to the purification beads.  
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Figure 5.9 Co-immunopurification of purified β-actin and Bac5 
As indicated, 1 µg purified non-muscle actin was mixed with 1 µg rabbit anti-actin IgG antibody and 
10 µg Bac5-FITC overnight. Bac5-FITC-β-actin complexes were precipitated with protein A-conjugated 
sepharose beads for 2 hours. The beads were isolated by centrifugation and prepared for SDS-PAGE 
analysis along with TCA precipitated supernatant samples. (A) CBB R-250 stain. (B) Molecular Imager 
FX scan at 488 nm excitation and 540 nm emission. (C) Semi-quantitative analysis of co-immunopurified 
Bac5-FITC. (D) Calculation of estimated proportions of Bac5-FITC binding to immunopurification 
components. Data represent the mean ± SEM for three independent experiments. Normalisation to control 
and calculations were performed for each experiment before calculating means. S, supernatant sample; IP, 
immunopurified protein. 
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5.3.6  Bac5 colocalises with cytoplasmic β-actin 
Confocal microscopy was used to assess the cellular localisation of Bac5-FITC and  
β-actin. Naïve neutrophils were treated with 2.5 µM Bac5-FITC for 60 minutes, washed 
extensively to remove extracellular Bac5-FITC, fixed, and stained with the polymerised 
actin-specific fluorescent conjugate phalloidin-TRITC (Figure 5.10) [265]. The  
phalloidin-TRITC signal was consistently strong at the membrane and within the 
cytoplasm of both Bac5-FITC-treated and untreated neutrophils. In treated neutrophils 
the Bac5-FITC signal was consistently stronger in the cytoplasm than at the membrane, 
and consistently co-localised with cytoplasmic rather than membranous actin. 
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Figure 5.10 Confocal microscopy of Bac5 and β-actin colocalisation 
Neutrophils were seeded onto glass coverslips and incubated with 2.5 µM Bac5-FITC for 60 minutes. 
Cells were washed extensively to remove excess Bac5-FITC, fixed, permeabilised, blocked and incubated 
with phalloidin-TRITC (5 µg/ml) for 1 hour. Images are representative of two independent experiments. 
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5.3.7 Bac5, intracellular ROS and β-actin have a cytoplasmic association 
Confocal microscopy was used to assess the cellular localisation of Bac5-FITC, 
intracellular ROS and β-actin. Naïve neutrophils were treated with 2.5 µM Bac5-FITC 
and CellROX Deep Red for 60 minutes, washed extensively to remove extracellular 
Bac5-FITC, fixed, and stained with the actin-specific fluorescent conjugate  
phalloidin-TRITC (Figure 5.11). The untreated controls showed minor intracellular 
ROS production in the absence of Bac5, which was confined to the cytoplasm. As seen 
in previous figures (Figure 5.4 and Figure 5.10), the strong cytoplasmic Bac5-FITC 
signal colocalises with both the CellROX Deep Red signal and the phalloidin-TRITC 
signal. This indicates that Bac5 binds to actin structures as phalloidin only binds 
filamentous actin, not free actin. At the membrane the CellROX Deep Red signal was 
virtually absent while the Bac5-FITC signal was present, albeit at a less intense level. 
This implies that a Bac5-β-actin interaction at the membrane does not stimulate 
intracellular ROS production, however this observation may account for extracellular 
ROS production observed in Chapter 4 (see Section 4.3.3.4 and Figure 4.8). 
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Figure 5.11  Confocal microscopy of Bac5, intracellular ROS and β-actin 
colocalisation 
Neutrophils were seeded onto glass coverslips and incubated with 2.5 µM Bac5-FITC and CellROX Deep 
Red for 60 minutes. Cells were washed extensively to remove excess Bac5-FITC, fixed, permeabilised, 
blocked and incubated with phalloidin-TRITC (5 µg/ml) for 1 hour. Images are representative of two 
independent experiments. 
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5.3.8 Activated neutrophils 
As Bac5 was able to inhibit PMA-induced extracellular ROS production (see Chapter 4, 
section 4.3.3.4), the effect of Bac5 on intracellular ROS production in PMA-activated 
neutrophils was assessed, as well as the cellular localisation of Bac5 in activated cells. 
 
5.3.8.1 Intracellular ROS is not inhibited by Bac5 
To assess the effect of Bac5 on intracellular ROS in activated cells, the fluorescent ROS 
indicator CellROX Deep Red was used as in section 5.3.2. Bac5-FITC was also used to 
determine whether higher concentrations of Bac5 were able to inhibit intracellular ROS 
production in a similar manner to the inhibition of extracellular ROS production 
observed in Chapter 4. The activated cells were analysed by flow cytometry, and 
confocal microscopy was used to assess the cellular localisation of Bac5 and 
intracellular ROS production. 
 
The flow cytometry gating strategy followed that used in section 5.3.2 and the data were 
analysed using CellROX Deep Red histograms of Bac5-FITC-positive cells  
(Figure 5.12 A). After 30 minutes a trend toward inhibiting PMA-induced ROS 
production at higher concentrations of Bac5 was observed, however intracellular ROS 
was still significantly greater than the activated control (Figure 5.12 B). After 
60 minutes this effect was no longer apparent, and intracellular ROS production 
increased in a dose-dependent manner.  
 
As Bac5 regulated extracellular PMA-induced ROS production, intracellular ROS 
production in naïve cells and activated cells was compared to determine if Bac5 also 
had a regulatory effect. After 30 minutes activated cells produced significantly more 
ROS at low Bac5 concentrations however ROS production was equivalent in naïve and 
activated cells at high Bac5 concentrations (Figure 5.12 C). After 60 minutes naïve and 
activated cells produced equivalent intracellular ROS at all Bac5 concentrations tested 
(Figure 5.12 D). This indicated that Bac5 does not regulate PMA-induced intracellular 
ROS. In fact, PMA has virtually no effect on intracellular ROS production. Instead 
Bac5 was the main determinant of the intracellular ROS response. In summary, the 
effect of Bac5 on extracellular ROS production is dependent on the activation state of 
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the neutrophils, whereas the effect of Bac5 on intracellular ROS production is 
independent of the activation state of neutrophils. 
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Figure 5.12  Flow cytometry analysis of PMA-induced intracellular ROS 
production in the presence of Bac5 
The fluorescent intracellular ROS indicator CellROX Deep Red was used to measure intracellular ROS 
induced by 100 ng/ml PMA in the presence of Bac5-FITC using flow cytometry. (A) Stacked histograms 
of Bac5-FITC-positive/CellROX-positive neutrophils at 30 and 60 minutes. (B) Dose-response curves for 
intracellular ROS production in activated cells in the presence of Bac5-FITC. Intracellular ROS 
production in naïve and activated neutrophils was compared after (C) 30 minutes and (D) 60 minutes of 
Bac5-FITC treatment. Data represent the mean ± SEM for three independent experiments performed in 
duplicate. Statistical significance was determined by one-way ANOVA with Tukey’s post-test comparing 
treatments with control. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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5.3.8.2 Bac5 prevents p47phox translocation in activated neutrophils 
Extracellular ROS production by activated neutrophils was significantly inhibited by 
10 µM Bac5 (Chapter 4, section 4.3.3.4). This concentration was used to inhibit PMA-
induced ROS production for 30 or 60 minutes. The neutrophils were then prepared as in 
section 5.3.4.1. Data were adjusted for protein loading (Figure 5.13 A) and p47phox 
signal (Figure 5.13 B). A trend toward increased translocation to the membrane was 
observed in the PMA-treated controls (Figure 5.13 C). In PMA-activated cells treated 
with Bac5 there was no trend toward translocation of p47phox at 30 or 60 minutes, 
indicating Bac5 prevents the translocation of p47phox. 
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Figure 5.13 Western blot analysis of p47phox translocation in activated cells 
Neutrophils were activated with 100 ng/ml PMA and treated with 10 µM Bac5 for 30 or 60 minutes. Cells 
were lysed, separated into cytosol and membrane fractions and 30 µg protein probed by western blot 
using anti-p47phox antibody. (A) Representative Ponceau S stain for loading controls. (B) Representative 
anti-p47phox antibody probe. (C) Semi-quantitative analysis of the relative abundance of p47phox in cytosol 
and membrane fractions. Data represent the mean ± SEM for three independent experiments. No 
statistical significance was found using a one-way ANOVA and Tukey’s post-test. C, cytosol; M, 
membrane. 
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5.3.8.3 Colocalisation of Bac5, intracellular ROS and β-actin is unchanged in 
activated cells 
Confocal microscopy was used to assess the cellular localisation of Bac5-FITC, 
intracellular ROS and β-actin in activated neutrophils. Cells were activated with PMA 
and were treated with 10 µM Bac5-FITC and CellROX Deep Red for 60 minutes, 
washed extensively to remove extracellular Bac5-FITC, fixed, and stained with the 
actin-specific fluorescent conjugate phalloidin-TRITC (Figure 5.14). The PMA-treated 
control showed significant CellROX Deep Red signal, although this signal was less 
intense than in Bac5-treated cells. As in naïve cells, activated cells produced 
intracellular ROS in a diffuse pattern throughout the cytoplasm, and the distribution of 
Bac5-FITC also colocalised with intracellular ROS in activated cells. These signals also 
strongly localised with the phalloidin-TRITC signal, indicating that as in naïve cells, 
Bac5 associates with actin to regulate intracellular ROS production in activated cells. 
The phalloidin-TRITC signal at the membrane was also less intense in Bac5-treated 
neutrophils than in PMA-treated controls, indicating association of actin with the 
membrane may be lost in activated cells treated with Bac5. 
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Figure 5.14 Confocal microscopy of Bac5, intracellular ROS and β-actin 
Neutrophils were seeded onto glass coverslips, activated with 100 ng/ml PMA and incubated with 10 µM 
Bac5-FITC and CellROX Deep Red for 60 minutes. Cells were washed extensively to remove excess 
Bac5-FITC, fixed, permeabilised, blocked and incubated with phalloidin-TRITC (5 µg/ml) for 1 hour. 
Images are representative of two independent experiments. 
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5.4 Discussion 
The aims of the experiments in this chapter were to determine whether Bac5 was 
internalised by neutrophils, and to elucidate the mechanism by which Bac5 modulates 
neutrophil function.  
 
Previously, FITC conjugates of bovine Bac5 and Bac7 have been reported to be rapidly 
internalised into non-bovine cell lines such as murine NIH 3T3 fibroblasts and human 
U937 lymphoma cells [247,248]. This occurs via both macropinocytosis and direct 
membrane translocation [248]. Once internalised, Bac5 and Bac7 were shown to 
localise to nucleoli and nuclear structures, and in fibroblasts initiate DNA synthesis and 
proliferation. The experiments in this chapter demonstrated that Bac5 was internalised 
by bovine neutrophils. Confocal microscopy showed the presence of both a diffuse and 
vesicle-like localisation of Bac5, indicating direct membrane translocation and active 
internalisation, respectively. However, in contrast to internalisation in other cell lines, 
Bac5 remained localised to the cytoplasm of neutrophils and did not appear to enter the 
nucleus. This suggested a different mode of action in immune cells, which corresponds 
with the observed modulation of neutrophil innate immune function seen in Chapter 4, 
rather than longer-term regulation of gene expression or cell proliferation as seen in 
other cell types. 
 
Internalisation of Bac5 was associated with intracellular ROS production. This appeared 
to occur within the cytoplasm and in intracellular vesicles. Interestingly, both naïve and 
activated neutrophils showed similar patterns of intracellular ROS production in the 
presence of Bac5, while cells treated with PMA alone only showed limited intracellular 
ROS. This indicated that Bac5 was the dominant agonist inducing intracellular ROS 
production. The results of Chapter 4 showed that PMA alone induced a huge increase in 
extracellular ROS, but in the presence of high concentrations of Bac5 the response was 
significantly inhibited. Taken with the results from Chapter 4, the role of Bac5 in regard 
to ROS production appears to be regulatory in which global ROS production, i.e. both 
intracellular and extracellular ROS production, is maintained at a relatively low but 
significant level independent of the activation status of the neutrophil.  
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The aims of the remaining experiments in this chapter were to elucidate the mechanism 
by which Bac5 was able to modulate neutrophil function, in particular the regulation of 
ROS production. To this end, the translocation of the p47phox NADPH oxidase subunit 
was assessed in naïve and activated neutrophils in the presence of Bac5 to determine if 
Bac5 upregulated NADPH oxidase activity at the membrane.  
 
The results showed p47phox was not translocated to the membrane in Bac5-treated naïve 
neutrophils, indicating p47phox is not required for Bac5-induced ROS production. As 
p47phox is required for agonist-induced (e.g. PMA) ROS production, but not basal ROS 
production [251], it appears that rather than fully activating the oxidase complex, Bac5 
may instead only increase basal ROS production in a p47phox-independent manner. This 
theory agrees with the low level of Bac5-induced extracellular and intracellular ROS 
production, compared to the 16-fold increase in extracellular PMA-induced ROS 
production. Further to this, p47phox regulates plasma membrane ROS production, but not 
phagosome ROS production [266]. This explains why intracellular ROS production was 
virtually absent in PMA-treated controls and why Bac5 was the dominant agonist in 
both naïve and activated cells. 
 
The results also suggested that p47phox was not translocated in activated cells treated 
with Bac5, which also exhibited decreased extracellular ROS production (Chapter 4, 
section 4.3.3.4). These data agree with the requirement of p47phox in PMA-induced ROS 
production. Therefore it appears that Bac5 blocks translocation of p47phox in PMA-
treated cells. Blocking of p47phox by Bac5 may also be part of the mechanism by which 
Bac5 enhances basal ROS production in naïve cells. Unphosphorylated p47phox inhibits 
ROS production at the plasma membrane [267,268] thereby maintaining low basal ROS 
production. The presence of Bac5 may block and remove the inhibitory function of 
unphosphorylated p47phox leading to enhanced basal ROS production. 
 
Surprisingly, far-western blotting did not identify an interaction of Bac5 with any of the 
NADPH oxidase components. Instead, Bac5 predominantly bound to β-actin. β-actin 
has an extensive role in cytoskeletal rearrangement, leading to migration, degranulation, 
phagocytosis and respiratory burst [43,257-261]. These roles are consistent with the 
modulation of neutrophil functions induced by Bac5.  
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Modulation of the actin cytoskeleton is closely involved with NADPH oxidase function 
[261]. In particular, Rac1, Rac2 and p47phox interact directly with actin [260]. 
Interestingly, the region of p47phox involved in binding to actin is a highly basic arginine 
and lysine-rich C-terminal domain called the autoinhibitory region [269]. Although the 
region of actin to which p47phox binds has not been defined, it is highly probable that 
Bac5 is able to bind in this same region of actin given the highly basic nature of the 
peptide. This lends further support to the theory that Bac5 differentially induces and 
inhibits extracellular ROS production by blocking assembly of p47phox on plasma 
membrane NADPH oxidase complexes. Competitive far-western blotting using p47phox 
to probe Bac5-β-actin complexes would clarify this Bac5-blocking theory. 
 
Although Bac5-induced ROS production at the plasma membrane and within 
endocytosed vesicles might involve blocking of p47phox, it is less clear if and how 
cytoplasmic ROS is induced by Bac5. Cytoplasmic ROS is generally produced in 
mitochondria by the electron transport chain during production of adenosine 
triphosphate [270]. To distinguish cytoplasmic and vesicular ROS, a mitochondrial 
ROS-specific stain could be employed to clarify whether Bac5 induces cytoplasmic 
ROS prior to further mechanistic research. 
  
A question remains as to how a Bac5-actin interaction might translate into the other 
functions that Bac5 modifies. As extensive actin remodelling must occur in order for 
these functions to be carried out, potential modes of action for Bac5 may include 
facilitation of β-actin turnover, activation of actin-binding proteins, or facilitation of 
actin branching in a similar role to the Arp2/3 complex [258]. Interestingly, the latter 
complex is activated by Wiskott-Aldrich syndrome protein/suppressor of G-protein-
coupled cyclic-AMP receptor (WASp/SCAR) proteins through binding to a C-terminal 
proline-rich domain [271], similar to the Bac5 sequence. Further research is required to 
uncover the relationship between Bac5, actin binding and modulation of neutrophil 
function.  
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Figure 5.15 Summary of the potential mechanisms of Bac5-induced ROS 
production in bovine neutrophils 
After Bac5 is internalised in naïve neutrophils (A) by passive diffusion or active uptake, the peptide binds 
to β-actin at the plasma membrane and enhances basal extracellular ROS production potentially by 
removing unphosphorylated p47phox. Bac5 may also bind to β-actin around endocytic vesicles to induce 
internal ROS production. It is unclear whether cytoplasmic ROS are the product of Bac5 interacting with 
mitochondria. After Bac5 is internalised in PMA-activated neutrophils (B), a similar localisation to  
β-actin occurs as in naïve cells. However, this potentially prevents the phosphorylated p47phox subunit 
binding to the oxidase complex thereby limiting extracellular ROS production to enhanced basal levels 
seen in naïve cells. The p47phox subunit does not regulate intracellular ROS therefore intracellular ROS 
production is induced by Bac5 at similar levels in naïve and activated cells. 
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5.5 Conclusion 
The results of this chapter demonstrate the ability of Bac5 to be internalised by bovine 
neutrophils and provides an explanation for the differential induction and inhibition of 
extracellular ROS production through inhibition of p47phox assembly. Although the 
mechanism of intracellular ROS production could not be determined, the identification 
of β-actin as a possible major intracellular target for Bac5 is consistent with the ability 
of Bac5 to modulate multiple neutrophil functions. Further in vitro studies are required 
to determine the exact interaction of Bac5 with actin and how this translates into the 
modulation of neutrophil innate immune functions. 
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6.1 Overview 
The cathelicidins are a family of innate immune host defence proteins containing a 
highly conserved C-terminal CLD and a highly variable AMP domain. The innate 
immune system of cattle has evolved to express seven isoforms of cathelicidin which 
vary significantly in their AMP domain. The high conservation of the CLD across 
species implies an important role in host defence which has not been clearly defined. 
Likewise, minimal progress has been made toward identifying the immunomodulatory 
effects of bovine cathelicidin AMPs on host immune cells, despite several advances in 
other species. 
 
The main aim of this thesis was to elucidate the role of bovine cathelicidins in innate 
host defence. Based on this aim, unpublished research findings (Food & Bio-based 
Products Group, AgResearch), and research from the literature, three hypotheses were 
tested. Firstly, due to the observed activity of a native cathelicidin-1 preparation, 
recombinant versions of cathelicidin-1 were hypothesised to have similar humoral 
activity and cytotoxicity. Secondly, due to the existence of several highly variable AMP 
domains in bovine, these different AMP domains were hypothesised to modulate bovine 
neutrophil function in different ways, depending on their structure and neutrophil 
activation status. Thirdly, as the Bac5 peptide exhibited an ability to regulate neutrophil 
respiratory burst in the absence of intracellular calcium mobilisation, Bac5 was 
hypothesised to act via an intracellular mechanism. 
 
Although recombinant versions of the CLD were unable to emulate the activity of 
native Cath1, the native Cath1 protein was able to bind LPS, agglutinate microbes and 
induce neutrophil death. The agglutinating activity of the CLD would be 
complementary to the antimicrobial effects of the AMP domains, while also acting to 
sequester bacteria and LPS from activating pro-inflammatory responses. This suggests 
an antimicrobial and anti-inflammatory role for the bovine CLD in host defence. In 
contrast, the necrosis of neutrophils induced by the CLD could be considered anti-
inflammatory and counterproductive in the context of host defence. However, excessive 
neutrophil infiltration and pro-inflammatory responses may cause damage to host 
tissues in the vicinity of inflammatory foci. Therefore necrosis induced by the CLD may 
act as a broad regulatory mechanism by controlling unchecked or excessive neutrophil 
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activity. Additionally, necrotic neutrophils have been shown to be anti-inflammatory via 
the release of α-defensins [272] and clearance of dead and dying neutrophils via 
phagocytosis by macrophages is a common route to the resolution of infection [273]. 
Hence necrosis induced by the CLD and the agglutination of microbes potentially 
contributes to a broad anti-inflammatory role for the CLD during infection. 
 
The bovine cathelicidin AMPs each had different effects on neutrophil function which 
in some cases were dependent on the activation status of the neutrophil. Low 
concentrations of AMP were able to enhance the pro-inflammatory functions of naïve 
cells or maintain the viability and effectiveness of activated cells. The enhancement of 
migration is an activity common to human [42,150,162,163], murine [163] and porcine 
[154] cathelicidins. Induction of ROS production has been observed in human 
neutrophils treated with LL-37, and suppression of apoptosis has been observed in 
macrophages treated with porcine PR-39 [185]. This suggests that enhancement of pro-
inflammatory functions at low AMP concentrations may be a common property, 
independent of structure, of cathelicidin AMPs from different species. 
 
High concentrations of AMP were able to promote phagocytosis but also induced 
necrosis, particularly in activated cells. Likewise, LL-37 and the structurally distinct 
defensins have been show to enhance phagocytosis [82,169,170]. This may also be a 
common property of structurally distinct AMPs as the structurally different bovine 
cathelicidins, namely linear Bac1, Bac5 and BMAP-34, each enhanced phagocytosis. 
The ability to induce necrosis appears to be a common activity of α-helical peptides. 
BMAP-28 and BMAP-34 each induced neutrophil necrosis, with BMAP-28 
demonstrating a distinct membrane permeating effect, as has been observed in other cell 
lines [157-159]. LL-37 has been shown to induce necrosis in apoptotic neutrophils 
[153,172,173] which appears to be an anti-inflammatory mechanism promoting 
clearance of neutrophils. At this stage it is unclear whether necrosis induced by bovine 
cathelicidins is anti-inflammatory. Nevertheless, high concentrations of cathelicidins 
appear to regulate proinflammatory neutrophil functions and neutrophil abundance 
during infection. 
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The regulatory effect of Bac5 on extracellular neutrophil respiratory burst was found to 
involve an interaction with β-actin. Low concentrations of Bac5 enhanced ROS 
production while high concentrations regulated excessive ROS production, possibly by 
blocking assembly of p47phox on NADPH oxidase. Blocking of p47phox assembly is also 
the mechanism by which porcine PR-39 is able to regulate activated neutrophil ROS 
production. However, PR-39 achieves this by binding to p47phox, rather than β-actin. 
The existence of two structurally similar cathelicidin AMPs which achieve a similar 
regulatory effect using slightly different mechanisms highlights the importance of the 
regulation of ROS production during neutrophil inflammatory responses. The most 
likely reason for this regulatory activity may be to prevent oxidative stress and damage 
to host cells. However, Bac5 also enhanced both extracellular and intracellular basal 
ROS production, suggesting that some of the activity exhibited by Bac5, in addition to 
β-actin interactions, may also involve ROS signalling. Further research is required to 
establish if this is the case. 
 
Taken together, the results of this thesis describe multifaceted roles for the bovine 
cathelicidins in host defence, which may coordinate to enhance function but also 
regulate excessive pro-inflammatory responses from neutrophils. These potential roles 
are summarised in the context of infection in vivo as follows (refer to Figure 6.1).  
 
The infiltration of pathogens is recognised by sentinel cells such as dendritic cells and 
macrophages (a). These cells respond to pathogen exposure by releasing chemokines to 
recruit neutrophils from the circulation (b). Epithelial cells also release chemokines 
upon recognition of pathogens (c). Neutrophils migrate from blood vessels, through the 
basement membrane, and between epithelial cells toward the area of infection using the 
chemoattractant gradients established by the epithelial and sentinel cells. (d). Here, the 
neutrophils may encounter pathogens directly (e), triggering degranulation of humoral 
components, or, chemokines secreted by the sentinel cells in response to pathogen (e) 
may also induce neutrophil degranulation. At this point the cathelicidins are released 
from the large granules and can be processed into the CLD and AMP domain by 
primary granule constituents. As the infiltration of neutrophils is rapid and pronounced, 
so too is the release of cathelicidins into the inflammatory environment.  
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Figure 6.1  Summary of the roles of bovine cathelicidins in host defence 
For (A) – (D), shading indicates the abundance relative to time. As time proceeds during infection, the 
severity of the bacterial load rapidly increases (A). As pathogens are detected, chemoattractant signalling 
surges (D) resulting in a rapid and pronounced infiltration of neutrophils to the site of infection (B).  
As neutrophils accumulate, the concentration of cathelicidins, both the CLD and AMPs, increases through 
neutrophil degranulation (C). Steps (a) – (o) are described in the text. 
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As different bovine cathelicidin AMPs are capable of enhancing migration at different 
concentrations, a minor positive feedback loop may be created (f) which further 
promotes neutrophil interaction with pathogens or cytokines. Neutrophils activated in 
this manner are further induced to degranulate by the increasing concentration of certain 
AMPs (g). Activated neutrophils are also likely to begin producing large amounts of 
ROS, however ROS production may be held in check by high concentrations of Bac5 
(h) or other peptides, thereby preventing oxidative damage of other immune cells and 
surrounding tissues. 
 
The parallel increase in CLD would begin to cause pathogen agglutination that would 
help to prevent the spread of infection (i). With continued degranulation and release of 
cathelicidins, the concentration of CLD and AMPs may quickly have a significant effect 
on the amount of free LPS (j) in the environment. The sequestration of LPS by both the 
CLD and AMPs may lead to a reduction in LPS-stimulated chemoattractant release by 
epithelial and sentinel cells, slowing the rate of migration of neutrophils into the 
inflammatory focus. 
 
Newly recruited neutrophils may not directly encounter pathogen. Despite this, different 
AMPs may act to enhance basal ROS production (k) to assist in pathogen elimination. 
The high concentration of AMPs may also act on newly recruited neutrophils to 
enhance phagocytosis, and in a coordinated effort with the CLD, aid in the clearance of 
agglutinated pathogens (l). Apoptotic or spent neutrophils may also be cleared via this 
enhanced phagocytic response. Macrophages would assist in these processes too (m). 
However as the infection is brought under control, an excess of neutrophils can lead to 
unnecessary damage to host tissues. While less pathogen recognition may have led to a 
drop in neutrophil infiltration rate, high concentrations of certain AMPs would induce 
neutrophil necrosis, allowing excess neutrophils to be cleared from the inflammatory 
focus (n). High concentrations of CLD would similarly induce necrosis in a concerted 
effort to promote clearance by macrophages (o).  
 
It is important to keep in mind that the effects of the cathelicidins were minor in some 
instances, and that other endogenous or exogenous signals may dominate over the 
effects induced by the cathelicidins. Although it is still unclear as to the range of 
Chapter 6: General Discussion  161 
 
 
concentrations at which bovine cathelicidins are bioavailable during infection, in most 
species the abundance of cathelicidins during infection is high. Therefore their impact 
on innate immune responses is likely to be significant. 
 
In summary, the bovine cathelicidins have multiple roles in host defence. The conserved 
CLD appears to have an anti-inflammatory role through an as yet undefined mechanism. 
The variable AMPs together have multifaceted roles which may act in concert to 
promote elimination of pathogens and regulate excessive detrimental neutrophil activity. 
The combined effect of these roles may act to enhance clearance of pathogens during 
infection and aid in the resolution of the innate inflammatory response. 
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6.2 Opportunities for future research 
6.2.1 The origin of the immunomodulatory activity of the CLD  
The work in this thesis clarifies a role for the bovine CLD in humoral and cellular innate 
immunity. However, the mechanism by which the CLD promotes microbe agglutination 
and neutrophil death was not identified. The reason for the activity exhibited by the 
native Cath1 preparation was likely due to the presence of a higher molecular weight 
form of the CLD. This has previously been observed in bovine but has not been 
completely characterised [58]. Hence, there are several questions about the activity of 
the CLD that need to be addressed.  
 
First and foremost, is the higher molecular weight protein the cause of the observed 
immunomodulatory activity? The best way to address this question would be to separate 
the different molecular weights by size exclusion chromatography and characterise the 
function of each CLD fraction separately. Hence, if the high molecular weight complex 
is the cause of the activity, why is it only present in the native Cath1 sample? As the 
protein would be lethal from the onset of translation, a structural rearrangement 
probably occurs after neutrophil degranulation during infection. This might also explain 
why the recombinant proteins could only be produced as monomers or dimers in 
bacteria. Exactly what conditions might cause this higher oligomerisation are unclear. 
However, the domain swapped dimers formed by protegrin-3 [97,109] were produced 
under acidic crystallisation conditions. Therefore lowering the pH of solutions 
containing recombinant CLD protein may allow multimeric structures to spontaneously 
form. Additionally, lowering the pH of the solutions used for on-column refolding may 
also give the desired result.  
 
Are the multimeric structures regular and ordered, or aggregates of misfolded protein? 
The increments in molecular weight observed in the western blot correspond to 
multimers containing an even number of monomers. Also, proline-rich regions in many 
proteins can act as ‘quaternary structure helpers’ [274] aiding oligomerisation. The loop 
section between β-sheets one and two of the CLD (the anti-parallel link in the dimerised 
structure [97]) contains a high content of proline and could function in this manner. 
These details suggest that the structures are regular and ordered. To address this 
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question, the different molecular weight fractions of the CLD could be subjected to 
crystallisation trials and analysed by X-ray crystallography or by solution NMR 
spectroscopy to determine if there is order to the structures.  
 
Considering the CLD is highly conserved across species, could this be a general 
property of all CLDs? To address this question the additional six bovine CLDs and 
CLDs from other species could be purified following the same protocol as native Cath1. 
Western blot analysis, size exclusion chromatography and functional and structural 
characterisation would determine whether the oligomeric structure of the CLD and any 
accompanying function are unique to bovine cathelicidin-1, unique to bovine, or 
common across species. 
 
6.2.2 Toward identifying in vivo production of the RITK peptide 
The potential secondary cleavage of cathelicidin-1 was of significant interest as this 
process would generate a novel undescribed bovine cathelicidin AMP. Although the 
RITK peptide could not be found after ex vivo stimulation of bovine neutrophils with 
either PMA or calcium ionophore, several other experiments may provide evidence for 
production of the peptide in vivo. Firstly, in vitro production of the peptide using 
rbCath1 and purified endogenous bovine elastase (or other bovine serine proteases) 
needs to be assessed. This would determine if the peptide can be produced by bovine 
neutrophil proteases. Secondly, if the peptide is produced, then the use of a more 
physiological activator for ex vivo stimulation, such as live bacteria, may provide the 
necessary conditions for production of the peptide. Finally, only extracellular release of 
the peptide was tested. The peptide may be produced in phagosomes or lysosomes, and 
MS analysis of neutrophil lysate after stimulation may reveal the peptide.  
 
6.2.3 Establishing the mechanisms of linear Bac1 and BMAP-34 activity 
Linear Bac1 and BMAP-34 exhibited dose-dependent effects on neutrophil function in 
the absence of intracellular calcium mobilisation. For linear Bac1 this included 
enhanced granule release, migration, ROS production, and phagocytosis. Linear Bac1 
may be able to cross the plasma membrane and modulate neutrophil function by an 
intracellular mechanism. At high concentrations, BMAP-34 was able to enhance 
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phagocytosis but was also cytotoxic. BMAP-34 also enhanced granule release and 
migration, but inhibited ROS production in naïve cells. The interaction of BMAP-34 
with the neutrophil membrane is unclear. Therefore, similar experiments to those 
employed to determine the mechanism of Bac5 function could be used here.  
 
6.2.4 Establishing the follow-on mechanisms of Bac5-actin interactions 
The mechanism of Bac5 regulation of ROS production was not completely clarified. 
Does Bac5 actually prevent the binding of p47phox to the plasma membrane NADPH 
oxidase assembly? To address this, a dot blot-binding assay could be used in which 
purified β-actin is immobilised on a transfer membrane, blocked, and probed with Bac5 
to create Bac5-β-actin complexes. This could then be probed with purified p47phox to 
determine if Bac5 blocks the binding of p47phox to actin. This technique assesses binding 
of proteins in their native state and should accurately reflect what occurs within 
neutrophils. 
 
The interaction of Bac5 with actin may also play a role in the Bac5-induced modulation 
of migration, degranulation and phagocytosis. These neutrophil functions are heavily 
reliant on cytoskeletal reorganisation [258,275] suggesting the Bac5-actin interaction 
may have further follow-on effects on the cytoskeleton. Firstly, does Bac5 directly 
affect actin polymerisation or depolymerisation? The simplest method to address this 
question would be to use a standard actin polymerisation assay kit to measure 
differences in actin polymerisation in the presence and absence of Bac5. The addition of 
actin destabilising reagents would also provide data on whether Bac5 stabilises actin 
filaments that are already established.  
 
Secondly, does the Bac5-actin complex bind other actin proteins? Together there are at 
least 100 actin-binding proteins from 30 different families [276]. Many of these proteins 
contain poly-proline binding motifs [249] which are possible targets for Bac5 
interactions. A Bac5-actin interaction with other actin-binding proteins warrants future 
investigation. A possible approach to identifying actin-binding proteins that interact 
with Bac5-actin might involve an in-depth co-immunopurification analysis using Bac5-
treated neutrophil lysates. 
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Additionally, a series of actin inhibitors (e.g. cytochalasins, phalloidin, latrunculin) 
could be used to establish which cytoskeletal remodelling processes are essential for 
Bac5-induced modulation of neutrophil function. This would clarify whether Bac5 
indirectly affects actin polymerisation, depolymerisation or both. This would also 
narrow down the number of possible interacting target proteins. 
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Appendix 1: Bovine AMP Interactions with 
Cytokine Antibodies 
ELISAs measuring bovine cytokines were intended for use in the assessment of 
cytokine release by isolated neutrophils treated with bovine cathelicidin AMP 
(Chapter 4, section 4.3.5). However, the bovine cathelicidin AMPs appeared to interfere 
or bind with ELISA antibodies, generating false-positive measurements, as illustrated 
by the supporting experimental evidence below. 
 
1 Interaction with ELISA antibodies 
To determine the extent of the false-positive reading, individual bovine AMPs (Bac1, 
linear Bac1, Bac5, indolicidin, BMAP-28, BMAP-34, LL-37) were diluted to 5 µM in 
culture media and tested in bovine-specific IL-1β, IL-6 and IL-10 ELISAs  
(Figure A1.1 A). Strong absorbance readings were measured for linear Bac1, BMAP-28 
and BMAP-34 across all three ELISAs. LL-37 produced a modest absorbance 
measurement in the IL-6 and IL-10 ELISAs in contrast to the two bovine α-helical 
peptides.  
 
To determine the origin of the false-positive signal, reagents of the IL-1β ELISA were 
systematically removed (Figure A1.1 B). Through this technique the potential for false 
positives due to a non-specific AMP interaction with TMB and streptavidin-HRP were 
eliminated (Figure A1.1 B (ii), (iii)). By immobilising the AMPs directly on the ELISA 
plate, blocking, and then incubating with detection antibody, streptavidin-HRP and 
TMB as normal, it was possible to show that the detection antibody bound to 
immobilised AMP (Figure A1.1 B (iv)). However, omitting the capture antibody and 
blocking the plate so as to remove all possible peptide binding sites resulted in 
absorbance measurements equivalent to the standard procedure (Figure A1.1 B (v)).  
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Figure A1.1  Analysis of false-positives in bovine cytokine ELISAs 
A standard ELISA procedure was used to determine the extent of false-positive signal in control samples 
containing only 5 µM cathelicidin AMP and RPMI 1640 medium. Maxisorp 96-well plates (Nunc) were 
coated with capture antibody overnight at room temperature. Between each step the plates were washed 
three times with wash solution A (Appendix 2). The plates were blocked with wash solution A containing 
1% (w/v) BSA (66.5 kDa) for 2 hour at room temperature. Samples were incubated for 2 hours at room 
temperature. Detection antibody was incubated for 1 hour at room temperature. Streptavidin-HRP was 
incubated for 30 minutes at room temperature. TMB substrate was added for 30 minutes at room 
temperature or until the blue colour developed sufficiently. The reaction was then stopped with an equal 
volume of 1 M H2SO4. Absorbance was measured at 450 nm using a Synergy 2 multi-mode microplate 
reader and Gen5 software. (A) Standard ELISA procedure for IL-1β, IL-6 and IL-10 antibodies. Bars with 
diagonal lines indicate samples in which TMB conversion was so complete that insoluble precipitates 
formed which affected absorbance readings. Data represent a single experiment performed in duplicate. 
(B) IL-1β ELISA reagents were systematically removed to determine the origin of the false-positive 
signal. (i) Standard procedure. (ii) Streptavidin-HRP was omitted to determine if the AMPs directly 
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converted TMB substrate to the blue product. (iii) The detection antibody was omitted to determine if 
streptavidin-HRP bound to the AMPs. (iv) The capture antibody was omitted and the AMP samples were 
used to coat the ELISA plates at room temperature overnight, the standard procedure was then followed 
to determine if the detection antibody bound to the AMPs. (v) The capture antibody was omitted from the 
standard procedure to determine if the AMPs bound to the block reagent. Data represent a single 
experiment performed in duplicate. Ab, antibody. 
 
These results indicated that BMAP-28 and BMAP-34 were able to bind to the blocking 
reagent as well as the antibodies (due to the difference observed between Figure A1.1 B, 
(iv) and (v)). Removal of the capture antibody did not affect the absorbance of samples 
containing linear Bac1, where it was observed, therefore it was possible that linear Bac1 
was able to bind in the spaces between blocking reagent molecules and establish a bond 
with detection antibody molecules. For these reasons several different blocking reagents 
were employed to test whether the type of blocking reagent affected the AMP-antibody 
interaction. However, neither 2% (w/v) polyvinylpyrrolidone (44 kDa, BDH 
Chemicals), 1% (w/v) polyvinyl alcohol (10 kDa, Sigma-Aldrich) or 1% (w/v) ficoll 
(400 kDa, Sigma-Aldrich) made a significant difference to any of the peptides 
generating the greatest false-positive readings (Figure A1.2). 
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Figure A1.2  Test of ELISA blocking reagents 
The IL-6 ELISA antibody pairs were used to test the effectiveness of different blocking reagents in 
reducing the AMP-antibody interaction. A standard ELISA method was used. Blocking reagent 
containing 1% (w/v) BSA is provided for comparison with 2% (w/v) polyvinylpyrrolidone, 1% (w/v) 
polyvinyl alcohol and 1% (w/v) ficoll. Data represent a single experiment performed in duplicate. 
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2 Significance of the AMP-antibody interactions 
Antibodies perform a number of important functions during infection such as 
opsonisation of pathogens and activation of complement. As it is unclear as to which 
part of the antibody molecule the AMPs might bind to, it is difficult to ascertain how the 
interaction may affect regular antibody activity. Several possibilities are presented here. 
 
The AMP-antibody interaction may enhance antibody function. Given the ability of the 
bovine α-helical AMPs to interact with bacterial membranes and different IgG 
molecules, the bovine α-helical AMPs may act as adapter molecules to allow non-
specific IgG opsonisation of bacteria. This would improve complement activation and 
clearance by phagocytes without requiring specific antigen-antibody recognition. 
Coincidently, a protein with significant homology to porcine cathelin and the CLD of 
cathelicidins has been found to associate with the porcine IgG receptor FcγRIIIaα [277]. 
This provides some evidence for a purposeful interaction between cathelicidins, 
antibody and antibody recognition. Hence, the AMP domain may somehow enhance 
receptor activation upon antibody recognition, thereby promoting bacterial clearance. 
 
Conversely, the AMP-antibody interaction may inhibit antibody function. The AMPs 
may non-specifically bind to the variable region of antibody molecules, thereby 
preventing antigen recognition and regulating immune responses. Alternatively they 
may bind to the constant region of antibody and prevent Fc receptor recognition of 
antibody-antigen complexes and likewise regulate immune responses.  
 
The AMP-antibody interaction could also possibly act to remove AMP from the 
inflammatory environment during the transition to the adaptive immune response. This 
would prevent re-activation of proinflammatory functions in immune cells when the 
cathelicidin concentration returns to low levels.  
 
Finally, the interaction may be transient in the inflammatory environment and may not 
result in changes to the function of either molecule. Despite all these possibilities, 
unforeseen interactions between AMPs and assay components, particularly antibody, 
should be carefully controlled against in assays which contain free AMP. Future 
research may clarify the significance of these cathelicidin AMP-antibody interactions. 
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Appendix 2: Solutions and Reagents 
All solutions were made in MQ.H2O to the required volume unless otherwise indicated. 
 
1 General solutions 
1.1 PBS 
Item Concentration Supplier 
NaCl 137 mM Thermo Fisher Scientific New Zealand Ltd. 
KCl 2.7 mM Thermo Fisher Scientific New Zealand Ltd. 
Na2HPO4 10 mM Thermo Fisher Scientific New Zealand Ltd. 
NaH2PO4 1.8 mM Fisher Scientific, Loughborough, UK 
Adjust pH to 7.4 using NaOH or HCl. Autoclave to sterilise. Store at room temperature. 
 
1.2 TBS 
Item Concentration Supplier 
Tris 50 mM Fisher BioReagents, NJ, USA 
NaCl 150 mM Thermo Fisher Scientific New Zealand Ltd. 
Adjust pH to 7.5 using HCl. Autoclave to sterilise. Store at room temperature. 
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2 Molecular biology solutions 
2.1 Solutions for protein expression 
2.1.1 LB/kan/tet/amp 
Item Concentration Supplier 
Luria Broth 20 mg/ml Life Technologies Inc. 
Kanamycin 15 µg/ml Sigma-Aldrich 
Tetracycline 12.5 µg/ml Sigma-Aldrich 
Ampicillin 50 µg/ml Applichem GmbH, Darmstadt, Germany 
Glucose 0.1% (w/v) Sigma-Aldrich 
Autoclave to sterilise. Store at 4 °C. 
 
2.1.2 LB/kan/tet/amp agar 
Item Concentration Supplier 
Luria Broth 20 mg/ml Life Technologies Inc. 
Luria Broth Agar 15 mg/ml Life Technologies Inc. 
Kanamycin 15 µg/ml Sigma-Aldrich 
Tetracycline 12.5 µg/ml Applichem GmbH 
Ampicillin 50 µg/ml Sigma-Aldrich 
Autoclave to sterilise. Store at 4 °C. 
 
2.2 Solutions for protein purification 
2.2.1 Column stripping solution 
Item Concentration Supplier 
EDTA 50 mM Thermo Fisher Scientific New Zealand Ltd. 
Na2HPO4 20 mM Thermo Fisher Scientific New Zealand Ltd. 
NaCl 500 mM Thermo Fisher Scientific New Zealand Ltd. 
Filter through 0.2 µm membrane (Minisart, Sartorius). Store at room temperature. 
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2.2.2 Nickel loading solution 
Item Concentration Supplier 
NiSO4 100 mM Sigma-Aldrich 
Filter through 0.2 µm membrane. Store at room temperature. 
 
2.2.3 Column storage solution 
Item Concentration Supplier 
Ethanol 20% (v/v) Thermo Fisher Scientific New Zealand Ltd. 
Filter through 0.2 µm membrane. Store at room temperature. 
 
2.2.4 5× TE 
Item Concentration Supplier 
Tris 50 mM Fisher BioReagents, NJ, USA 
EDTA 5 mM Thermo Fisher Scientific New Zealand Ltd. 
Adjust pH to 8.0 with HCl. Filter through 0.2 µm membrane. Store at room temperature. 
 
2.2.5 Lysis buffer A 
Item Concentration Supplier 
NaCl 500 mM Thermo Fisher Scientific New Zealand Ltd. 
NaH2PO4 29 mM Thermo Fisher Scientific New Zealand Ltd. 
Na2HPO4 471 mM Fisher Scientific 
Imidazole 10 mM JT Baker Chemical Co., NJ, USA 
Adjust pH to 7.4 with NaOH or HCl. Filter through 0.2 µm membrane. Store at room 
temperature. 
 
2.2.6 Wash buffer A 
Item Concentration Supplier 
NaCl 500 mM Thermo Fisher Scientific New Zealand Ltd. 
NaH2PO4 365 mM Thermo Fisher Scientific New Zealand Ltd. 
Na2HPO4 135 mM Fisher Scientific 
Imidazole 20 mM JT Baker Chemical Co. 
Adjust pH to 7.4 with NaOH or HCl. Filter through 0.2 µm membrane. Store at room 
temperature. 
 
Appendix 2: Solutions and Reagents  201 
 
 
2.2.7 Elution buffer A 
Item Concentration Supplier 
NaCl 500 mM Thermo Fisher Scientific New Zealand Ltd. 
NaH2PO4 365 mM Thermo Fisher Scientific New Zealand Ltd. 
Na2HPO4 135 mM Fisher Scientific 
Imidazole 500 mM JT Baker Chemical Co. 
Adjust pH to 7.4 with NaOH or HCl. Filter through 0.2 µm membrane. Store at room 
temperature. 
 
2.2.8 Lysis buffer B 
Item Concentration Supplier 
NaCl 500 mM Thermo Fisher Scientific New Zealand Ltd. 
NaH2PO4 20 mM Thermo Fisher Scientific New Zealand Ltd. 
Imidazole 10 mM JT Baker Chemical Co. 
Guanidine HCl 6 M Life Technologies Inc. 
Glycerol 10% (v/v) Thermo Fisher Scientific New Zealand Ltd. 
Dithiothreitol 1 mM Roche Diagnostics N.Z., Ltd. 
Adjust pH to 7.4 with NaOH or HCl. Filter through 0.2 µm membrane. Store at 4 °C. 
 
2.2.9 Wash buffer B 
Item Concentration Supplier 
NaCl 500 mM Thermo Fisher Scientific New Zealand Ltd. 
NaH2PO4 20 mM Thermo Fisher Scientific New Zealand Ltd. 
Imidazole 20 mM JT Baker Chemical Co. 
Guanidine HCl 6 M Life Technologies Inc. 
Glycerol 10% (v/v) Thermo Fisher Scientific New Zealand Ltd. 
Cysteine 1 mM Sigma-Aldrich 
Cystine 0.1 mM Sigma-Aldrich 
Adjust pH to 7.4 with NaOH or HCl. Filter through 0.2 µm membrane. Store at 4 °C. 
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2.2.10 Refold buffer B 
Item Concentration Supplier 
NaCl 500 mM Thermo Fisher Scientific New Zealand Ltd. 
NaH2PO4 20 mM Thermo Fisher Scientific New Zealand Ltd. 
Imidazole 20 mM JT Baker Chemical Co. 
Glycerol 10% (v/v) Thermo Fisher Scientific New Zealand Ltd. 
Cysteine 1 mM Sigma-Aldrich 
Cystine 0.1 mM Sigma-Aldrich 
Adjust pH to 7.4 with NaOH or HCl. Filter through 0.2 µm membrane. Store at 4 °C. 
 
2.2.11 Elution buffer B 
Item Concentration Supplier 
NaCl 500 mM Thermo Fisher Scientific New Zealand Ltd. 
NaH2PO4 20 mM Thermo Fisher Scientific New Zealand Ltd. 
Imidazole 500 mM JT Baker Chemical Co. 
Glycerol 10% (v/v) Thermo Fisher Scientific New Zealand Ltd. 
Adjust pH to 7.4 with NaOH or HCl. Filter through 0.2 µm membrane. Store at room 
temperature. 
 
2.2.12 Dialysis buffer 
Item Concentration Supplier 
NaCl 150 mM Thermo Fisher Scientific New Zealand Ltd. 
NaH2PO4 20 mM Thermo Fisher Scientific New Zealand Ltd. 
Adjust pH to 7.4 with NaOH or HCl. Filter through 0.2 µm membrane. Store at room 
temperature. 
 
2.2.13 10× rEK cleavage capture buffer 
Item Concentration Supplier 
NaCl 500 mM Thermo Fisher Scientific New Zealand Ltd. 
Tris 200 mM Fisher BioReagents 
CaCl2 20 mM BDH Chemicals, Poole, England 
Adjust pH to 7.4 with HCl. Filter through 0.2 µm membrane. Store at 4 °C. 
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2.3 Solutions for protein detection 
2.3.1 SDS-PAGE solutions 
2.3.1.1 3× SLB 
Item Concentration Supplier 
Glycerol 10% (v/v) Thermo Fisher Scientific New Zealand Ltd. 
β-mercaptoethanol 5% (v/v) Acros Organics, NJ, USA  
SDS 2% (w/v) Bio-Rad Laboratories Inc., CA, USA 
Tris pH 6.8 As required Fisher BioReagents 
Bromophenol blue 1 or 2 grains BDH Chemicals 
Adjust pH to 6.8 with HCl. Store at -20 °C. 
 
2.3.1.2 4× stacking buffer 
Item Concentration Supplier 
Tris 500 mM Fisher BioReagents 
SDS 0.4% (w/v) Bio-Rad Laboratories Inc. 
Adjust pH to 6.9 with HCl. Store at 4 °C. 
 
2.3.1.3 4× resolving buffer 
Item Concentration Supplier 
Tris 1.5 M Fisher BioReagents 
SDS 0.4% (w/v) Bio-Rad Laboratories Inc. 
Adjust pH to 8.8 with HCl. Store at 4 °C. 
 
2.3.1.4 10× Running buffer 
Item Concentration Supplier 
Tris 25 mM Fisher BioReagents 
Glycine 192 mM Bio-Rad Laboratories Inc. 
SDS 0.1% (w/v) Bio-Rad Laboratories Inc. 
Store at 4 °C. 
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2.3.1.5 Fixative/destain solution 
Item Concentration Supplier 
Methanol 40% (v/v) Fisher Scientific 
Acetic acid 10% (v/v) BDH Chemicals 
Store at room temperature. 
 
2.3.1.6 CBB R-250 stain solution 
Item Concentration Supplier 
CBB R-250 0.1% (w/v) Bio-Rad Laboratories Inc., CA, USA 
Methanol 20% (v/v) Fisher Scientific 
Acetic acid 10% (v/v) BDH Chemicals 
Store at room temperature. 
 
2.3.2 Western blot, dot blot and far-western blot solutions 
2.3.2.1 CAPS transfer buffer 
Item Concentration Supplier 
CAPS 10 mM Sigma-Aldrich 
Methanol 10% (v/v) Fisher Scientific, Loughborough, UK 
Store at room temperature. 
 
2.3.2.2 Ponceau S stain solution 
Item Concentration Supplier 
Ponceau S 0.1% (w/v) Sigma-Aldrich 
Acetic acid 5% (v/v) BDH Chemicals 
Store at room temperature. 
 
2.3.2.3 Blocking solution A 
Item Concentration Supplier 
Non-fat skim milk 4% (w/v) Foodstuffs Ltd., Auckland, New Zealand 
PBST To volume required See 2.3.2.5 
Make fresh as required. Discard after use. 
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2.3.2.4 Blocking solution B 
Item Concentration Supplier 
Non-fat skim milk 4% (w/v) Foodstuffs Ltd., Auckland, New Zealand 
TBST To volume required See 2.3.2.6 
Make fresh as required. Discard after use. 
 
2.3.2.5 Wash solution A 
Item Concentration Supplier 
PBS 1 L See 1.1 
Tween 20 0.05% (v/v) BDH Chemicals 
Store at room temperature. 
 
2.3.2.6 Wash solution B 
Item Concentration Supplier 
TBS 1 L See 1.2 
Tween 20 0.05% (v/v) BDH Chemicals 
Store at room temperature. 
 
2.3.2.7 Antibody diluent A 
Item Concentration Supplier 
BSA 0.1% (w/v) MP Biomedicals 
PBST To volume required See 2.3.2.5 
Store at 4 °C. 
 
2.3.2.8 Antibody diluent B 
Item Concentration Supplier 
BSA 0.1% (w/v) MP Biomedicals 
TBST To volume required See 2.3.2.6 
Store at 4 °C. 
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3 Solutions for neutrophil function assays 
3.1 Serum-free RPMI 1640 medium 
Item Concentration Supplier 
RPMI 1640 1× Life Technologies Inc. 
Penicillin &  
Streptomycin 1 U/ml &1 µg/ml Life Technologies Inc. 
GlutaMAX 2 mM Life Technologies Inc. 
Store at 4 °C. 
 
3.2 10× Annexin-V binding buffer 
Item Concentration Supplier 
HEPES 100 mM BDH Chemicals 
NaCl 1.4 M Thermo Fisher Scientific New Zealand Ltd. 
CaCl2 25 mM BDH Chemicals 
Adjust pH to 7.4 with HCl. Filter through 0.2 µm membrane. Store at 4 °C. 
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4 Solutions for protein interaction assays 
4.1 10× Protease inhibitor stock 
Item Concentration Supplier 
Complete mini 
EDTA-free protease 
inhibitor tablets 
5 tablets Roche Diagnostics N.Z., Ltd. 
MQ.H2O 5 ml  
Store at -20 °C. 
 
4.2 Fractionation buffer 
Item Concentration Supplier 
HEPES pH 7.4 10 mM BDH Chemicals 
MgCl2 2.5 mM Thermo Fisher Scientific New Zealand Ltd. 
EGTA 5 mM Sigma-Aldrich 
Sucrose 250 mM Sigma-Aldrich  
PMSF 0.1 mM Sigma-Aldrich  
Protease inhibitors 1× stock See 4.1 
Make fresh as required. Add PMSF and protease inhibitors prior to use.  
 
4.3 Hypotonic buffer 
Item Concentration Supplier 
Tris-HCl, pH 7.4 20 mM Fisher BioReagents 
NaCl 10 mM Thermo Fisher Scientific New Zealand Ltd. 
MgCl2 3 mM Thermo Fisher Scientific New Zealand Ltd. 
NaF 5 mM BDH Chemicals 
Na3VO4 1 mM Sigma-Aldrich 
EDTA 5 mM Thermo Fisher Scientific New Zealand Ltd. 
PMSF 1 mM Sigma-Aldrich 
Protease inhibitors 1× stock See 4.1 
Make fresh as required. Add PMSF and protease inhibitors prior to use. 
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5 Mass spectrometry solutions 
5.1 MS gel fixative solution 
Item Concentration Supplier 
Methanol 50% (v/v) Fisher Scientific 
Phosphoric acid 2% (v/v) Sigma-Aldrich 
Store at room temperature. 
 
5.2 CBB G-250 stain solution 
Item Concentration Supplier 
CBB G-250 0.25% (w/v) Bio-Rad Laboratories Inc. 
Methanol 40% (v/v) Fisher Scientific 
Acetic acid 10% (v/v) BDH Chemicals 
Store at room temperature. 
 
5.3 MS gel destain solution 
Item Concentration Supplier 
Methanol 5% (v/v) Fisher Scientific 
Store at room temperature. 
 
5.4 Destain wash solution 
Item Concentration Supplier 
NH4HCO3 25 mM Sigma-Aldrich 
Acetonitrile 50% (v/v) Merck, Darmstadt, Germany 
Make fresh as required.  
 
5.5 Trypsin digest solution 
Item Concentration Supplier 
Trypsin 50 μg/ml Promega, WI, USA 
NH4HCO3 25 mM Sigma-Aldrich 
ObG 0.1% (w/v) Calbiochem, CA, USA 
Make fresh as required. 
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5.6 TFA working solution (Trifluoroacetic acid) 
Item Concentration Supplier 
TFA 2.5% (v/v) Merck 
Make fresh as required. 
 
5.7 Acetonitrile/TFA Solution 
Item Concentration Supplier 
Acetonitrile 50% (v/v) Merck 
TFA 0.1% (v/v) Merck 
Make fresh as required. 
 
5.8 Matrix solution 
Item Concentration Supplier 
CHCA 10 mg/ml Bruker Daltonics GmbH, Leipzig, Germany 
Acetonitrile 67% (v/v) Merck 
TFA 0.1% (v/v) Merck 
Make fresh as required. 
 
5.9 Spot wash solution 
Item Concentration Supplier 
Ethanol 80% (v/v) Thermo Fisher Scientific New Zealand Ltd. 
TFA 0.1% (v/v) Merck 
Make fresh as required. 
 
 
